


















Glucocorticoid (GC) therapies are widely used to treat chronic inflammatory diseases.
Synthetic GCs can augment the safe clearance of apoptotic, yet potentially histotoxic
cells by 2 classes of phagocytes- macrophages (M(()s) and mesangial cells (MC) - in a
dose dependent, glucocorticoid receptor (GR)-mediated fashion in vitro. Furthermore,
failure to clear apoptotic cells in vivo has been implicated in the progression of tissue
injury, chronic inflammation and autoimmunity. Recently it has been found that pre-
receptor metabolism of GCs by tissue specific 11 (3-hydroxysteroid dehydrogenase 1
(11 (3-HSD1) can act as an important determinant of GC action by reactivating GCs from
inert 11-keto forms. Sufficient levels of unbound 11-keto products circulate and may
therefore provide a means to increase intracellular GC concentrations in specific cells.
This study characterises 11 (3-HSD 1 expression and activity in rat MC and cells of
human and murine M({) lineage, and suggests an immunomodulatory role for murine
11 (3-HSD 1 in the course of sterile, acute peritonitis.
Firstly, all phagocytes studied expressed 11 (3-HSD1 mRNA and the resulting enzyme
activity was exclusively in the GC-reactivating, reductase direction. In vitro, the
functional consequence of this is that inert 11-dehydrocorticosterone (A) was converted
to active corticosterone (B), which augmented phagocytic capacity for apoptotic
neutrophils (aPMNs). Upon induction of sterile peritonitis, there was a dramatic up-
regulation of 11 (3-HSD 1 activity within the cells resident to, or recruited to, the
peritoneal cavity. For peritonitis to resolve, aPMNs within the peritoneal cavity must be
cleared by M0s. In 11 (3-HSD 1-deficient M0s, A failed to promote phagocytosis, and
phagocytic competency was attained 24h later than WT M(J)s. In vivo, 11 (3-HSD 1-
deficient mice showed a clearance deficiency of aPMNs, suggesting a physiological role
of 11 (3-HSD 1 in promoting clearance of apoptotic cells.
This is the first report in which local modulation of an endogenous factor has been
shown to influence apoptotic cell fate.
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1.1 A GLOBAL PERSPECTIVE
Glucocorticoid (GC) therapies are widely used to treat inflammatory diseases, but can be
limited by adverse side effects. They act through multiple mechanisms affecting the
tissue distributions, effector functions, proliferation and survival of inflammatory cells.
GCs are now believed to play a physiological role as well as a pharmacological role in
the regulation of inflammation, and such study is opening up new therapeutic
approaches to the treatment of inflammatory diseases.
Target cell responses to GCs are controlled by the concentration of circulating adrenal
GC and the cellular density of intracellular receptors, of which the glucocorticoid
receptor (GR) is the predominant form in most immune tissues. Recent evidence
suggests that key modulation of GC action can occur by pre-receptor metabolism of GCs
by 11 (3-hydroxysteroid dehydrogenases (ll(3-HSDs) (reviewed in (Seckl and Walker
2001)). Two 11(3HSD iso-enzymes have been characterised; 11P-HSD2 is an exclusive
dehydrogenase that rapidly inactivates GCs preventing binding of GCs to corticosteroid
receptors. In contrast, lip-HSDl is a reductase in many intact cells in vitro,
regenerating GCs from inactive 1 lketo-forms, thus amplifying GC action in specific
tissues (Low, Chapman et al. 1994; Jamieson, Chapman et al. 1995; Kotelevtsev,
Holmes et al. 1997). Although the role of the liP-HSDs in metabolic tissues and the
CNS are being elucidated, their role in GC modulation in immune tissues, especially in
macrophages (Mtjis), has been poorly addressed.
The inflammatory response is a host defence mechanism that evolved in order to kill
invading pathogens and repair damaged tissues. It can resolve and restore tissue
function, but can become undesirably persistent in a number of disease states. The
selective recognition and subsequent phagocytosis of apoptotic neutrophils (aPMNs) by
M0S is crucial for resolution of inflammation (Savill, Wyllie et al. 1989). Failure to
adequately clear aPMNs results in the release of pro-inflammatory mediators and is
associated with persistent inflammation, such as glomerulonephritis (Botto, Dell'Agnola
et al. 1998; Taylor, Carugati et al. 2000). Recent studies demonstrate a role for GCs,
2
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acting via GR, in promoting the safe clearance of aPMNs by M<[)s (Liu, Cousin et al.
1999).
1.2 GLUCOCORTICOIDS
GCs have a diverse range of physiological functions. Their action is characterised by the
stress response - a culmination of both an anticipatory and a reactive adaptation to the
environment. Metabolism, immune function, homeostasis and behaviour are all
responsive to GC action however, it is essential that GC secretion is regulated to
minimise the detrimental effect of inappropriate exposure (reviewed in (De Kloet,
Rosenfeld et al. 1988)).
1.2-1 Synthesis:
GCs are steroid hormones predominantly synthesised in the zona fasiculata/ reticularis
of the adrenal cortex. There is however, evidence that in vitro, they may also be
synthesised by cells within the thymus, although this is still controversial (Vacchio,
Papadopoulos et al. 1994). All steroids are derived from cholesterol; containing a cyclo-
pentane ring and 3 cyclohexane rings (Fig. 1-1). Each steroid is synthesised by sequential
enzymatic action - predominantly by hydroxylases located in either mitochondria or
smooth endoplasmic reticulum. Since rodents lack 17a-hydroxylase in the adrenals, the
major GC is corticosterone (B), whilst in humans, Cortisol (F) predominates. The
adrenals do not store GC, thus it is synthesised de novo and released when required. The
mineralocorticoid, aldosterone is also synthesised in the adrenal gland and acts primarily
in the kidneys to control solute homeostasis (De Kloet, Rosenfeld et al. 1988).
1.2-2 Regulation:
Neuro-endocrine signals, acting via the hypothalamic-pituitary-adrenal (HPA) axis
stimulate the production of GCs from the adrenal cortex. A variety of inputs can
stimulate the hypothalamus to produce corticotrophin releasing hormone (CRH) and
arginine vasopressin (AVP), which are then transported to the pituitary. In response,
3
Chapter 1: Introduction
Figure 1-1: The steroid hormones. GCs (Cortisol and aldosterone) are steroid
hormones for which cholesterol is the common precursor. Diagram adapted from
(O'Riordan JLH)
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adrenocorticotrophic hormone (ACTH) is rapidly released into the systemic circulation
and stimulates the synthesis of GCs and other adrenocorticosteroids from within the
adrenal cortex (Axelrod and Reisine 1984). GCs regulate their own suppression via a
negative feedback loop in which the circulating concentrations of GCs inhibit the
production ofCRH and ACTH (Fig. 1-2).
GC biosynthesis is also subject to a diurnal rhythm, which peaks at or just prior to the
start of the active period (morning for humans, evening for rodents) and is under control
of the suprachiasmatic nucleus of the hypothalamus (reviewed in (Dallman, Strack et al.
1993)).
To exert an action, lipophilic GCs cross the membrane of target cells and bind to
intracellular cytosolic receptors - GR or mineralocorticoid receptors (MR). Whether
GCs freely diffuse across cell membranes or are actively transported is still open to
question (Kralli, Bohen et al. 1995). Most mammalian cells express GR, although
heterogeneity in GR expression between cell types is observed (Miller, Spencer et al.
1998). MR expression largely is restricted to mineralocorticoid target tissues (including
kidney, colon and salivary gland). In the absence of 11(3-HSD2 (refer to section 1.3-2),
GCs can bind to both GR and MR, with the latter being the higher affinity interaction.
Ligand-free GR is normally bound by cytosolic heat shock proteins (HSP), which
dissociate upon ligand binding (Pratt 1993), then the ligand-receptor complex
translocates to the nucleus, dimerises, and binds specific regions of exposed DNA where
it acts as a transcription regulator (reviewed in (Beato 1989)). Induction of GC-
responsive genes normally occurs by binding of GR dimers to palindromic
glucocorticoid response elements (GRE) in promoter regions of target genes (Fig. 1-2).
Alternatively, GR can bind to negative-GREs (nGRE) leading to repression of the
transcription of specific genes. However, gene repression may also occur indirectly
through the trans-repression of transcription factors (reviewed in (Beato 1989; Beato,
Chavez et al. 1996)). In addition to direct effects on transcription initiation, the GC-GR
complex has also been shown to recruit chromatin-remodelling complexes in order to
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Figure 1-2: A classical view ofGC action and regulation by the HPA axis.
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Many of the metabolic effects of GCs are due to direct GRE-mediated gene induction,
whereas repression of inflammatory genes is often a result of GR/ transcription factor
associations. Most commonly GR interfere with activator protein-1 (AP-1) and nuclear
factor-kb (NF-kB) function thus preventing their activation of inflammatory response
genes (reviewed in (Barnes 1998)). The mechanism of repression is still open to debate.
Reichardt et al generated mice with GRs that could not bind DNA due to a dimerisation
mutation yet GCs still retained the capacity to repress both AP-1 and NF-kB function in
these mice (Reichardt, Kaestner et al. 1998). However, whether the dimerisation
mutation completely abrogated DNA binding is questionable, and residual levels of
DNA binding may be sufficient to mediate repression.
1.2-3 GC actions:
Much of our knowledge about GC action comes from clinical observation of adrenal
malfunction, pharmacological GC treatment and use of GR antagonists. GC excess and
deficiency manifest themselves in the conditions Cushing's syndrome and Addison's
disease, respectively. The first is characterised by insulin insensitivity, truncal obesity,
glucose intolerance, hypertension, change in mood, myopathy and increased
susceptibility to infection. Conversely, Addison's disease leads to hypoglycaemia,
hyperpigmentation, anorexia, and impaired kidney function (hypotension and
hyponatraemia). Such syndromes are rare, however it is believed that subtle yet chronic
alterations in GC metabolism can play a causative role in common disorders such as
obesity, hypertension and diabetes (Seckl and Walker 2001).
One of the best established effects of GC is that of inducing apoptosis of thymocytes, in
vitro - an effect that requires high levels (10~7M-10~6M). Stress levels of GC are enough
to cause thymus involution, in vivo, suggesting that this effect is physiologically
relevant. Immature thymic T-cells have been found to express high levels of GR,
consistent with GC-sensitivity, however mature splenic T-cells are less sensitive to GC
and accordingly have been shown to express lower levels of GR (Miller, Spencer et al.
1998). GC-mediated selection of immature thymic T cells has been suggested to be
accomplished by synergistic action between GC and T-cell receptor (TCR) ligation
7
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(Jamieson and Yamamoto 2000). T cell survival is determined by the avidity of the TCR
for self-antigen (and possible auto-immunity) or major histocompatibility complex (and
adaptive immunity) (reviewed in (Janeway CA 1999)). Only simultaneous signalling
through GR and TCR-mediated pathways ensures survival through a, as yet unclear,
mechanism dependent on GR density and TCR avidity for auto-antigens (reviewed by
(Ashwell, King et al. 1996)). Interestingly, it has been proposed that the GC synthesised
in the thymus itself (thymic epithelium) facilitates this selection (Vacchio, Papadopoulos
et al. 1994). Furthermore, studies by Vacchio et al, which utilised transgenic mice
carrying a transgene for TCR, showed that T cells that would normally have survived
were deleted by apoptosis after treatment with a GC-biosynthesis inhibitor (Vacchio and
Ashwell 1997).
However, this subject is still controversial, since mice which lack GR have an apparently
normal thymus at birth (Purton, Boyd et al. 2000). The lack of GR causes neo-natal
lethality, precluding analysis of the adult phenotype (Purton, Boyd et al. 2000), and thus
the role ofGR in T-cell selection remains to be resolved.
1.2-4 Anti-inflammatory effects:
GCs are rapidly induced during the stress response, in which stimuli to the
hypothalamus increase CRH release (Munck, Guyre et al. 1984). The source of stress
varies, but can include the direct action of pro-inflammatory cytokines upon cells of the
hypothalamus or pituitary, or the adrenal cortex itself (Mandrup-Poulsen, Nerup et al.
1995). The absolute importance of adrenal GC action during inflammation can be
crudely demonstrated by adrenalectomy and subsequent challenge with LPS or TNFa
(Bertini, Bianchi et al. 1988). Animals that were previously tolerant to moderate doses
of LPS or TNFa die if adrenalectomised; however they survive if administered GCs.
Despite the side effects of GC excess, GC treatments are established therapies for a
number of acute and chronic inflammatory conditions including asthma and arthritis.
Although their anti-inflammatory actions at the cellular and molecular levels are yet to
be completely elucidated, it is clear that they exert a multifaceted action on many
immune cell types, in particular the GC-sensitive leukocytes - monocytes, M(J)s and
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lymphocytes (Miller, Spencer et al. 1998). However, extensive study of GC effects has
produced a somewhat confused literature; subject to dosage, species, in vitro and in vivo
anomalies. With increasing understanding of cellular processes these issues are
gradually being resolved and it is clear that the pleiotropic effects of GCs upon
leukocyte gene transcription can alter protein synthesis, processing and secretion, as well
as cell growth, division and apoptosis (Goulding and Guyre 1993). GCs have been
shown to repress the expression of cytokines, adhesion molecules, receptors and
enzymes to produce an overall effect of immune suppression. This can include the
inhibition of leukocyte circulation, recruitment and infiltration, and inhibition of pro¬
inflammatory mediator release by monocytes/ M(|)s (reviewed in (Schleimer 1993;
Barnes 1998)).
As alluded to in section 1.2-2, many target genes suppressed by GCs have no GRE or
nGRE within promoter regions, but instead have binding sites for transcription factors
AP-1 and NF-kB (Cato and Wade 1996). AP-1 and NF-kB are potent inducers of pro¬
inflammatory cytokines, and their actions are antagonised by GCs. The mechanisms by
which the GC-GR complex interferes with the binding of AP-1 and NF-kB is unclear,
however, it is possibly through direct binding interactions or through the induction of
inhibitory intermediary molecules (such as ikb-a) (Ray and Prefontaine 1994; Auphan,
DiDonato et al. 1995). Some of the myriad of GC-mediated transcriptional effects on
immune cells are summarised in Table 1-1.
Whilst pharmacological doses of GCs are immunosuppressive, there is growing
realisation that physiological levels of endogenous GCs are immunomodulatory rather
than solely immunosuppressive. Prolonged stress, leading to chronic adrenal activation
can increase susceptibility to, or severity of, infection whereas a blunted adrenal
response can predispose towards inflammatory, autoimmune and allergic diseases
(Sternberg 2001). The innate immune system is largely regulated by M(j)s, whilst the
adaptive response is regulated by T-helper lymphocytes (Thl and Th2 subclasses).
Although the distinction between Thl and Th2 populations is less clear than previously
thought, physiological concentrations of GCs are known to shift cytokine production by
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Increased Decreased Cellular Effects
Transcription Transcription
IL-4, -5, and -10, IL-1,-2,-3, -6,-8,-11. - Suppression of leucocyte
TGF-3, MIF, 12, and -13, TNFa, IFN- adhesion, migration and
lipocortin-1, IL-1 Y, GM-CSF, RANTES, infiltration. Reduction in numbers
receptor agonist, iNOS, MCP-1, -2, -3, of circulating monocytes and
IKB-CC and -4, phospholipase inhibition of M(J) activation,
A2, ICAM-1, elastase, mediator release and antigen
plasminogen activator, presentation. Suppression of
cyclooxygenase. lymphocyte activation and
proliferation, and induction of
apoptosis. Inhibition of antibody
production.
Table 1-1. Effects of GC on immune cells. Adapted from (Lee, Tsou et al. 1988;
Schleimer 1993; Barnes 1998).
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lymphocytes from the largely pro-inflammatory Thl profile to the anti-inflammatory
Th2 profile (Elenkov and Chrousos 1999). The Thl response is co-ordinated by M0
activation and is characterised by the production of IL-2 and IFN-y, whilst a Th2
response is associated with an adaptive response, characterised by IL-10 and IL-4
production (reviewed in (Elenkov and Chrousos 1999)). Therefore GC function may not
be to necessarily defend against the pathogen, but rather to act as a physiological brake
by limiting the tissue damaging potential ofM())s and other Thl cells.
1.2-5 Access of glucocorticoids to the glucocorticoid receptor:
Access of GCs to the GR can be controlled at various levels. Firstly, as detailed above,
release of adrenal-GC into the systemic circulation is regulated by HPA activity, subject
to control by negative feedback. However it is believed that 95% of endogenous
circulating GC is bound to corticosteroid binding globulin (CBG) and is therefore
unavailable as a ligand for GR. Apart from drastically reducing the concentration of GC
made available to cells, CBG may actually be a GC delivery mechanism to cells in a
manner which ensures equal distribution of ligand to peripheral GC-target cells
(Pardridge 1987). Release ofGC from CBG can be influenced by environmental factors
rather than the HPA - for example dissociation has been shown to occur following
proteolytic cleavage by elastase released by activated PMNs (Hammond, Smith et al.
1990).
Secondly, the density of GR in target tissues is a major determinant of cellular
sensitivity to GC. Lack of GR causes neo-natal lethality in transgenic mice (Finotto,
Krieglstein et al. 1999). In vitro, GR expression is proportional to GC sensitivity
(Vanderbilt, Miesfeld et al. 1987), and the expression of GR anti-sense RNA in vivo,
which causes a 30-50% reduction in GR levels, leads to GC resistance in mice (Pepin,
Pothier et al. 1992). Syndromes of GC resistance have been identified in patients with
rheumatoid arthritis (Poznansky, Gordon et al. 1984) and asthma (Alvarez, Surs et al.
1992; Adcock, Lane et al. 1995) and there is evidence that limiting concentrations ofGR
determine the GC-sensitivity of target cells. For instance, in GC-resistant rheumatoid
arthritis, GR levels in lymphocytes can be reduced by up to 50% (Poznansky, Gordon et
11
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al. 1984; Chikanza, Petrou et al. 1992), and in cases of GC-resistant asthma, decreased
GR expression in leukocytes is associated with reduced GC-suppression of cytokine
release from monocytes (Alvarez, Surs et al. 1992; Chikanza, Petrou et al. 1992; Lane,
Wilkinson et al. 1993; Adcock, Lane et al. 1995). GR levels appear to be negatively
regulated in an autocrine fashion by the levels of circulating GC, which increase with
chronic stress and GC therapy (Makino, Smith et al. 1995; Kitraki, Karandrea et al.
1999), and in some cases with age (Sapolsky, Krey et al. 1984).
An additional possible modulator of GC function is an alternatively spliced isoform of
GR, GRp, which cannot bind ligand due to a truncated C-terminus. It has been suggested
that GRp is constitutively expressed and acts as a dominant negative inhibitor of the full
length GR (GRa), although its action has only been demonstrated, in vitro to date
(Bamberger, Bamberger et al. 1995). However, since GRp is not expressed in rodents
(the splice site is not conserved) its physiological significance remains questionable
(Hecht, CarlstedtDuke et al. 1997; Otto, Reichardt et al. 1997).
Thirdly, non-genomic effects of steroids have been described (reviewed in (Losel and
Wehling 2003)) and whilst there is evidence for a rapid, non-genomic cellular response
to progesterone through a membrane-associated receptor (reviewed in (Bramley 2003))
there is, as yet, little convincing evidence that similar mechanisms exist for GCs. In fact,
one might expect to find a percentage of the cell's GR associated with the membrane as
it sequesters its lipophilic ligand.
Lastly, recent evidence suggests that key modulation of GC action can occur by pre-
receptor metabolism of GCs by 11 p-hydroxysteroid dehydrogenases (1 lP-HSDs) (Seckl






Amelung described the inter-conversion of GCs (B and F) and their inert 11-keto forms
(A and E) in the liver in 1953 (Amelung D 1953). This activity was later characterised
and purified by Monder et al in 1985, and was believed to represent a route of GC
clearance from the circulation. (Lakshmi and Monder 1985; Lakshmi and Monder 1985;
Lakshmi and Monder 1988). The importance of 11P-HSD was subsequently realised
when its action was found to provide an explanation to the 'mineralocorticoid receptor
paradox' of the kidney; namely, that MR sites within the distal nephron bind both GCs
and mineralocorticoids in vitro, but are mineralocorticoid-specific in vivo. Therefore the
inactivation of GCs by lip-HSD activity was credited with this in vivo selectivity,
particularly once it had been shown that 11P-HSD inhibition with liquorice-derivatives
allowed the non-selective and inappropriate binding of GCs to MRs, leading to
hypertension (Stewart, Valentino et al. 1987; Funder, Pearce et al. 1988). Therefore the
specificity of mineralocorticoid target tissues is enzyme mediated, not receptor
mediated.
However it was found that polyclonal Abs raised against 11 P-HSD purified from liver
unexpectedly stained the kidney proximal tubules, not the MR-rich distal nephron area
(Agarwal, Monder et al. 1989). Subsequently a second iso-enzyme with different
kinetics and tissue distribution, 11P-HSD2, was purified and cloned (Agarwal, Mune et
al. 1994; Albiston, Obeyesekere et al. 1994; Brown, Chapman et al. 1996; Brown,
Chapman et al. 1996). 11P-HSD1 and 11P-HSD2 are distantly related members of the
short chain alcohol dehydrogenase family, sharing only approximately 20% identity, but
which have conserved regions of co-factor binding and active site (reviewed in (Stewart






Figure 1-3: Contrasting roles of the lip-HSDs. lip-HSD2 is an exclusive
dehydrogenase that acts in aldosterone target tissues (eg. kidney) to exclude B from
otherwise non-selective MR. lip-HSDl is a reductase that acts in predominantly GC-
target tissues (eg. liver) to amplify intracellular B concentrations. Figure adapted from
(Seckl and Walker 2001).
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1.3-2 11P-HSD2:
11(3-HSD2 is a high affinity, NAD-dependent enzyme that, through 11 ^-dehydrogenase
action, inactivates GCs thus preventing access to otherwise non-selective MR in
aldosterone target tissues such as the distal nephron, and in placenta where it protects
against detrimental over-exposure to maternal GCs (Table. 1-2) (Edwards, Stewart et al.
1988; Funder, Pearce et al. 1988; Krozowski, MaGuire et al. 1995; Seckl, Benediktsson
et al. 1995). This can be demonstrated in utero where 11(3-HSD2 inhibition or
chronicadministration of GCs to pregnant rats programs the pups to have lowered birth
weights and increased risk of hypertension (Benediktsson, Lindsay et al. 1993; Lindsay,
Lindsay et al. 1996).
1.3-3 11P-HSD1:
11P-HSD1 has a lower affinity for GC than 11P-HSD2, is NADP(H)- dependent and is
widely expressed, with highest levels in classical GC-target tissues where it probably
functions as an 1 lP-reductase, reactivating B from inert A (F from E in humans)
(Table.1-2) (Jamieson, Chapman et al. 1995; Kotelevtsev, Holmes et al. 1997). Purified
11P-HSD1 acts as a dehydrogenase, but in intact cells 11P-HSD1 cDNA encodes 11 P~
reductase activity (Agarwal, Monder et al. 1989; Low, Chapman et al. 1994).
Furthermore, depending on the steroid substrate and co-factor present, llp-HSDl
activity has been shown to be bi-directional in tissue homogenates - thus it is clear that
the direction of 11P-HSD1 activity is cell context dependent (Lakshmi and Monder
1988). Most evidence suggests that the in vivo activity is that of a reductase (Low,
Chapman et al. 1994; Kotelevtsev, Holmes et al. 1997; Jamieson, Walker et al. 2000),
and that the enzyme is located within the lumen of the endoplasmic reticulum (ER)
(Ozols 1995). Figure 1.4 shows the inter-conversion ofA and B by 1 lP-HSDl.
Although in normal physiology plasma A levels are substantially lower than B levels,
(because 95% of B is bound by CBG) the level ofA is similar to, if not greater than, that








Size 34 kDa 40 kDa
Km for steroid
substrate
120nM for A 14nM for B
Sites of expression Widespread, including liver,
kidney (proximal tubules),
adipose tissue, brain, lung,
pituitary, gonads, skeletal











Altered blood glucose after





cognitive decline, raised levels
of high-density lipoprotein







increased risk of post¬
natal death.
Table 1-2. Characteristics of 11|3-HSD1 and 110-HSD2. 11 (3-HSD1 data from
(Kotelevtsev, Holmes et al. 1997; Harris, Kotelevtsev et al. 2001; Morton, Holmes et al.
2001; Yau, Noble et al. 2001). 11 (3-HSD2 data from (Brown, Chapman et al. 1993;





Figure 1-4: The inter-conversion of A and B by 11J3-HSD1. liP-HSDl can
catalyse the inter-conversion of inert 11-dehydrocorticosterone (A) and active
corticosterone (B). Cortisone and Cortisol differ from A and B due to the presence of a
hydroxyl group at position C-17.
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in the kidney) and in mice it circulates at concentrations of approximately 5nM without
being subject to a diurnal rhythm (Whitworth, Stewart et al. 1989; Harris, Kotelevtsev et
al. 2001). Therefore a sufficient pool of A circulates to provide a means to amplify
intracellular B concentrations in specific cells in order, for example, to maintain glucose
homeostasis during circadian rhythm or enhance the stress response (Seckl and
Chapman 1997).
1.3-4 11P-HSD1 deficiency:
Recent clinical observations have attributed the failure of a Cushing's patient to present
with a 'Cushingoid' phenotype to a partial defect in 11J3-HSD1 activity (Tomlinson,
Draper et al. 2002). Failure to regenerate F from E, led to a relative increase in the
metabolic clearance of F, and thus protected the patient from the effects of excess GC
(Tomlinson, Draper et al. 2002). There is also evidence of 11P-HSD1 dysregulation in a
small number of patients with syndromes linked to androgen excess and in primary
obesity, although no gene mutations have yet been described (reviewed in (Seckl and
Walker 2001)). However, in mice the evidence suggests that 11P-HSD1 deficiency
attenuates the normal increases in expression of gluconeogenic enzymes and
hyperglycaemia seen upon stress or obesity (Table. 1-2) (Kotelevtsev, Holmes et al.
1997). Following stress, levels of A in plasma 11P-HSD1-deficient mice rise to levels
comparable to B, suggesting that under conditions where the HPA axis is activated
conversion of A to B by 11P-HSD1 may contribute substantially to the activation of
GRs (Harris, Kotelevtsev et al. 2001).
Additionally, recent work shows that inability to regenerate B confers protection from
age-associated cognitive decline (Yau, Noble et al. 2001). 11P-HSD1-deficient mice
hyper-secrete B, presumably to compensate for the inability to regenerate B from A
(Kotelevtsev, Holmes et al. 1997). Intriguingly the high plasma B levels in 11P-HSD1-
deficient mice are not reflected in brain tissue, which, in fact, has lower B levels than
wild type (WT) mice (Yau, Noble et al. 2001), suggesting that some tissues are largely




Inflammation was first described centuries ago as redness and swelling, with heat and
pain. Typically, symptoms are effected by a plethora of chemical mediators, which
control haemodynamic changes, vascular permeability and white cell influx in a
regulated fashion in the affected tissues. The entry of pathogens into the body induces
the release of chemotactic factors, such as prostaglandins, histamine, complement-
derived peptides and cytokines, which recruit leukocytes from the bloodstream towards
the site of inflammation. To accomplish this, cells have to undergo tethering and
adhesion to, and translocation through the endothelial layer of the vessel wall at the
appropriate site, and then migrate through the interstitium towards the inflammatory
foci. In the peritoneum for example, the resident cell population is almost exclusively
resident peritoneal (RP) M(|)s, and during peritonitis, the recruited cell population are
predominantly activated PMNs and monocytes (Andrews 1998)- the primary effectors of
micro-organism ingestion and killing.
When activated by the inflammatory environment, PMNs release oxygen radicals and
proteolytic enzymes such as elastase, which aid the killing of micro-organisms, but also
have the capacity to damage host tissues when inappropriately released (Henson and
Johnston 1987). Whilst it has been shown that a degree ofPMN-mediated tissue damage
is necessary for the proper induction of an acute inflammatory response, when this level
of control is lost the response is exacerbated by a chronic accumulation of potentially
damaging activated PMNs and inflammatory diseases may develop (Henson and
Johnston 1987; Malech and Gallin 1987)
M())s differentiate and mature from recruited monocytes. Maturation is accompanied by
increased secretion of, and sensitivity to inflammatory cytokines, and numerous changes
in surface antigens (refer to section 1.4-1) (reviewed in (Janeway CA 1999)). This leads
to an enhancement of recognition and phagocytosis of micro-organisms (reviewed in
(Greenberg and Grinstein 2002)). However, such changes also equip a dysfunctional M(J)
to perpetuate the inflammatory response through tissue damage.
19
Chapter 1: Introduction
In the event that regulation of the inflammatory process is lost, resolution cannot occur
and inflammation often persists. In order to limit the chance of tissue damage, pathogen
removal must be followed by the dissipation of pro-inflammatory mediators, cessation
of leukocyte influx and induction of anti-inflammatory mediators. Finally, cell removal
or emigration must occur (Haslett 1992). Evidence suggests that extravasated PMNs that
cannot be cleared via a return to the bloodstream or incorporation into excreta meet their
fate directly at the site of inflammation (Hughes et al. 1997). In contrast, inflammatory
M(|)s do not die in situ, but emigrate to the draining lymph nodes (Bellingan, Caldwell et
al. 1996).
1.4-1 Inflammatory macrophages:
M())s influence almost all aspects of the inflammatory response and play a crucial role in
linking the innate and acquired arms of immunity. Not only are pathogens phagocytosed
and degraded, but also their antigenic components are presented to T cells.
In 1973, van Furth et al showed that inflammatory peritoneal M(|)s were predominantly
derived from blood-borne monocytes, and that the increased numbers present after the
onset of inflammation were therefore predominantly due to recruitment rather than
proliferation in situ (Van Furth, Diesselhoff-den Dulk et al. 1973). Inflammatory M0S
differentiate from blood-borne monocytes, which are themselves derived from precursor
monoblasts, resident in the bone marrow. Monoblasts proliferate in the presence of IL-3
and GM-CSF then differentiate into monocytes in the presence of M-CSF. Once a
monocyte has left the peripheral blood and entered a tissue, differentiation is triggered
(again under the influence of IL-3, GM-CSF and M-CSF which M0 themselves can
elicit). As M<J)s mature they increase their numbers of mitochondria, induce the
production of an array of lysosomal enzymes and reactive oxygen intermediates, up-
regulate Fc and complement receptor expression and develop phagocytic capacity
(Beelen and Walker 1983; Hamilton 1993; Ogawa 1993). Whilst mature M0s retain the
ability to proliferate, their function and lifespan are tissue-dependent. For example,
splenic M(|)s remove erythrocytes from the blood, in the bone marrow they transfer iron
to erythroblasts and in tissues they co-ordinate an inflammatory response in which they
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not only induce injury, but also orchestrate resolution and repair (reviewed in (Janeway
CA 1999)). The mechanisms by which M0 phenotypes are determined are unclear and
are likely to be influenced by exposure to growth factors, transcription factors and pro¬
inflammatory mediators (reviewed in (Valledor, Borras et al. 1998)), including
peroxisome proliferator-activated receptory (PPARy) and members of the
CCAAT/enhancer binding protein (C/EBP) family (refer to section 1.4-3). For example,
Thl cytokine (IFN-y) exposure induces differentiating M0s towards a pro-inflammatory
phenotype, whereas early exposure to Th2 cytokines (IL-4) primes the M0 towards a
non-inflammatory 'alternative' phenotype (Riches 1995; Erwig, Kluth et al. 1998).
The distinction between resident tissue M0s (eg. peritoneal RP M0s) and inflammatory
M0s is less clear. RP M0s appear to be quiescent in as much as they have low synthetic
activity, low RNA content, low oxygen consumption, little or no cytokine secretion but
they do retain phagocytic ability. They are long lived (>50 days) (Melnicoff, Horan et al.
1988; Melnicoff, Horan et al. 1989), and are thought to be replenished by low level
proliferation and immigration from monocytes (Sawyer, Strausbauch et al. 1982).
1.4-2 11P-HSD1 and the immune system:
Previous studies with glycyrrhetinic acid, an 11 P-HSD inhibitor have suggested a role
for 1 lP-HSDs in immunity (Finney and Somers 1958). For example glycyrrhetinic acid
has been shown to inhibit growth and cytopathology of a number of viruses (Pompei,
Flore et al. 1979), an effect that is probably due to the increased GCs associated with the
inhibition of 11(3-HSD2. Also, vascular permeability to leukocytes is decreased by
vasoconstriction after topical administration of GCs, but when combined with
glycyrrhetinic acid, this effect is greatly enhanced (Teelucksingh, Mackie et al. 1990).
However, despite such circumstantial evidence of 11P-HSD involvement, there are only
limited reports of 11 P-HSD expression and activity in the immune system.
Hennebold was the first to suggest an immune function for the 11 P-HSD isoenzymes.
11 P-dehydrogenase activity was detected in homogenates of stromal cells of the
lymphoid organs and thus it was postulated to protect immature lymphocytes from the
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pro-apoptotic effects of GCs (Hennebold, Ryu et al. 1996). Furthermore, inhibition of
this intra-lymphoid 11 P-HSD activity was reported to shift cytokine production by
activated T lymphocytes from a Thl to Th2 profile, and increase susceptibility to
bacterial disease (Hennebold, Ryu et al. 1996; Hennebold, Mu et al. 1997).
Although not in the immune system, a physiological role for the llp-HSDs in the
regulation of ovulatory cycle has been postulated. Tetsuka et al have shown that 11(3-
HSD1 and 11(3-HSD2 in granulosa cells are reciprocally expressed during the ovulatory
cycle, with the expression of 11(3-HSD2 prior to ovulation in a "pro-inflammatory
phase" (culminating in the release of the oocyte), followed by expression of 11 (3-HSD1
in an "anti-inflammatory phase" (the tissue repair of the ovary) (Tetsuka, Thomas et al.
1997; Tetsuka, Milne et al. 1999). Additionally, luteinizing hormone and IL-1 j3 have
been shown to up-regulate 11()-HSD1 gene expression by granulosa cells in vitro, and
therefore increased GCs, generated through the amplification of A to B, may have an
anti-inflammatory role during ovulation (Tetsuka, Haines et al. 1999).
In 2000, 11(3-HSD1 was identified in a subtractive hybridisation screen as induced
during the in vitro differentiation of a human myelomonocytic cell line (Gingras and
Margolin 2000). Later, definitive work by Thieringer described induction of 11 (3-HSD1
expression in human monocyte-derived (MD) M(j)s (Thieringer, Le Grand et al. 2001).
1.4-3 Regulation of 11P-HSD1:
The transcription of 11 P-HSD 1 can be modulated by both endogenous and exogenous
factors. For example, 11 P-HSD 1 is up-regulated by GCs (Low, Moisan et al. 1994) and
thyroid hormone in vitro (Whorwood, Sheppard et al. 1993), and by chronic stress
induced by adjuvant arthritis in vivo (Low, Moisan et al. 1994). In contrast, there is
evidence that down-regulation can be effected by sex steroids (Low, Assaad et al. 1993;
Low, Chapman et al. 1994) and insulin (Hammami and Siiteri 1991; Jamieson, Chapman
et al. 1995). Hepatic sexual dimorphism of 11 P-HSD 1 expression is observed in rats but
not mice, with females having 2-fold lower 11P-HSD 1 expression (Low, Chapman et al.
1994; Rajan, Chapman et al. 1995). This was shown to be due to the continuous (female)
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or pulsatile (male) nature of growth hormone secretion, under the control of sex steroids
(Low, Chapman et al. 1994).
The idea of 11P-HSD1 as a modulator ofGC action within immune cells is an attractive
one. Induction of 11 (3-HSD1 could suffice to amplify GC levels locally within the
inflammatory foci. Likely sources of effector, particularly during inflammation, would
be the cytokines and other mediators of the inflammatory response. The two phagocyte
studies that have been published to date show conflicting results (Escher, Galli et al.
1997; Thieringer, Le Grand et al. 2001). Firstly, studies of mesangial cells (MC), which
share some characteristics with M(|)s, demonstrated up-regulation of 11P-HSD1 by the
pro-inflammatory cytokines, TNF-a and IL-1 (3 (Escher, Galli et al. 1997). In contrast to
this Thl effect, 11P-HSD1 expression in human MD M(|)s was recently shown to be
induced by the Th2 cytokines IL-4 and IL-13; an effect that was abrogated in the
presence of pro-inflammatory IFN-y (Thieringer, Le Grand et al. 2001). In the same
study, the potent inflammatory agent LPS was shown to up-regulate 11P-HSD1
expression in the M())-like cell line, THP-1 (Thieringer, Le Grand et al. 2001).
There is an increasing literature on the regulation of adipocyte differentiation, which
may show parallels to monocyte differentiation. Increased concentrations of GCs in
adipose tissue have been implicated in the pathogenesis of visceral obesity by inducing
adipogenesis and increasing adipocyte lipid metabolism (Ringold, Chapman et al. 1986;
Hauner, Entenmann et al. 1989; Bujalska, Kumar et al. 1997). Adipose tissue exhibits
substantial 11P-HSD1 activity, and 11|3-HSD1 -deficient mice have been shown to resist
insulin resistance and hyperglycaemia (Kotelevtsev, Holmes et al. 1997). In contrast,
transgenic mice which over-express 11P-HSD1 in fat, develop visceral obesity and other
symptoms of the "metabolic syndrome" (Masuzaki, Paterson et al. 2001). Recently,
adipocyte specific induction of 11P-HSD1 by cytokines was shown in vitro (Tomlinson,
Moore et al. 2001). 11P-HSD1 expression in primary adipocytes was increased by




PPARs are ligand-regulated transcription factors. PPARa and y have been shown to be
induced during monocyte differentiation, and PPARy during adipocyte differentiation
(Brun, Tontonoz et al. 1996; Chinetti, Griglio et al. 1998; Tontonoz, Nagy et al. 1998).
In adipocytes, activation of PPARy induces differentiation and genes involved in lipid
metabolism (Rosen, Sarraf et al. 1999), and, in an adipocyte cell line has been shown to
negatively regulate 11P-HSD1 expression (Berger, Tanen et al. 2001). Also, PPARa
agonists have been shown to reduce 11P-HSD1 expression in liver cells (Hermanowski-
Vosatka, Gerhold et al. 2000). Recently associations has been found between PPAR
signaling pathways and monocyte differentiation and lipid metabolism, with PPARy
acting as a negative regulator for M(J) activation (Ricote, Li et al. 1998; Tontonoz, Nagy
et al. 1998). It is unknown whether M(j) llp-HSDl expression would be affected by
PPAR agonists. However it has been shown that PPAR-y expression is inducible by IL-
4, and negatively regulates some M([) pro-inflammatory genes through antagonism of
AP-1 and NF-kB mediated gene transcription (Huang, Welch et al. 1999) (Jiang, Ting et
al. 1998; Ricote, Li et al. 1998). An exacerbated inflammatory response to LPS seen in
PPARa-deficient mice (Delerive, De Bosscher et al. 1999).
Similarly, PPARy has been shown to co-operate with C/EBPa in the promotion of
adipocyte differentiation (Wu, Rosen et al. 1999). Binding sites for C/EBP have been
identified within the 11P-HSD1 promoter region, and C/EBPa has been shown to
positively regulate llp-HSDl expression in hepatoma cells (Williams, Lyons et al.
2000). However, whilst there are no reports of 11P-HSD1 regulation by C/EBP in
immune cells, C/EBP binding sites have been located in promoters ofmonocyte and M<j)
genes such as TNFa and IL-6 (Matsusaka, Fujikawa et al. 1993; Pope, Leutz et al. 1994;
Tanaka, Akira et al. 1995), and C/EBPP has been proposed to be an important regulator
of genes involved in inflammation (Poli 1998). Moreover, C/EBP-e-deficient mice have
been shown to have dysfunctional M(])s (Tavor, Vuong et al. 2002).
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Successful resolution of an inflammatory response is, in part, controlled by the apoptosis
(programmed cell death) of granulocytes. Whilst facilitating PMN deletion (and the safe
disposal of their histotoxic contents) from the inflamed site, apoptosis is also associated
with the functional isolation of the granulocyte from the inflammatory environment by
the loss of stimulated chemotaxis, phagocytosis, degranulation and respiratory burst
(Haslett, Lee et al. 1991; Whyte, Meagher et al. 1993). The crucial distinction between
this form of death and uncontrolled necrosis is that cells dying by apoptosis do not fall
apart and liberate their intracellular contents but rather they retain their membrane
integrity and disappear without damaging surrounding tissue and inciting further
inflammation (Wyllie, Kerr et al. 1980).
1.5.1 Apoptosis:
Wyllie and colleagues first described apoptosis in 1972 (Kerr, Wyllie et al. 1972). Since
then it has been found to permeate almost every aspect of cell biology; blastocyst
formation, tissue re-modelling during development and after damage, negative selection
of lymphocytes, growth and regression of tumours, regulation of haemopoietic cell
number and maintenance of all healthy adult tissues that require cell renewal (Vaux and
Korsmeyer 1999). Despite its occurrence in many different settings, there is uniformity
in the molecular mechanisms and morphology of apoptosis. Typically morphological
changes include loss of contact with neighbouring cells, condensation of nuclear
chromatin, DNA cleavage by endonucleases, cell shrinkage, Golgi disruption, surface
'blebbing' and finally disintegration into membranes-bound bodies (Kerr, Wyllie et al.
1972). Maintenance ofmembrane integrity can be demonstrated by the exclusion of vital
dyes such trypan blue and propidium iodide. Necrotic cells are permeable since they
cannot maintain the ion gradients required to actively pump out the dyes.
The importance of apoptosis is reflected in the level of redundancy between its multiple
effector mechanisms. However, the most completely understood mechanism is that
under the control of a family of cysteine proteases known as the caspases. First
elucidated in Caenorhabditis elegans, activation of the mammalian homologues of
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CED-3 are thought to commit cells to the death pathway through a cascade of protein
cleavage (including nuclear lamins and cytoskeletal actin), disrupting the cellular repair
processes and inducing the morphological changes described above (reviewed in
(Nicholson and Thornberry 1997)). In this mechanism, apoptosis is under negative
regulatory control by CED-9, which can bind CED-4 thereby preventing caspase
activation (Chinnaiyan, O'Rourke et al. 1997; Spector, Desnoyers et al. 1997).
1.5-2 Neutrophil apoptosis:
Early studies showed that aged PMNs, in contrast to fresh PMNs, are recognised by M^s
(Newman, Henson et al. 1982). It was later shown that PMNs are programmed to
undergo constitutive apoptosis, a process sufficient for the specific recognition and
ingestion by M(|)s, whilst still intact (Savill, Wyllie et al. 1989). Apoptotic cells are
swiftly recognised and engulfed by their neighbours or by specialised phagocytes
(Savill, Wyllie et al. 1989; Savill, Smith et al. 1992). Failure or delay in this process
allows the apoptotic cells to undergo secondary necrosis, leakage of intracellular
contents and increases the risk of tissue damage.
However, the lifespan of immune cells can be influenced by exogenous factors. For
example, PMN apoptosis is delayed in response to LPS, complement factor C5a and
GCs - a characteristic not shared by close lineage relatives, the eosinophils (Lee, Whyte
et al. 1993; Meagher, Cousin et al. 1996). Conversely, pro-inflammatory cytokines such
as TNFa accelerate the rate ofPMN apoptosis (Takeda, Watanabe et al. 1993).
There is great debate upon the specificity of the aPMN/ phagocyte recognition process,
and the extent to which PMNs decide their own fate through the expression of surface
markers. Fadok has shown that aPMNs can be characterised by the 'flipping' of
phosphatidylserine (PS) residues from the inner leaf of the cell membrane to the cell
surface, and that M(|)s recognise aPMNs via putative PS-receptors (Fadok, Voelker et al.
1992; Fadok, Bratton et al. 2000). Furthermore, recent work has also shown that healthy
PMNs 'fend off inquisitive M(()s through surface expression of CD31, and when
apoptotic, a now dysfunctional CD31 on the aPMN surface cannot prevent tethering and
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phagocytosis occurring (Brown, Heinisch et al. 2002). Figure 1-5 shows the array of
ligands and receptors that are thought to be involved in recognition and phagocytosis.
1.5-3 Phagocytes:
In 1891 the Russian biologist Metchnikoff observed the engulfment of PMNs by M(j)s in
a 'pricked' tadpole tail (Metchnikoff 1891). These fundamental observations were
extended when the successive events of streptococci ingestion by PMNs, followed by
PMN engulfment by M())s was observed in an erysipelas (acute cellulitis) model
(Metchnikoff 1891). Later, in studies of peritonitis, PMN fate was shown to be that of
engulfment by inflammatory M(j)s (Sanui, Yoshida et al. 1982). Only in recent years
have the importance of these observations been realised. In 1989 Savill et al
demonstrated the non-inflammatory, injury-limiting ingestion of intact aPMNs by M(j)s
in vitro and in vivo (Savill, Wyllie et al. 1989). Subsequently this was found to be
dependent on specific recognition signals, including M(j) vitronectin receptor,
thrombospondin, CD 36 and/ or PS receptor systems (Savill, Henson et al. 1989; Fadok,
Savill et al. 1992; Savill, Hogg et al. 1992).
Of great importance to the inflammatory process are responses elicited by phagocytes
during phagocytosis. The engulfment of pathogenic particles, such as opsonized (Ab-
coated) zymosan, induces M(J) release of thromboxane B2 and other pro-inflammatory
cytokines (Meagher, Savill et al. 1992). However, phagocytosis of aPMNs is crucially
distinguished from the engulfment of pathogenic particles by the failure of the M(j) to
secrete pro-inflammatory factors upon aPMN ingestion (Meagher, Savill et al. 1992;
Stern, Savill et al. 1996). Furthermore, it has been shown that this response is dependent
on the specificity of the recognition process rather than the nature of the 'feed' since
M(J)s elicit a pro-inflammatory response after ingestion of opsonized aPMNs (Meagher,
Savill et al. 1992).
Inflammatory M(j)s secrete pro-inflammatory cytokines when activated by LPS or IL-1(3
(Trinchieri 1997). However, after phagocytosis of aPMNs, not only do M())s fail to
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Figure 1-5: Overview of molecules thought to participate in the recognition and
phagocytosis of apoptotic cells. Diagrammatic representation of molecules active at
apoptotic-cell surfaces and at phagocyte surfaces. Some molecules, TSP, |32gpl and
complement components appear to act as molecular bridges between apoptotic cells and
phagocytes. For convenience, the phagocyte shown is a 'hybrid' of multiple professional
and non-professional phagocytes. Details of receptor-ligand interactions are unknown
but it is thought that the interaction persists once the repulsive effects of CD31 are
down-regulated by the apoptotic process. ABC1- ATP-binding cassette transporter 1,
f32gpl- b(2) glycoprotein I, CR- complement receptor, PS- phosphatidylserine, SR-
scavenger receptor, TLR- Toll-like receptor. Diagram adapted from (Gregory 2000;
Brown, Heinisch et al. 2002).
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regulate Th-1 cytokine release upon subsequent activation (Voll, Herrmann et al. 1997).
This appears to be due to the M0 release of anti-inflammatory TGF(3 (Fadok, Bratton et
al. 1998). This is possibly a mechanism for autocrine deactivation in which a 'fed' M())
secretes TGF(3, which in turn suppresses TNF-a release, thus shifting towards an anti¬
inflammatory phenotype, which may be fundamental to successful resolution.
So far my introduction has focused solely on the M(|) as phagocyte. However phagocytes
can be divided into 2 groups, depending on their primary roles. 'Professional
phagocytes' are those such as human MD M(|)s, M(|)s of the human liver, alveolar and
synovial fluid, murine thioglycollate-elicited peritoneal (TEP) M0s and bone marrow-
derived (BMD) M0s (Savill, Wyllie et al. 1989; Fadok, Savill et al. 1992; Cox, Crossley
et al. 1995; Falasca, Bergamini et al. 1996). In contrast, 'semi-professional phagocytes'
are cell types with a predominantly different function that can also assume a phagocytic
role when required, such as glomerular MC and fibroblasts. They are thought to ingest
neighbouring cells undergoing apoptosis in non-inflammatory situations, as well as
assist 'professional phagocytes' in instances where they are overwhelmed by the number
of aPMNs (Savill, Smith et al. 1992; Hall, Savill et al. 1994).
1.5-4 Mesangial cells:
MC are myofibroblasts that serve a structural role for the glomerulus and provide
housekeeping functions for the maintenance of normal renal physiology. Inflammatory
disease of the kidney, glomerulonephritis, may resolve but since it is usually presents
late it often persists leading to the loss to MC, glomerular scarring and renal failure
(Shimizu, Masuda et al. 1996; Sugiyama, Kashihara et al. 1996). MC can assume a
potentially damaging inflammatory role in such diseases through the release of enzymes,
vasoactive endobiotics, extra cellular matrix components, prostaglandins and cytokines
such as TNFa and IL-P (Pfeilschifter, Schalkwijk et al. 1993). Such pro-inflammatory




In a rat model of glomerulonephritis, Savill and colleagues presented evidence that
aPMNs are cleared, in vitro and in vivo, by both inflammatory M(J)s and MC (Savill,
Smith et al. 1992). Furthermore, as well as ingesting aPMNs, MC can phagocytose
neighbouring apoptotic MC, thus preventing necrosis and protecting the glomerulus
from the release of pro-inflammatory mediators (Baker, Mooney et al. 1994; Shimizu,
Kitamura et al. 1995). In accordance with M(J) studies, the injury limiting potential of
MC was further demonstrated when it was shown that the MC-release of pro¬
inflammatory mediators is down-regulated after the phagocytosis of aPMNs (Hughes,
Liu et al. 1997). Curiously however, phagocytosis of aPMNs by cultured human MC
requires the presence of serum, whereas the same reaction with M(J)s does not (Savill,
Smith et al. 1992).
The untimely apoptosis ofMC and the consequences of necrosis have been implicated in
the development of renal scarring (Shimizu, Masuda et al. 1996; Sugiyama, Kashihara et
al. 1996). Resolution of glomerulonephritis necessitates tissue re-modelling. Recent in
vitro evidence suggests that M())s within inflamed glomeruli can regulate the numbers of
MC present by inducing their apoptosis via NO or TNF-a release (Sugiyama, Savill et
al. 1999; Duffield, Erwig et al. 2000). Addition of pro-inflammatory cytokines increased
MC susceptibility to apoptosis (Duffield, Erwig et al. 2000). This suggests that killing of
resident cells mediated by dysfunctional, inappropriately activated M(j)s may be an
additional source of tissue injury.
1.5-5 Resolution:
To summarise, recognition, phagocytosis and complete degradation of an apoptotic cell
is an extremely efficient form of deletion which has been estimated, in vivo, to take less
than lh (Savill 1997). For example, if 1% of cells in a tissue at any one time were
apoptotic, a deletion time of lh would result in the deletion of a quarter of the tissue
over 24h. However, from the discussion above, it can be postulated that a failure to clear
aPMNs would result in uncontrolled release of toxic contents from secondary necrotic
cells and deprive M(j)s of down-regulatory signals. The resulting persistence of both
inflammation and macrophage-directed killing of resident cells is associated with
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chronic inflammation and autoimmunity (Savill and Fadok 2000; Taylor, Carugati et al.
2000).
1.6 DEFECTS IN CLEARANCE OF APOPTOTIC CELLS
In the previous section I discussed some of the factors that can modulate the rate of
PMN apoptosis (refer to section 1.5-2). One can envisage that necrosis and tissue injury
would result from any dysregulation in which the rate of apoptosis exceeded the
clearance capacity of phagocytosis.
Several causes of perturbed clearance have been identified. Mediators present in the
chronic inflammatory environment such as charged molecules and hydrogen ions have
been shown to impede phagocytosis of aPMNs (Savill, Henson et al. 1989).
Additionally, autoimmunity has been implicated in deficient clearance, and it was
recently shown that treatment with anti-neutrophil autoantibodies accelerated both
apoptosis and secondary necrosis of activated PMNs, thus reducing the time necessary
for safe recognition and phagocytosis (Harper, Ren et al. 2000).
A genetic deficiency of Clq, a complement molecule that bridges between the aPMN
and phagocyte, predisposes humans to the kidney pathology systemic lupus
erythematosus (Morgan and Walport 1991). Clq-deficient mice display severe
glomerular inflammation, and Clq-deficient M(|)s show a clear defect in clearance of
administered aPMNs during thioglycollate-elicited (TE) peritonitis (Taylor, Carugati et
al. 2000).
1.7 POTENTIATION OF PHAGOCYTE CLEARANCE OF APOPTOTIC
CELLS
Many chronic inflammatory conditions are thought to be exacerbated by accumulation
and necrosis of granulocytes. It would therefore be of great therapeutic benefit if an
increase of phagocytosis could be effected in a defective or overwhelmed phagocyte.
Previous reports have shown that phagocytosis of apoptotic cells can either be
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augmented by treatment of M(])s with pro-inflammatory cytokines, or ligation of M<J) CD-
44 (Ren and Savill 1995; Hart, Dougherty et al. 1997). Interestingly, Hart showed that
the CD-44 effect was selective to ingestion of aPMNs, with no ingestion of apoptotic
lymphocytes (Hart, Dougherty et al. 1997). Clearly, potential therapies based on pro¬
inflammatory cytokine treatment could produce undesirable side affects, but the possible
efficacy ofCD-44 treatment remains unexplored.
My research follows from the valuable work of Liu et al, who showed that short-term
treatment ofM0s with synthetic GCs promoted non-inflammatory clearance of aPMNs
(Liu, Cousin et al. 1999). A concentration-dependent promotion of phagocytosis was
seen with pharmacological doses of GCs in human MD M())s as well as murine BMD
M(j)s and TEP M(|)s. Furthermore, the GC-mediated effect was not restricted to the
ingestion of aPMNs since the ingestion of eosinophils and Jurkat T-cells was also
augmented. Nor was it specific to 'professional phagocytes', and it was shown that
human and rat MC responded in a similar fashion. In these in vitro experiments, the GC
effect was mediated via GR (Liu, Cousin et al. 1999).
The specific recognition and phagocytosis of aPMNs by human MD M(|)s, murine M(j)s
and MC have previously been attributed to distinct receptor mechanisms (Fadok, Savill
et al. 1992; Hughes, Liu et al. 1997; Savill 1997). Therefore the effects of synthetic GCs
may represent a novel pan-phagocyte response, and suggest a hitherto unrecognised
facet of the anti-inflammatory effects of GC treatment during the resolution of
inflammation.
In later studies, MD M(J)s that were differentiated in the presence of GC became
programmed to adopt a pro-resolution phenotype in which phagocytic capacity was
enhanced via cytoskeletal reorganisation (Giles, Ross et al. 2001). The degree of
augmentation of phagocytic response was related to both dose ofGC and length of time
of exposure (Giles, Ross et al. 2001). Thus, targeting GC action to the blood borne
monocytes, or to the phagocyte during an inflammatory response may be attractive for
promoting a safe outcome to an inflammatory disease. Clearly the success of this
approach would be dependent on minimising the adverse effects of systemic GC
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exposure, and therefore administration of GCs locally, and directly to the inflammatory
foci would be advantageous.
1.8 AIMS OF THIS STUDY
Many cell types have the ability to amplify GC levels through the re-activation of active
GC from inert 11 -keto steroids. This is accomplished by the expression and activity of
11(3-HSD1. Pharmacological doses of exogenous GCs have been shown to increase M(|)
capacity for aPMNs, whilst endogenous GCs appear to be immunomodulatory. Whilst
immunological phenomena such as the induction of apoptosis in thymocytes by
endogenous GCs have been described, the extent to which adrenal GCs influence the
resolution of inflammation is unexplored. In particular it is intriguing to postulate that a
M0 may act autonomously and regulate its own exposure to GC through 11 (3-reductase
action.
I set out to test the hypothesis that 'the local modulation of GC action by 11P-HSD1
within the M<|) augments clearance of aPMNs during inflammation'.
There were several key aims of the work described in this thesis. For the hypothesis to
be valid M0s must express 11P-HSD1 and the enzyme would be active in the reductase
direction. Therefore the first aim was to establish llfi-HSD isoform expression and
determine enzymatic direction in various types ofM(f)s and in MC.
The hypothesis implies that endogenous GCs would confer an effect in situ so therefore
it should be possible to augment phagocytosis with physiological concentrations of
native GCs. In particular, providing 11 p-reductase activity is present, it would be
expected that augmentation could be conferred by administration of inert A. Therefore
the second aim was to determine the effect of 11 (/-reductase action on the phagocytosis
ofaPMNs by M(j)s in response to native GCs / and to demonstrate the role of 11 (i-HSDl
through the use ofenzyme inhibitors.
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Inflammation is a dynamic process tightly regulated by a plethora of inducers and
repressors. It follows that M0 11 (3-reductase activity should be regulated such that GC is
amplified if and when required. The third aim was to examine the regulation of 11(3-
HSD1 in M(j)s by cytokines and otherpro- and anti-inflammatory mediators.
GCs are required for the differentiation of some cell lineages, and induction of 11(3-
HSD1 and its associated transcription factors are known to influence cell maturation.
M([)s differentiate, activate, mature and down-regulate and, if 11 (3-HSD1 expression is
important for M(|> biology, it is probable that M(J) function or phagocytic ability would be
altered in the absence of 11 (3-HSD 1. Finally, the fourth aim was to use 11 (3-HSD1-










All culture media Invitrogen (Life Technologies), PO Box 35, Free
Phosphate buffered saline (PBS)
Fountain Drive, Incsinnan Business Park,
(without calcium and magnesium) Paisley, PA4 9RF
Hank's balanced salt solution
(HBSS) (without calcium and
magnesium)
Supplements-
Sterile tissue-culture plasticware etc- Costar, Corning Incorporated, Corning, NY
1481.
Teflon culture pots- Roland Vetter Laborbedarf, e.K,
Herrenbergerstr.5, 72119 Ammerbuch, Ger.
Ceil Tracker™ lluorophores Molecular Probes Europe BV, PoortGebouw,




2.1-2 Reagents and antibodies:
Unless otherwise stated all reagents
were purchased from-
Sigma-Aldrich Company Ltd, Fancy Road,
Poole, Dorset, BH12 4QH.
Agarose- BioWhittaker Molecular Applications,
Wokingham, Surrey, UK.
Amberlite ion exchange resin- VWR, Merck House, Poole, Dorset, BH15 1TD.
Antibodies (Rat R PE monoclonal
antibodies to mouse F4-80 and GR-1
and the corresponding IgG-2b
control)-





Brewer's thioglycollate powder- Difco Laboratories, PO Box 331058 Detroit, MI.
Dextran and Percoll- Amersham Pharmacia, Biotech UK Limited,
Amersham Place, Little Chalfont, Bucks HP7
9NA,UK.




IF-4 (Recombinant human IL-4) R&D Systems, 19 Barton Lane, Abingdon
Science Park, Abingdon OX14 3NB
Hybond-H nylon membrane- Amersham Pharmacia (see above).
Hyper film- Amersham Pharmacia (see above).
Methanol- VWR (see above).
Nick columns- Amersham Pharmacia (see above).
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Quantikine ELISA system- R&D systems (see above).
Radio-isotopes ([1,2,6,7-
3H]Corticosterone, specific activity
70.0 Ci/mmol and [cc32P]-dCTP,
specific activity >3000 Ci/mmol).
Amersham Pharmacia (see above).
RNaseZAP- Ambion, 2130 Woodward St, Suite 200, Austin,
Texas.
Saranwrap SC Johnson Wax (Dow), Frimley Green Road,
Frimley, Surrey, GU16 5AJ
Scintillation proximity assay beads- Amersham Pharmacia (see above).
Scintillation fluid (Pico-fluor 40)- Canberra Packard, 14 Station Rd, Pangbourne,
Berkshire RG8 7DT.
Sephadex G-50 column- Amersham Pharmacia (see above).
IX trypsin/EDTA- 0.05% (w/v) trypsin, 0.53mM EDTA, made up in
Ca2+, Mg2+ free Hank's (HBSS).






Promega Corporation, 2800 Woods Hollow
Road, Madison, WI.
DNA size markers (100 Base-Pair
Ladder-
Amersham Pharmacia (see above).
Random primed DNA labelling kit- Roche diagnostics Ltd, Bell Lane, Lewes, East
Sussex, BN7 1LG
Reverse Transcription System- Promega Corporation (see above).
Restriction enzymes- Promega Corporation (see above).
RNA polymerases- Promega Corporation (see above).
TagBeadTM HotStart Polymerase- Promega Corporation (see above).
TLC plates (aluminium sheets,





Cytocentrifuge (Shandon 3)- Shandon Scientific Ltd, 93-96 Chadwick Road,
Astmoor, Runcorn, Cheshire, WA7 1PR.
Eppendorf Centrifuge 5415C(<2ml
vol)-
Eppendorf AG, Hamburg, Germany.
FACS Calibur, FACS Vantage- Becton Dickinson, 21 Between Towns Road,
Cowley, Oxford, 0X4 3LY.
FujiFilm FLA-2000 phosphorimager
and Fuji BAS phosphorimager
tritium screen-
Raytek Scientific Ltd, Sheffield, UK.
Fuji Photofilm Company Ltd, Tokyo, Japan.
Gene Quant RNA/DNA calculator- Amersham Pharmacia (see above).
Labofuge 400R Centrifuge (>15ml
vol)-
Heraeus, Brentwood, Essex, UK
Scintillation counter- Wallac 1450 Microbeta Plus liquid scintillation
counter, 20 Vincent Ave, Crownhill Business
Centre, Crownhill, Milton Keynes,MK8 OAB.
Techne hybridisation oven and
hybridisation bottles-
Techne, Jencons-PLS, Cherrycourt Way,
Stanbridge Road, Leighton Buzzard, LU7 8UA






Becton Dickinson (see above).
Multicalc- Wallac (see above)
Phosphorimage analysis (Aida) Raytek Scientific Ltd, (see above).
Statistical analysis (Excel) Microsoft Corporation
2.1-6 Preparation of buffers and solutions:
Borate buffer- 8.25g Boric acid, 2.7g NaOH, and 3.5ml HC1
(33M) made up to 1L with dfEO, pH to 7.4, then
add 0.5% BSA (0.5g/100ml).
Carbenoxolone solution- Carbenoxolone (Fw=614.7g) was dissolved in
100% EtOH to a stock concentration of lOmM
and stored at 4°C.
C buffer- 63g glycerol, 8.77g sodium chloride, 186mg
EDTA and 3.03g Trizma base made up to 500ml
with dEEO and pH to 7.7.
CM-Green solution- lmg Cell Tracker GREEN CMFDA
resuspended in 1ml DMSO and stored in lOpl
aliquots at -20°C.
DEPC-treated H2O- 0.5L dFEO with 5 drops diethylpyrocarbonate,
left o/n before autoclaving.
De-ionised formamide- Mix 50ml formamide with 3g Amberlite ion
exchange resin for lh, then filter twice.
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DNA polymerase reaction buffer
(10X)
500mM KC1, lOOmM Tris-HCl pH 9, 1% Triton
X-100.
0.5M EDTA (pH 8) 0.8L dH20 with 186.1g Na2EDTA.2H20. pH was
adjusted to 8.0 with NaOH, and volume made to
1L with dH20, before autoclaving.
ELISA Abs Capture Ab- Goat anti-mouse TNFa at 0.8p,g/ml
in PBS. Detection Ab- biotinylated goat anti-
mouse at 300ng/ml in reagent diluent.
ELISA Block buffer: 1% BSA, 5% sucrose in PBS with 0.05% NaN3.
ELISA Reagent diluent: 1% BSA in PBS, pH 7.2, 0.2ftM filtered.
ELISA Substrate solution: 1:1 mixtute of colour reagents A (H202) and B
(tetramethylbenzidine).
ELISA Wash buffer: 0.05% Tween 20 in PBS, pH 7.2.
FACS wash: 2g NaN3, lg BSA in 1L IX PBS.
Griess assay reagents Sulfanilic acid; 470ml dH20, 30mls
orthophosphoric acid stock and lOg
sulphanilamide. N-ethelenediamine solution; lg
N-(l-naphthyl)ethelendiamide dissolved in
500ml dH20. Both stored at 4°C in the dark.
Loading buffer 250mM Tris-HCl pH 7.5, 0.25% (w/v)
bromophenol blue, 0.25% (w/v) xylene cyanol,
40% glycerol.
10X MOPS buffer 200mM 3-[N-morpholino]propanesulfonic acid,




MPO-specific stain for PMNs 300jil DMB (1.25mg/ml o-dianisidine in dH20),
15ml HBBS, 15ml PBS pH 6.2, 4jll1 (30%) H202.
Phosphate buffer 0.2M NaH2P04, 0.6M Na2HP04, 5mM EDTA
made to 1L in dH20 and autoclaved.
Reverse transcription buffer (10X) lOOmM Tris-HCl pH 9, 500mM KC1, 1% Triton
X-100.
20X SSC buffer 175.3g NaCl, 88.23g Na Citrate made to 1L with
dH20 and autoclaved.
Steroids- Dexamethasone (Dex) (FW=392g),
corticosterone (B) (FW=346.5g) and
dehydrocorticosterone (A) (FW=344.4g) were
dissolved in 100% ETOH to a stock
concentration of lOmM and stored at -20°C.
10X TBE buffer 108g Trizma base, 55g boric acid, 20ml 0.5M
EDTA, made to 1L in DEPC H20 and
autoclaved.
TE buffer lOmM Tris-HCl pH 8, ImM EDTA, made to 1L
with dH20, then autoclaved.
Thioglycollate solution (3%) 2.98g ofBrewer's thioglycollate powder




Mice homozygous for a targeted disruption of the 11(3-HSD1 gene have been described
previously (Kotelevtsev, Holmes et al. 1997). The disrupted 11 (3-HSD1 allele was
backcrossed to a C57BL/6 background (8 backcrosses) by Dr. Janice Paterson. Male
mice, aged 8-10 weeks, and age-matched C57BL/6 controls (purchased from Harlan
Orlac, Bicester, UK) were used in all experiments. Animals were housed under
controlled conditions (12h light, 21°C) with unrestricted access to water and standard
chow.
2.2 METHODS
2.2-1 Isolation of human leukocytes from fresh blood:
Leukocytes were isolated from fresh human blood by dextran sedimentation of
erythrocytes, followed by the fractionation of leukocytes by centrifugation on a
discontinuous Percoll gradient as previously described (Savill, Wyllie et al. 1989). This
protocol typically yields populations of granulocytes (98% PMNs) and mononuclear
cells (25% monocytes/ 75% lymphocytes).
40mls fresh blood was drawn from a healthy volunteer through a 19g butterfly needle
and added to 4ml of 3.8% sodium citrate in sterile 50ml polystyrene tubes. 4 such tubes
of blood were usually collected and gentle handling procedures were used to minimise
PMN activation. The tubes were then centrifuged at 350g for 20min at room temperature
(with the centrifuge set on slow deceleration), which separated the erythrocyte fraction
from the platelet-rich plasma. This plasma layer was gently aspirated and 10ml was re-
calcified with 200jLil (5mM) CaCh in a sterile glass vial for lh at 37°C to give platelet-
rich plasma-derived serum (PRPDS), to be used later as autologous serum in the aging
of PMNs and the differentiation ofMD M(J)s.
In order to sediment red cells, 6ml of 6% Dextran (500,000 molecular weight, in normal
saline) was added, the total volume made to 50ml with normal saline and then cells were
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re-suspended by inversion. After 30min, the leukocyte-enriched upper layer was
collected by gentle aspiration into sterile 50ml tubes and centrifuged at 350g for 6min.
Meanwhile, 3 working solutions of Percoll (79%, 68% and 55%) were prepared by
diluting a 90% stock (generated by diluting Percoll 9:1 with 10X PBS at 4°C) with IX
PBS. These dilutions are expressed as percentage of the 90% stock. 2.5ml of the 68%
mixture was slowly overlaid by pipette on 2.5ml of the 79% mixture in a 15ml
polystyrene tube. Next, the pelleted leukocytes from 2 of the 50ml tubes were re-
suspended in 2.5ml of the 55% Percoll mixture and overlaid on the 68% layer to form a
(3-layer) discontinuous gradient. Thus, the 4 tubes collected would yield 2 sample
gradients, which were then centrifuged at 720g for 20min (with no brake).
The mononuclear cells and the granulocytes sedimented to the interfaces between the
79%:68% and 68%:55% layers, respectively. Each cellular layer was carefully removed
into fresh 50ml tubes and washed twice by centrifugation at 220g in IX PBS. The cells
were then counted by haemocytometer, before either the granulocytes (PMNs) were
aged for 24h or the mononuclear cells were differentiated into MD M())s (refer to
sections 2.2-3 and 2.2-4.1).
2.2-2 Preparation of cytospins:
In some experiments cells were prepared for light and fluorescent oil microscopy by
adherence onto glass slides by cytocentrifugation. Cytospins of PMNs and M0s were
prepared by cytocentrifuge (Shandon 3) with appropriate chambers and slide clips.
1 OOjLtl PBS or media containing approximately 0.2X106 cells was loaded into a cytospin
chamber and cells were adhered onto a glass slide by centrifugation at 300 rpm for 3min.
Slides were then air dried, fixed in methanol (2min), stained with standard eosin (2min)
and haematoxylin (2min) and cover-slipped, unless otherwise stated.
2.2-3 Constitutive apoptosis of neutrophils in culture:
Careful isolation of the granulocyte layer from the discontinuous Percoll gradient
(section 2.2-1) would typically yield a 98% pure population of PMNs (assessed by
cytospin), which were viable (not necrotic) when assessed by the ability to exclude 0.2%
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trypan blue solution. PMNs were re-suspended at a density of 4X106/ml in 'complete
PMN/ MD M(J) medium' (Table 2-1), and aged overnight in teflon pots at 37°C, 5%C02.
Examination by cytospin would typically show that >60% of PMNs had condensed,
rounded nuclear chromatin formations and were therefore considered apoptotic (Savill,
Wyllie et al. 1989). Figure 2-1 contrasts the morphology of healthy PMNs and aPMNs
in an aged culture.
2.2-4 Generation of macrophages:
2.2-4.1 Differentiation of human monocyte-derived macrophages:
Mononuclear cells isolated from the Percoll gradient (refer to section 2.2-1) were re-
suspended at a density of 4X106/ml in 'serum-free PMN/ MD M(J) medium'. The
mononuclear cells were initially cultured in 24 well plates for lh before gentle washing
with PBS in order to remove non-adherent lymphocytes. The remaining adherent
monocytes were differentiated into MD M(j)s in 'complete PMN/ MD M<[> medium' over
the course of 4d, with a medium change at d2.
2.2-4.2 Differentiation of murine bone marrow-derived macrophages:
Male mice (aged 8-10 weeks) were killed by cervical dislocation and immersed in 75%
ethanol. In the sterile conditions of a safety cabinet, the skin was removed from the
lower limbs then, using autoclaved surgical instruments, the muscle was dissected from
both femurs. After careful separation of the femurs from the pelvis and tibias, the femurs
were removed into ethanol-filled universal containers then washed in IX PBS. The
femurs were transferred to a sterile petri dish and cleaned by scraping with a sterile
scalpel blade. The proximal and distal ends of each femur were removed just below each
joint and, by inserting a 25g needle into the bone cavity, the soft marrow was gently
flushed with 5ml 'serum-free M0 medium' and collected into a universal container. This
was repeated once from the opposite end of the bone.
Cell number was determined using a haemocytometer and yield was normally -50X106
cells from each mouse. Cells were cultured in 24 well plates at a density of 0.4X106/ml
in 'BMD M(J) medium'. Medium was replaced every 3d and cells were differentiated by
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Growth medium: Contents:
BMD M({> medium Dulbecco's modification ofEagle's Medium (DMEM)/
Ham's F12 (F12) with 'glutamax', 10% v/v heat
inactivated (HI) foetal calf serum (FCS), 10% v/v
conditioned L929 supernatant (see below), supplemented
with penicillin 500U/ml, streptomycin 500U/ml (final
concentration).
Serum-free M(j) medium DMEM/F12 with 'glutamax', supplemented with penicillin
500U/ml, streptomycin 500U/ml.
Complete M<f> medium DMEM/F12 with 'glutamax', 10% v/v HI FCS,
supplemented with penicillin 500U/ml, streptomycin
500U/ml.
Serum-free PMN/ MD M(|)
medium
Iscove's/DMEM, supplemented with penicillin 500U/ml,
streptomycin 500U/ml.
Complete PMN/ MD M0
medium
Iscove's/DMEM, 10% v/v autologous serum (PRPDS)
supplemented with penicillin 500U/ml, streptomycin
500U/ml.
L-929 cells are a murine fibrosarcoma cell line that secretes macrophage colony
stimulating factor (M-CSF), essential for the differentiation of BMD M(|)s. In order to
limit batch variability in M-CSF concentration, a large volume of L-929 conditioned
media was collected and stored at -80°C, to be used when necessary. 15 T162 flasks
were each seeded with 5X106 cells in 'complete M(j) medium' and grown to confluence
over 6d. The conditioned medium was removed from the cells and filtered through a
0.5pm pore filter, combined into a general batch and stored in 10ml aliquots.
Table 2-1: Composition of cell culture media.
















Figure 2-1: Characteristic morphology of aged PMNs. PMNs were isolated from
discontinuous Percoll gradients and aged for 24h (as described in section 2.2-3). A
healthy polylobular PMN (-»), an aPMN (—-), a necrotic PMN ( ) and a contaminating
eosinophil (-►) are indicated.
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d7. BMD M(J)s were considered as differentiated upon up-regulation of surface F4/80
antigens (by flow cytometry), and attainment of phagocytic competency. This
differentiation procedure has previously been validated (Fadok, Savill et al. 1992).
2.2-4.3 Collection ofmurine peritoneal macrophages:
Inflammatory M())s were elicited into the peritoneum by sterile i.p injection of 1ml of 3%
thioglycollate solution. TEP M())s were then harvested at various time-points. Mice were
killed by cervical dislocation (taking care not to rupture the peritoneal cavity) then a
subcutaneous incision was made in the abdomen and the skin was separated from the
intact peritoneum by blunt dissection. The peritoneal surface was wiped with 75%
ethanol and 5ml cold PBS was forcibly injected through a 19g needle. Whilst retaining
the needle in position, at least 4ml of peritoneal exudate was withdrawn, transferred into
a 15ml Falcon tube and kept on ice. TEP M(|)s were then washed by centrifugation at
4°C and counted using a haemocytometer. At 4d after thioglycollate elicited (TE)
peritonitis, a return of 15-20X106 cells was typical.
RP M(|) were collected in a similar fashion from non-injected, healthy mice. It was usual
for a healthy mouse to yield approximately 5X106 RP M([)s. In the event that this number
was significantly higher, or neutrophilia was observed, the cells were discarded because
an un-induced peritonitis was in progress.
2.2-4.4 Selective monocyte depletion:
Access to a murine transgenic model of selective monocyte depletion (on a fvb/nj
background) was generously provided by Dr. Jeremy Hughes, CIR. These mice are
transgenic for human diphtheria toxin receptor (DTR) placed under the control of the
CD1 lb monocyte promoter. Therefore, when challenged with diphtheria toxin, blood
borne monocytes are selectively deleted from the circulation for approximately 48h.
PMNs and tissue M(j)s do not appear to be affected and no evidence of tissue damage is
observed (Dr. Jeremy Hughes, personal communication). A toxin dose of 25ng/g body
weight was given intravenously, 24h before sterile peritonitis was induced.
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2.2-5 Establishment of mesangial cell cultures:
The mesangial cells (MC) were a gift from Dr. Jeremy Duffield, CIR, and have been
described and characterized previously (Kitamura, Burton et al. 1995; Duffield, Erwig et
al. 2000). They were originally derived by clonal selection from single cell preparation
of glomeruli from young Sprague-Dawley rats. MC grow clonally in culture for up to
100 passages, but are typically used between the 10th and 15th passage. MC were
cultured in 'complete M<() medium' and were split every 4d. 24h prior to experiments,
MC were removed from flasks by Trypsin/EDTA treatment and re-seeded in 1ml at a
density of 0.1X106 cells/ml in 24 well plates. Typically each treatment would be over
the course of 24h, and consequently, 48h after seeding, confluency would be reached.
2.2-6 RNA extraction and analysis:
Great care was taken to protect RNA samples from contamination and degradation by
nucleases. All glassware and tubes were autoclaved, and all equipment was treated with
RNaseZap prior to use. All solutions were made with DEPC H2O or were used from
previously unopened nuclease-free stocks.
2.2-6.1 Extraction of total RNA by TRIzol:
TRIzol reagent enables a single step isolation based on a modification of the
Chomczynski and Sacchi method of RNA extraction using guanidium thiocyanate
(Chomczynski and Sacchi 1987).
Portions of liver and kidney were dissected onto dry ice then ground to a paste in liquid
N2 by mortar and pestle. The liquid N2 was allowed to evaporate and, following the
manufacturer's protocol, 1ml of TRIzol solution was added to ~75mg of powdered
tissue. Alternatively, 1ml of TRIzol was added to 7.5X106 cells harvested from M0 or
MC monolayers. The cell suspension was mixed thoroughly and either frozen at -80°C
for later use, or used immediately. 0.2ml chloroform (per 1ml TRIzol) was added to the
suspension, inverted several times, incubated at room temperature for 3min, and then
centrifuged at 12,000g at 4°C for 15min to separate the phenol and aqueous phases. The
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upper aqueous phase containing RNA was removed (care was taken not to touch the
DNA containing interface or the lower protein-containing phenol-choloform phase) and
RNA precipitated by the addition of 0.5ml isopropanol with thorough mixing, incubation
at room temperature for lOmin and centrifugation at 12,000g at 4°C for lOmin. The
supernatant was removed and the RNA pellet was washed with 1ml 75% ethanol by
centrifugation at 7,500g at 4°C for 5min. The pellet was finally allowed to partially air
dry (so as not to compromise solubility) and was then dissolved in 20pl nuclease-free
water by pipetting and incubation for lOmin at 60°C. Samples were stored at -80°C until
required.
2.2-6.2 Assessing RNA integrity:
Concentration and purity were assessed by measurement of optical density, using a
GeneQuant RNA/DNA calculator, lpl RNA solution was diluted in lOOpl DEPC H2O
and quantified by UV absorbance at wavelengths of 260nM and 280nM. A ratio of >1.6
indicates RNA that is free of protein and not de-purinated. RNA integrity was also
checked by electrophoresis of 500ng on a standard 50ml 1% Agarose/ TBE gel
containing 0.005% ethidium bromide (EtBr). Visualisation of the gel under UV light
showed 2 distinct bands (28S and 18S rRNA) above a larger, more diffuse band of
mRNA.
2.2-6.3 Reverse transcription of mRNA to cDNA:
Reverse transcriptase synthesizes single-stranded cDNA from total RNA, and the cDNA
product can be used directly in PCR reactions.
Using Promega's Reverse Transcriptase System, a 20pl reaction mixture was prepared
containing 50ng/pl total RNA, 5mM MgC^, IX Reverse Transcription Buffer, ImM
each dNTP, lU/p.1 RNasin (ribonuclease inhibitor), 15U/pl reverse transcriptase and
0.5pg oligo(dT)i5 primer. Using a 'quick-ramping' thermal cycler the mixture was
incubated at 42°C for 30min to allow extension of the primer, then heated at 99°C for
5min to inactivate the reverse transcriptase and finally rapidly cooled to 4°C. Negative
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controls containing DEPC H2O instead of either reverse transcriptase or total RNA were
performed in parallel.
2.2-6.4 Detection of 11P-HSD1/2 mRNA by PCR:
Promega's 7krgBead Hot Start Polymerase protocol allows the release of Taq polymerase
from a paraffin bead at 60°C, thus minimising the risk of amplifying products generated
from primer-dimer formation or non-specific priming occurring in the reaction mixture
at low temperatures.
The following components were combined in a thin walled 0.5ml PCR reaction tube in
DEPC H2O to a volume of 50p,l; 5pl of reverse transcription reaction product, IX DNA
polymerase reaction buffer, 0.2mM of each dNTP, 1.5mM MgC^, 0.1 pM of each
primer. Lastly, 1 TaqBead (1.25U/bead) was added. Upon melting, the wax is not
enough to seal the reaction, therefore each reaction was additionally sealed with mineral
oil. Negative controls containing DEPC H2O instead of either reverse transcriptase or
total RNA were performed in parallel.
The primer sequences were:
11 p-HSD 1, 5' primer, 5AGGATCCAG/AAGCAAACTTGCTTGCA -3'
3' primer, 5'- AAAGCTTGTCACA/TGGGGCCAGCAAA -3'
11 (3-HSD2, 5' primer, 5'- GCTGCTGCAGATGGACCTGACCAAGC -3'
3' primer, 5'- GCTCATGTATTTCATCCACCACTA -3'
The cycle conditions were 95°C for 4min, 62°C for 45s, 72°C for lmin. A total of 35
cycles were carried out followed by a lOmin extension at 72°C, before being held at 4°C
for retrieval. The 11(3-HSD1 amplify a 461bp fragment ofmouse, human and rat cDNA
and have been described previously (Rajan, Chapman et al. 1995). The 11(3-HSD2
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primers were a gift from Dr. Roger Brown, MMC. They amplify a 144bp fragment in
the C-terminal half of the coding region ofmouse, human or rat cDNA.
2.2-6.5 Assessing RT-PCR product:
RT-PCR products were run on a 150ml 1% Agarose/ TBE gel containing 0.005% EtBr.
10|il product was mixed with lpl loading buffer and electrophoresis was carried out in
TBE at 150V for 30min, then the gel was viewed under UV light (wavelength 260nm).
l|ig of DNA size markers (100 base-pair ladder) was used in order to confirm sizes of
amplified products. 11 (3-HSD1 and 11[3-HSD2 amplification is confirmed by the
presence of 461 bp and 144bp bands respectively.
2.2-7 Northern blotting
2.2-7.1 RNA electrophoresis :
Total RNA was separated on a 100ml 1.2% agarose/ formaldehyde denaturing gel. 1.2g
of agarose was dissolved in 98ml IX MOPS buffer in a microwave oven. Once cooled to
50°C, 2ml formaldehyde (37% stock) was added. The molten gel was poured into a
sealed gel tray with combs in place, allowed to set over lh, and pre-soaked in an
electrophoresis tank filled with IX MOPS buffer for approximately 30min.
25|ig samples of RNA were added to DEPC H2O to give a volume of 10pl, and then
2.5pl formaldehyde (37%), 2.5pl 10X MOPS buffer and lOpl de-ionised formamide
were added and mixed thoroughly. Samples were then heated for 15min at 65°C in order
to denature the RNA. On ice, 2pl loading buffer was added to each sample before
electrophoresis at 100V for approximately 3-4h, or until the bromophenol blue dye front
had advanced 3/4 of way down the gel. The inclusion of 0.005% ethidium bromide to
each sample at the loading stage allowed the RNA to be briefly visualised under UV,
permitting the integrity of the RNA and the equivalence of loading to be assessed.
2.2-7.2 Capillary transfer to nylon membrane:
To allow capillary transfer of RNA, a piece of nylon membrane, and 3 pieces of filter
paper of identical sizes to the gel to be blotted were pre-soaked in 20X SSC. A wick of
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similar width to the gel, but double the length was cut from filter paper and placed on an
up-turned gel tray so that the ends were immersed in a reservoir of 20X SSC which
would later act as the source of transfer buffer.
On completion of electrophoresis the gel was pre-soaked for 20min in 20X SSC and
then inverted onto the wick. The nylon membrane was then placed upon the gel, and the
rest of the surface of the gel (apart the area containing RNA) was sealed with clingfilm-
thereby ensuring that all capillary transfer of fluid would have to pass directly through
the portion of the gel that was in contact with the membrane. Bubbles were gently
smoothed from the membrane and the 3 layers of filter paper were placed on top
followed by a stack (approximately 3 inches) of dry paper towels. A glass plate was
placed on top so as evenly distribute weight across the stack and capillary transfer was
left to proceed overnight at room temperature. Following transfer, the apparatus was
dismantled and the membrane rinsed in 20X SSC. Both membrane and gel were viewed
under UV light to ensure complete transfer of RNA. The RNA was cross-linked by UV
irradiation of 700,000 Joules and then the membrane was baked at 80°C for 2h.
2.2-7.3 Hybridisation to 32P- labelled 11P-HSD1 cDNA:
The nylon membrane was soaked in 20X SSC for lOmin, and then pre-hybridised by
placing in a pre-warmed hybridisation bottle containing 12ml phosphate buffer and 6ml
20% SDS at 55°C. Sonicated salmon testis DNA (lOmg/ml; lOOpl) was denatured at
99°C for lOmin, cooled on ice and then added to the hybridisation mixture and pre-
hybridisation proceeded at 55°C for 3h.
Meanwhile, rat 11P-HSD1 cDNA was labelled with [a32P]-dCTP using a random
primed DNA labelling kit (Boehringer Mannheim). The cDNA encoding rat 11P-HSD1
was a 1.1 kb EcoRl fragment which has previously been described (Agarwal, Monder et
al. 1989). 25ng of cDNA , made to 9pl with dFEO was denatured at 100°C for lOmin and
immediately placed on ice. To this was added 2|il hexanucleotide primer reaction mix
supplied with the kit, lp,l each of dTTP, dATP and dGTP, 5pl [a32P]-dCTP and lpl
(5U) Klenow enzyme before briefly mixing and incubating for lh at 37°C. After this
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time, the reaction was briefly heated to 99°C to inactivate the polymerase and then the
labelled cDNA was separated from unincorporated [a32P]-dCTP by passage over a Nick
column equilibrated with 3ml TE buffer. The reaction was added to the Nick column and
two 400pl volumes of TE buffer were eluted through the column. The first was
discarded and the second, (containing 32P-labelled cDNA) was collected, lpl of this
purified probe was added to 1ml of scintillant fluid and counted on a liquid scintillation
counter. Typically a lpl aliquot of purified probe contained 4X107 cpm. The probe was
then denatured (100°C for 5min) and added to the pre-hybridisation mixture for over¬
night hybridisation at 55°C.
The hybridisation mixture was disposed of and the membrane was washed to remove
non-specific hybridisation. An initial rinse in IX SSC, 0.1%SDS was followed by 2
room temperature washes in IX SSC, 0.1%SDS each for 20min. The membrane was
then washed in 0.3X SSC, 0.1%SDS for 20min at 55°C. The [a32P] on the membrane
was monitored by Geiger-Muller counter, and if deemed too high, the final wash was
repeated. Without letting the membrane dry, it was wrapped in Saranwrap and exposed
to autoradiographic film for up to 2 weeks at -80°C.
2.2-8 Steroid/ drug treatment of macrophages and mesangial cells
2.2-8.1 Steroid/ carbenoxolone treatment in vitro:
Stock steroids and carbenoxolone were diluted in lxPBS to working concentrations.
Control cultures were treated with the appropriate concentration of ethanol (EtOH)
vehicle (equivalent to that of the treatment groups). No effects are of EtOH were found
at concentrations less than 0.001%. Steroids were added for 24h or 48h, as stated in the
text.
2.2-8.2 Collection of pro-inflammatory supernatant:
4h after sterile i.p injection of 1ml of 3% thioglycollate solution, mice were killed by
cervical dislocation and their peritoneal cavities were exposured by dissection as
described in section 2.2-4.3. A 19g needle was inserted intra-peritoneally and with
gentle pressure by hand to either side of the peritoneum, fluid pooled in the cavity
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formed by the bevel of the needle. Typically, approximately 1ml of exudate fluid was
recovered from each mouse. The exudate was centrifuged at 300g for 6min to remove
cell debris and the supernatant collected under sterile conditions. The active constituents
of this supernatant were not investigated, however 50pl was added to 1X106 M(J>s
cultured in each well of a 24-well plate. Control cells were treated with PBS.
2.2-8.3 Steroid treatment in vivo:
0.4 mg/kg of Dex was injected i.p on d2 of TE peritonitis using a 25g needle. This gave
a total body concentration of approximately 200nM, assuming a 25g mouse had a total
volume of 25ml.
2.2-9 Measurement of 11P-HSD activity
11P-HSD activity is reported as % conversion of 200nM A to B, or 200nM B to A,
representative of 11 P-reductase activity or 11 P-dehydrogenase, respectively.
2.2-9.1 Preparation of [3H] 11-dehydrocorticosterone:
[3h]-a is generated from commercially available [3h]-b by incubation with rat placental
homogenate. This provides a rich source of 11P-HSD2, which has exclusive lip-
dehydrogenase activity. a high concentration of nad ensures that co-factor is not
limiting.
240)0,1 of stock [3H]-B (in toluene) was dried under a flow of air and re-suspended in
lOOpl pure ethanol. Approximately one half of a rat placenta was homogenized in 1ml C
buffer and 600jol was added to the re-suspended [3H]-B with 400jol 2mM NAD and
8.9ml C buffer. The mixture was split between two 50ml glass tubes, covered and
incubated with gentle shaking at 37°C for 3h. The reaction was stopped and steroids
extracted by addition of 2 vol ethyl acetate followed by centrifugation (Labofuge) at
2000rpm for 15min. The upper solvent layer was transferred into a clean 5ml glass
bottle, dried under air then re-suspended in 500p,l ethanol. lpl aliquots were analysed by
HPLC (by C. Christy, MMC) to ascertain purity (routinely >98%) and by scintillation
counter to determine specific activity. Subsequent re-analysis showed that [ H]-A is
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stable at -20°C for at least 4 months before any discernable loss of purity through
reversion to [3H]-B occured.
2.2-9.2 liP-reductase and liP-dehydrogenase assays:
11 (3-HSD reductase and dehydrogenase activity in intact cell monolayers was
determined as previously described (Low, Chapman et al. 1994), with minor
modifications. Tritiated steroids and 'cold' steroids were added to 1ml culture medium
so that the final concentrations were 2nM [3H]-A or -B combined with 200nM unlabeled
A or B respectively. Thereby the specific activity was reduced 100-fold, and the total
steroid concentration was 202nM. 1ml steroid was then overlaid onto monolayers of
IX106 M())s or MC in 24-well plates and, in order to measure product formation with
time, 200pl samples were taken at various times. A control in which steroid was added
to an empty well was included to give background level of conversion and sample
purity.
2.2-9.3 Thin layer chromatography:
Steroids were extracted from culture medium in 2 vol ethyl acetate by centrifugation
(Eppendorf) at 12,000 rpm for lOmin. The organic phase was removed to a glass vial
and dried under air. [ H]-steroids were re-suspended in 50pl ethanol (containing a
mixture of unlabeled A and B in ethanol, each at 5mg/ml, in order to aid visualisation of
product separation under UV light at a later stage). lOpl of the samples was repeatedly
spotted onto a thin layer chromatography (TLC) plate until all 50pl had been loaded
onto its lane and the plate placed in a solvent tank containing 100ml of chloroform/
ethanol (92:8). After approximately 45min the solvent front had reached the top of the
plate and, once dry, the separation of A and B was evident by the ability of the steroids
to fluoresce under UV light. Quantitation of conversion was achieved by 5d exposure of
the TLC plate to tritium sensitive phosphorimager screen and phosphorimager analysis,
using Aida software. 11(3-HSD1 activity is calculated as % conversion of 200nM A to B
(11 (3-reductase) or B to A (1 l(3-dehydrogenase). This was achieved by imaging plate IP
analysis, during which the intensity (pixelation) of background was subtracted from the
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intensities of samples. % conversion was then calculated by comparison with the
treatment only control.
2.2-10 Phagocytosis assays
2.2-10.1 In vitro phagocytosis assay:
The in vitro phagocytosis assay for both M([)s and MC has been previously described
(Savill, Henson et al. 1989; Savill, Wyllie et al. 1989; Savill, Smith et al. 1992). It takes
advantage of the fact that myeloperoxidase is present in PMNs but not M(j)s or MC.
Using hydrogen peroxide and dimethylbenzidine as substrate, myeloperoxidase (MPO)
activity stains PMNs brown and therefore PMN engulfment within translucent M(|)s can
be easily scored by inverted light microscopy (Newman, Henson et al. 1982).
Phagocytosis assays were only performed with aged PMN populations that were >60%
apoptotic by morphological analysis. Aged PMNs were washed in IX PBS by
centrifugation at 220g, and re-suspended in the appropriate medium at a number
approximately 3-4 times that of the M<J) or MC monolayer. PMN suspensions for McJ)
interactions were in 'serum-free PMN/ MD M(() medium', whilst those for MC
interactions were in 'complete M0 medium' (Savill, Smith et al. 1992).
M(J) (MD, BMD and TEP M(J)s) and MC monolayers were gently washed with IX PBS,
and 1ml of the aged PMN suspension was overlaid onto the phagocyte monolayer. After
incubation for 30min or 2h (M(j) and MC respectively) at 37°C, 5% CO2, medium was
removed and cells were gently washed by aspiration with cold IX PBS to remove non-
ingested PMNs then fixed with 2% formalin solution for 15min.
After fixing, the cells were washed with IX PBS and stained with 500|il MPO-specific
PMN solution for 30min at 37°C and cells visualised by inverted light microscopy. In
vitro, PMNs are still largely intact within the M([>s after these short incubation times, and
therefore it was possible to determine both the number of M())s which have ingested one
or more PMNs and the 'phagocytic index'- a more accurate measure of phagocytic
capacity in which the number of aPMNs ingested by 100 M(j)s were scored.
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In experiments in which latex beads were used as phagocytic feed, 0.2pm fluorescent
beads were suspended in 'serum-free PMN/ MD M0 medium' and added to 1X106 M(J)s
(at a ratio of 5:1) for 30min. Latex beads are easily observed by either light or
fluorescent microscopy.
2.2-10.2 In vivo phagocytosis assay:
A fluorescent based assay to measure TEP M(J) phagocytic capacity in vivo was
developed (Dr. Graham Thomas, CIR) in which CM-Green labelled PMNs were
exogenously administered by i.p injection. CM-Green is a lipophilic thiol group-reactive
dye that has been shown to reproducibly label PMNs without compromising the
constitutive apoptotic pathway or ability to be ingested (Stuart, Lucas et al. 2002).
Prior to aging, freshly harvested PMNs were suspended at 20X106/ml in 'serum-free
PMN/ MD M(|) medium' containing 5pl of lmg/ml CM-Green solution. Cells were
incubated for 25min to allow labelling, after which time cells were diluted to 4X106 with
'complete PMN/ MD M(J) medium'. The addition of serum for aging at this stage is also
advantageous since serum proteins 'mop up' free CM-Green that has not been taken up
by the PMNs and which would otherwise be carried over into the phagocytosis assay.
PMNs were then aged as described in section 2.2-3.
CM-Green labelled aged PMNs were washed once in IX PBS by centrifugation at 220g
and re-suspended at 30X106/ml in IX PBS. Using a 19g needle, 30X106 PMNs
(approximately 2:1 ratio to TEP M([), see section 2.2-4.3) were carefully injected i.p into
mice at various stages of TE peritonitis. After exactly lOmin, mice were killed by
cervical dislocation and peritoneal exudate was collected onto ice using a 5ml bolus of
PBS through a 25g needle as described in section.
2.2-10.3 Immuno-labelling of macrophages for fluorescent microscopy and
flow cytometry analysis:
To inhibit antibody capping, all procedures were carried out at 4°C. 0.5X106 M0s or
peritoneal cells were washed with IX PBS by centrifugation at 220g and re-suspended in
200|ll FACS wash containing 10% FCS (in order to block non-specific binding) by
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gentle agitation in polystyrene tubes. After 15min, anti-F480 PE or rat IgG2b-PE isotype
antibody was added at a 1:50 dilution (manufacturer's suggested concentration) and
incubated in darkness for 45min. (F4/80 is a M0 surface antigen that is commonly used
as a marker of differentiation). Unbound antibody was removed by 2 washes with IX
PBS by centrifugation at 300g for 5min.
For fluorescent microscopy, cells were fixed in 2% formalin for 15min and cytospins
prepared as described in section 2.2-2. Once air-dried, cover-slips were applied in order
to view the cells under oil.
For flow cytometry analysis, cells were re-suspended in 300pl PBS and specific and
non-specific fluorescence determined by processing >5000 cells/sample through a FACS
Calibur machine, using Cellquest software. It was necessary to include appropriate
controls to aid gating. Controls included PMNs alone and TEP M(j)s/ peritoneal cells
alone. For flow cytometry-based experiments in which surface GR-1 expression was to
be detected, anti-GR-1 PE antibody was used under identical conditions as anti-F4/80
PE.
2.2-10.4 Quantifying phagocytosis by flow cytometry:
Due to the time-consuming nature of scoring MPO-stained cells by eye, a flow
cytometry based protocol was developed to quantify phagocytosis levels. PMNs were
stained with CM-Green prior to interaction with Mcjis. Once harvested, the cell
population was stained with anti-F4/80 (refer to in section 2.2-10.3) and taken to FACS
Calibur. Controls included PMNs alone and M<|)s alone, and appropriate rat-anti mouse
isotype. F4/80 labelled M(])s and CM-Green-labelled PMNs are gated in FL2 and FL1,
respectively. The comparative shift of a population into the red/green quadrant is
representative of interaction between a M0 and an aged PMN, and was analysed using
CellQuest software. The geometric mean fluorescence of cells positive to isotype control
was used in analysis. Such are the fluid pressures exerted upon the cells during flow
cytometry that this interaction is most probably that of ingestion, rather than binding.
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2.2-11 Analysis of peritoneal supernatant
2.2-11.1 Measurement of TNFa levels:
TNFa levels were measured by ELISA. Following collection of TEP M(J)s, the
supernatant from the lavage was collected by centrifugation at 4°C, 220g for 15min, and
stored at -80°C until use. TNFa levels were detected by Quantikine ELISA system
carried out according to the manufacturer's instructions. 96 well plates were coated with
capture antibody (100p.l per well), sealed and incubated o/n on a shaker at room
temperature. Each well was aspirated and carefully washed 3 times with wash buffer.
Each well was blocked with 300pl blocking buffer for 2h, and washed as before.
Standards (1:2 dilution of 0-1000pg/ml) were prepared with recombinant mouse TNFa
diluted in reagent diluent. 1 OOpil of either standards or samples were added per well,
sealed and incubated for 2h at room temperature. The plates were washed as before and
lOOpl Streptavidin-HRP (1:200 dilution of manufacturer's stock in reagent dilutent) was
added to each well and the plate was incubated in darkness for 20min, before the
washing procedure was repeated. 100p.l substrate solution was added to each well and
the plate was incubated in darkness for 20min before addition of 50pl stop solution (2N
H2SO4). Optical densities were determined using a microplate reader set to 450nM, and
TNFa concentrations were determined by comparison to the standard curve.
2.2-11.2 Measurement ofNO levels:
NO activity was measured indirectly by Griess assay which detects nitrite, the major
stable product ofNO generation.
Equal volumes of Griess reagents (sulfanilic acid and N-ethelenediamine) were mixed
together immediately prior to the assay. 140p,l peritoneal supernatant was mixed with an
equal volume of Griess reagents in a 96-well plate and absorbance measured after 15min
at 540 nm. A standard curve was generated using a serial dilution of sodium nitrite (0-
100p,M), mixed with equal volumes of Griess reagent and absorbance measured as
above. Nitrite concentration in the supernatants was calculated as |iM concentration by
comparison to the standard curve.
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2.2-11.3 Measurement of corticosterone levels:
"5
B levels were measured by radioimmunoassay, in which unlabelled sample B and [ H]-B
compete for anti-B Ab. The concentration of B in each sample was determined from the
standard curve. However, this method is not a quantitative method for determining free
B levels since B is dissociated from CBG. It therefore measures total B concentration.
Samples of peritoneal fluid were diluted 1:5 in borate buffer and heated at 65°C for
30min to denature CBG and allow dissociation of B. A series of B standards were
prepared (0-320nM) to allow production of a standard curve. Samples and standards
• ••• .. 3
were incubated in duplicate in flexible 96-well plates with a mixture of [ H]-B
(10,000cpm added per sample) and B antibody (1 in 10,000 dilution of rabbit anti-rat B
antiserum in borate buffer; kindly provided by Dr. Chris Kenyon, MMC) in borate
buffer in a total volume of 70jo,l for lh at 37°C. Anti-rabbit scintillation proximity assay
beads were then added to each sample and the plates sealed and incubated overnight at
37°C. The beads bind to the primary antibody and, if the primary antibody is bound to
[3H]-B, the beads cause scintillation of the radioactive signal, detectable by (3-
scintillation counter using Multicalc software. The inter- and intra-assay coefficients of
variation were <10%, and the detection limit was 0.15p,g/dl.
2.3 STATISTICAL ANALYSIS
Data are expressed as Mean of values +/- Standard Error ofMean (SEM) as noted in the
figure legends. Single or low repetition experiments are described in the text and where
appropriate Mean of values +/- data range is shown.
Analysis was performed using Microsoft Excel software. Significance between 2
variables was determined using the student's t-test and, where appropriate, significance
between multiple variables was determined by ANOVA. For data analysis, p was set to
<0.05 or <0.001, as illustrated in the text by * for p<0.05 or ** for p<0.001 respectively.
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3.1 INTRODUCTION
Recent studies demonstrate a role for Dex in promoting the safe clearance of aPMNs by
M(t> and MC (Liu, Cousin et al. 1999). In these in vitro studies, GC was acting via GR;
since the effects were abrogated by pre-treatment with the GR antagonist RU38486
(reviewed in Chapter 1). There is considerable evidence that the association between
endogenous GC and GR can be profoundly modulated by pre-receptor metabolism of
GC by liP-HSDs (Seckl and Chapman 1997). Of the 2 11P-HSD isoenzymes
characterised; 11(3-HSD2 exhibits exclusively dehydrogenase activity both in vitro and
in vivo, and 11 (3-HSD1 is a reductase in most intact cells in vitro (and amplifies GC
action in specific tissues) (Kotelevtsev, Holmes et al. 1997).
There are only limited reports of 11(3-HSD expression in the immune system. 11(3-
dehydrogenase activity has been detected in stromal cells of the lymphoid organs and,
although unproven, the activity is presumed to be that of 11 (3-HSD2 (Hennebold, Ryu et
al. 1996). Indeed, inhibition of this activity was reported to switch cytokine production
by activated T cells from a Thl to Th2 profile. By drawing an analogy with adipocyte
differentiation (refer to section 1.4-3), it is possible that local GC action in immune cells
could be modified in a cell-specific or stage-specific fashion by the action of 1 l(3-HSDs.
M<J)s and MC are GC-sensitive, and may therefore exhibit 11P-HSD action. The first aim
of this work was to establish which, if either, iso-enzyme was expressed and the
direction of its activity - thereby establishing a potential for local GC modulation.
3.2 RESULTS
3.2-1 11{3-HSD1, but not 11P-HSD2, is expressed in macrophages and mesangial
cells
To determine whether 11P-HSD1 and/ or 11P-HSD2 are expressed by phagocytes, RT-
PCR was carried out on lpg RNA isolated from a range of human and murine M0s, as
well as rat MC (Table 3.1).
64
Chapter 3:11 P-HSD1 is expressed in macrophages and mesangial cells, and is active as a reductase
Cell type Species
Bone Marrow-derived Macrophages (BMD M<j>s) C57 BL/6 mouse
Resident Peritoneal Macrophages (RP M(j)s) C57 BL/6 mouse
Thioglycollate-elicited Peritoneal Macrophages (TEP M())s) C57 BL/6 mouse
1 lp-HSDl -deficient BMD M0s C57 BL/6 mouse
Monocytes Human
Monocyte-derived Macrophages (MD M0s) Human
Cultured Mesangial Cells (MC) Rat
Table 3.1 Range of GC-responsive phagocytes chosen for study.
RNA from liver (which expresses llp-HSDl) and kidney (which expresses both
isoenzymes) were used as positive controls. Appropriate negative controls were included
(section 2.2-6.4). Note that the 11 (3-HSD1/2 primers utilised are not species-specific.
A 461 bp RT-PCR product of identical size to the hepatic 11(3-HSD1 RT-PCR product
(Rajan, Chapman et al. 1995) was synthesized from RNA from murine BMD M0S, RP
M([)s and TEP M(|)s. In contrast, no 11(3-HSD2 RT-PCR product was detected in murine
M<J) samples, whilst being clearly present in kidney RNA, giving rise to a 144 bp product
(Fig.3-1 A). No 11P-HSD1 or 11(3-HSD2 RT-PCR products were detected in 11(3-HSD1-
deficient BMD M(j) samples, confirming the specificity of the reaction (Fig.3-1B).
Interestingly no 11 (3-FTSD1 RT-PCR product was generated by RNA from human
monocytes, but was detected in MD M(j) RNA taken at d2 and d4 of differentiation
(Fig.3-lC). Again, no 11(3-HSD2 RT-PCR product was detected in these samples.
Similarly, rat MC expressed 11 (3-HSD1 but not 11(3-HSD2 mRNA (Fig.3-lC).
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11P-HSD1
11p-HSD2
Figure 3-1: lip-HSD mRNA is expressed in cells of M<|) lineage. A, RT-PCR
showing that mRNA for 11[5-HSD1 was detected in murine BMD M<f>s, RP M<j>s, and
TEP M<j)S (harvested at d3 of TE peritonitis). B, mRNA for 11 (3-HSD1 was not detected
in either BMD M<j)s from 1 lp-HSDl-deficient mice or, human monocytes freshly
isolated from peripheral blood (dO) (C). C, both human peripheral blood monocytes (on
d2 and d4 of culture) and rat MC expressed 1 ip-HSDl. 11P-HSD2 mRNA was not
detected in any of the cell types studied. Kidney and liver were used as positive controls
for 1 ipHSD-2/1 respectively (kidney expresses both). 1 pg RNA yielded 11(3-HSD1 or
11(1-HSD2 RT-PCR products of 461 or 144 bp respectively. Images are of single gels,
and are representative images of RT-PCR reactions carried out on at least 3 different
mRNA samples of each cell type.
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3.2-2 Macrophage and mesangial cell 11P-HSD1 mRNA is detected by Northern
blot analysis
RT-PCR is a very sensitive method of analysis, detecting even very low levels of
expression. Northern blot analysis provides a more quantitative assessment of RNA
levels. The expression of 11P-HSD1 mRNA in mouse M0s and rat MC was examined
by analysis of 25|ig total RNA, separated on a denaturing agarose gel. Hybridisation to
radiolabeled rat 11P-HSD1 cDNA (91% homology to murine 11P-HSD1 (Rajan,
Chapman et al. 1995) identified a single 11P-HSD1 mRNA transcript of 1.4 kb in
differentiated BMD M(|)s, TEP M(|)s and rat MC, albeit at lower levels than in liver and
kidney (the loading of liver RNA was less than intended due to error) (Fig.3-2). The size
of the sample 11P-HSD1 mRNA transcript was verified by comparison to known and
well established 11P-HSD1 mRNA transcripts in liver and kidney. Rajan et al used rat
11P-HSD1 cDNA probe to detect murine 11P-HSD1 mRNA by Northern blot (Rajan,
Chapman et al. 1995). Very small amounts, if any, 11P-HSD1 mRNA was detected in
fresh bone marrow, blood, RP M0 or 11P-HSD1-deficient BMD M(j) samples, despite
the loading of approximately equivalent amounts of total RNA. No 11P-HSD2 mRNA
was detected in any of the samples, consistent with the negative RT-PCR results (data
not shown).
3.2-3 11P-HSD1 functions exclusively as a reductase in intact macrophages and
mesangial cells
With very few exceptions, 11P-HSD1 functions in the reductase direction only, although
it is bi-directional in homogenates (reviewed in section 1.3).
To determine whether the 11P-HSD1 mRNA present in murine and human M0s, and rat
MC encodes an enzyme with dehydrogenase or reductase activity, both 11P-
dehydrogenase and 1 lP-reductase assays were carried out on intact cells.
All WT murine M0S displayed 1 ip-reductase activity (Fig.3-3). Similarly, 11P-
reductase activity was detected in murine WBC and rat MC, but not in 11P-HSD1-
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Figure 3-2: Murine M<j> lip-HSDl mRNA is detectable by Northern blot
analysis. 1 lp-HSDl mRNA was detected in BMD M<|)S cultured for 7d (d7), TEP M<|)s
harvested at d3 of TE peritonitis and rat MC. Little or no lip-HSDl mRNA was
detected in bone marrow cells (dO), fresh blood collected by cardiac puncture, RP M<(>s
and BMD M<j>s from 11 (3-HSD1 -deficient mice. Inclusion ofEtBr during electrophoresis
allowed equivalence of loading to be confirmed under UV light (data not shown). 25pg
of each sample was analysed, whereas 40pg of kidney and liver were included as
positive controls. Blot exposed to film for 12d.
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Figure 3-3: Murine 11J3-HSD1 functions exclusively as a reductase in intact
cells. 11(3HSD-1 activity is reported as % conversion of200nM A to B (11 (3-reductase)
or B to A (11 (3-dehydrogenase) by 106 cells over 24h. BMD M(()s (cultured for 7d), TEP
M())s harvested at d3 of TE peritonitis and rat MC exhibited significant and exclusive
11 (3-reductase activity, whereas RP M0s and white cells (isolated by red cell lysis from
fresh peripheral blood drawn by cardiac puncture) (WBC) exhibited a moderate
reductase activity. No 11 (3-reductase activity was detected in BMD M(J)s from 11(3-
HSD1 -deficient mice (KO). No samples had a 11 (3-dehydrogenase activity above
background level. Values are Mean +/- SEM of 4 separate experiments carried out in
duplicate.
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deficient Mcjis (Fig.3-3). 11 (3-reductase activity levels detected in cultures of RP M<()s
and WBC appeared lower than in BMD and TEP M(J)s (Fig.3-3). M(J)s retained the ability
to exclude trypan blue exclusion after completion of bioassays, suggesting that the
comparative levels measured were representative of inherent M(J) activity differences
rather than unequal loss of cell viability over 24h.
In contrast, 11 (3-dehydrogenase activity was undetectable in all intact cell types studied
(Fig.3-3). The marginal 11 (3-dehydrogenase activity observed in rat MC culture medium
was most probably due to the low percentage of cell death and lysis associated with
highly proliferative cell cultures, since it was not present in cultures seeded at low
densities (data not shown).
In accordance with the 11P-HSD1 RT-PCR results, no 11 (3-reductase activity was
detected in human monocytes. However, activity was induced by d2 of in vitro
differentiation (Fig.3-4).
In contrast to murine WBC, no 11 p-reductase activity was detected in either human
whole blood, or isolated PMNs (Fig.3-4). No 11 (3-dehydrogenase activity was detected
in any human blood cell or MD M<() culture (Fig.3-4).
3.3 DISCUSSION
This study shows that 2 classes of phagocytes (M(j)s and MC) express 11P-HSD1, and
not 11P-HSD2. 11P-HSD1 transcripts were detectable by RT-PCR and, in some cases,
by Northern blotting. Significantly, phagocyte lip-HSDl acted exclusively in the 11P-
reductase direction in intact cells and reactivates B from inert A.
11 P-dehydrogenase activity was not detected - consistent with a failure to detect 11P-
HSD2 by RT-PCR.
Whilst the same is true for human MD Mc|)s, monocytes did not express 11P-HSD1, and
expression and activity were not detected until the d2 of differentiation. Indeed no 11P-
70












dO d2 d4 hBlood hPMN
hMonocytes
Figure 3-4: Human MD M<J> 11|3-HSD1 functions exclusively as a reductase in
intact cells. 1 1(3HSD-1 activity is reported as % conversion of 200nM A to B (11(3-
reductase) or B to A (11 (3-dehydrogenase) by 106 cells over 24h. Reductase activity was
not exhibited by monocytes (dO) but was present by d2 of in vitro differentiation.
Reductase activity was also undetectable in either fresh peripheral blood or freshly
isolated PMNs. No dehydrogenase activity above background level was detected in any
sample. Values are Mean +/- SEM of 4 separate experiments carried out in duplicate.
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reductase activity was detected in human blood-borne leukocytes. It is likely therefore
that, in culture, 11 (3-HSD1 expression is induced upon differentiation.
Whilst murine 11 (3-HSD 1 could be detected by Northern blot, inconsistency in detection
rate necessitated large amounts ofRNA to be used, in contrast to liver and kidney where
11 (3-HSD 1 is abundant. Therefore, activity was routinely measured by bioassay as this
was reliable, sensitive and provided data on protein, rather than mRNA. Nevertheless,
RNA analysis was important in establishing that the enzyme activity was due to 11 (3-
HSD1.
A difference between the 11 (3-reductase activity in cultures of murine and human blood
leukocytes was observed. The activity detected in murine cells was unlikely to be due to
sample collection and handling since appropriate sterility and culture practices were
observed. It will be of interest to determine if this species difference is indicative of a
small mammal's higher metabolic rate and response to stress, or more specifically the
C57BL/6 strain's predisposition to a Thl slanted immune response (Mills, Kincaid et al.
2000). Moreover, it may reflect the animal's health status, or age. Indeed, there is
evidence that chronic stress can up-regulate 11 [3-HSD 1 expression in some tissues (Low,
Moisan et al. 1994), and indirect evidence that age-associated increases in plasma B may
be the result of increased 11 (3-HSD1 activity (Hennebold, Ryu et al. 1996).
In any case, evidence from this chapter suggests that monocytes and other blood-borne
leukocytes have low 11 [3-HSD 1 expression, if any at all. If so, it is of interest that whilst
both monocytes and M(j)s are exquisitely sensitive to GC, M(|)s may have a greater
potential to amplify GC action through 11 (3-HSD 1 conversion of A to B. Few studies
have addressed tissue levels of either A or B, but there is evidence that in areas such as
the brain, a significant proportion of the available B is generated from A, locally in the
tissue rather than diffusing directly from plasma (Yau, Noble et al. 2001). Monocytes
have been shown to strongly express GR (Miller, Spencer et al. 1998). Therefore whilst
in circulation they may be entirely under the influence of adrenal-synthesised B, and the
differentiation process, if triggered by an inflammatory response may give the
72
Chapter 3: 11P-HSD1 is expressed in macrophages and mesangial cells, and is active as a reductase
inflammatory TEP M0 a level of autonomy from the HPA axis (through the induction of
11 (3-HSD 1) which could be controlled by factors at the inflammatory foci.
The generation of oxygen radicals by NADP(H) oxidase action is a component of the
M(j)'s innate response against invading pathogens (Vazquez-Torres and Fang 2001).
However, not only is NADP(H) the cellular co-factor which drives 11 (3-HSD1 reductase
direction but it has been shown to be induced in leukocytes taken from inflammatory
exudates (Karlsson, Follin et al. 1998).
Thus far the data is consistent with that published by others during my studies.
Thieringer et al, studying the presence and induction of 11 (3-HSD 1 during human
monocyte differentiation observed a similar phenomenon (Thieringer, Le Grand et al.
2001). Furthermore they reported that 11(3-HSD1 expression was induced upon exposure
to the anti-inflammatory cytokines IL-4 and IL-13 (Thieringer, Fe Grand et al. 2001).
Induction was shown to occur with differentiation of human monocytes on plastic or
Teflon, demonstrating that 11 (3-HSD1 induction was not solely a response to plating. As
yet it is unknown to what extent the timing of induction in vitro is determined by
components of the autologous serum, without which differentiation does not occur
(Musson and Henson 1979; Newman, Musson et al. 1980).
Rat MC express 11 (3-HSD 1 but not 11(3-HSD2 mRNA, whereas whole kidney expresses
both. This is consistent with previous studies in which 11 (3-HSD 1 expression was
localised to the mesangium and 11(3-HSD2 expression was high in MR-rich distal
nephron (Krozowski, Albiston et al. 1995; Krozowski, MaGuire et al. 1995; Escher,
Galli et al. 1997). As yet, there is no evidence whether MC 11 (3-HSD 1 expression is
only induced in culture, or whether it is omnipresent in normal renal physiology.
Primary MC are, like M0s, GC-responsive (Liu, Cousin et al. 1999) and this therefore
may necessitate a constitutive expression of the enzyme to ensure sufficient supply of B.
Escher et al have shown that MC 11 (3-HSD 1 expression is up-regulated by cytokine
exposure, although in contrast to Thieringer's work, by pro-inflammatory cytokines
TNFa and IL-1 (3 (Escher, Galli et al. 1997).
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It is attractive to speculate on the reasons why such GC-responsive regulators of the
inflammatory response as M<|)s and MCs require a mechanism for GC-amplification,
particularly since cells sharing the same precursor origins such as PMNs do not appear
to have the mechanism. GCs are immunosuppressive and are thought to mediate a
protective shift from a Thl to a Th2 profile in M(j)s in order to prevent an over-reaction
to the immune challenge. In addition, recent evidence shows that they also increase M(J)
and MC capacity to ingest apoptotic cells - a key process in determining inflammatory
outcome (Liu, Cousin et al. 1999).
These data show that M<J)s demonstrate potential for the amplification of GC and
therefore such action may contribute to the clearance of apoptotic cells. Furthermore this
potential is acquired upon differentiation from monocytes, implying a selective role
within the peripheral tissues rather than the circulation. In the Chapter 4, the functional
consequences of these findings are explored.
3.4 SUMMARY
• Murine bone marrow-derived M0s, resident peritoneal M(J)s, and thioglycollate-
elicited M(|)s, rat mesangial cells and human monocyte-derived MQs exclusively
expressed llp-HSDl, not 11(3-HSD2 mRNA. Furthermore, the encoded 11(3-
HSD1 was active solely in the 11 (3-reductase direction and therefore should be
capable of performing a GC amplifying role.
• Human monocytes did not express 11[3-HSD1 mRNA. However, 11[3-HSD1
mRNA and activity was detectable at d2 of differentiation.
• Fundamental differences between human and murine blood cells were found. No
11 (3-reductase activity was detected by human blood cells, whereas murine white
blood cells displayed significant 11 (3-reductase activity over 24h.
• 11(3-HSD1 -deficient M0S did not express 11 (3-HSD1 mRNA, and consequently
11 (3-reductase activity was not detected. This demonstrated the specificity of the
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RT-PCR and the Northern blotting. Furthermore, this data confirmed that the
only enzyme capable of 11 P-reductase action in murine M<|)s is 11P-HSD1, and
demonstrated its validity for use as a model to investigate the role of 11P-HSD1
in the M<|).
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4.1 INTRODUCTION
The capacity of synthetic GCs to promote the phagocytosis of apoptotic cells by M(j)s
and MC has recently been reported (reviewed in section 1.7) (Liu, Cousin et al. 1999).
Given the expression of 11 j3-HSD 1 reductase activity in M(J)s and MC, there might be a
functional consequence in terms of phagocytic function. To determine the potential for a
role of 11(3-HSD1 in this process, it was investigated whether the action of 11 (3-HSD1
permitted otherwise inert A to exert the same phagocytic effect as synthetic GCs.
Ultimately the role of 11 (3-HSD1 in the M0 should be tested in vivo by utilising 11(3-
HSD1-deficient mice. During the course of this work 11 (3-HSD 1-deficient mice
(Kotelevtsev, Holmes et al. 1997) were bred from a MF1/129 background onto
C57BL/6, and were later to become the model of choice to determine the in vivo
relevance of M<|) 11(3-HSD1. However, much preliminary work was undertaken in this
chapter to, firstly determine the GC-responsiveness of M<j)s from a C57BL/6 background
and, secondly, to establish the potential of 11 (3-HSD 1 to influence GC action in M<j).
Liu et al described phagocytic effects of GCs upon murine M0s from a BALB/C
background. M0S from BALB/c and C57BL/6 mice are considered to display Th-1 and
Th-2 slanted immune responses respectively, which can result in fundamentally different
inflammatory responses to the same stimuli (Mills, Kincaid et al. 2000). This fact, and
the well documented ability of GCs to influence an immune cell's cytokine repertoire,
made it imperative to validate Liu's observations on M<])s from the C57BL/6 mouse. In
addition, it was by no means certain that physiological GCs would elicit an identical
response to dexamethasone (Dex), since the nature of the synthetic steroid is to achieve
increased receptor avidity and longer 1/2 life due to an additional halogen group at its 9-
alpha position. It was therefore of interest to discover whether these phagocytic effects
extended to the physiological adrenal-GC, B and if so, whether physiological
concentrations of B were effective.
Next the question of 11 (3-reductase relevance was addressed. Would the re-activation of
B from inert A deliver the M0 with a sufficient concentrations of GC to mediate
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phagocytic augmentation? If so, could specificity and manipulation be demonstrated by
abolishing the effect with the use of 11(3-HSD inhibitors?
From the absence of 11 |3-HSD expression in human monocytes, it is predicted that
monocytes and MD M(])s ought to have differing responses to A. Is the expression of
1 lp-HSDl simply a consequence of differentiation or more intriguingly, a pre-requisite
for the phagocytosis of apoptotic cells?
Therefore, a series of in vitro experiments were devised to (i) validate the Dex effect on
C57BL/6 M(|)s, (ii) investigate the efficacy of physiological steroids and (iii) the
consequences of 11P-HSD inhibition on phagocytosis of aPMNs by M<|)s and MC. These
studies were then extended to investigate whether a correlation existed between 11 (3-
HSD1 induction and phagocytosis.
4.2 RESULTS
4.2-1 Dexamethasone augments the phagocytosis of apoptotic neutrophils by
C57BL/6 macrophages
The effect of Dex on the phagocytic capacity of C57BL/6 M(J) for aPMNs was
determined in vitro and in vivo. In vitro, BMD M(|)s were treated with 200nM Dex after
6d in culture (24h prior to phagocytosis assay) and aged PMNs were overlaid (at a ratio
of 4:1) 24h later (refer to section 2.2-10). Similarly, TEP M(J)s harvested 3d after onset of
TE peritonitis were adhered to plastic and treated with 200nM Dex for 24h before being
overlaid with aged PMNs. In both cases, after an interaction time of 30 min, non-
ingested PMNs were removed and M4> phagocytosis of aPMNs scored (refer to section
2.2-10.1). Figures 4.1A and 4.2 show that Dex treatment significantly augmented the
capacity for phagocytic uptake of aPMNs by BMD M0s and TEP M0s in vitro,
consistent to previous reports (Liu, Cousin et al. 1999). Not only did Dex treatment
increase the percentage of M(J)s that phagocytose aPMNs but the number of aPMNs
ingested by an individual phagocytic M(J) was also augmented (Fig. 4.2B).
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Figure 4-1: Dex treatment of M(j)s from C57BL/6 mice augments phagocytosis of
aPMNs (1). A, 24h Dex treatment (200nM) prior to a 30 min in vitro phagocytosis assay
significantly augmented the phagocytosis of aPMNs by BMD M([)s (d7) and TEP M(|)s
(harvested on d3 ofTE peritonitis).
B, in vivo, an i.p injection of Dex (200nM) on d2 of TE peritonitis augmented the ability
of d3 TEP M(])s to ingest i.p administered aPMNs during a 10 min phagocytosis assay.
Values are Mean +/- SEM of counts of 600 Mps from at least 4 separate experiments
carried out in duplicate. *P<0.05, **P<0.001 by ANOVA.
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Figure 4-2: Dex treatment of M0S from C57BL/6 mice augments phagocytosis of
aPMNs (2). Untreated d7 BMD M())s (A), and M(|)s treated with Dex (200nM) for 24h
(B), were assayed for phagocytosis in vitro. Dex increased both the percentage of M0s
that phagocytosed, and the number of aPMNs that individual M())s ingested (phagocytic
index). Ingested PMNs were selectively stained for myeloperoxidase activity.
C, F4/80 labelled BMD M0S and CM-Green labelled aged PMNs separated on the FL-2
and FL-1 axis respectively by flow cytometry analysis. Phagocytosis levels were
determined by the percentage of gated cells that shifted into the red/ green positive
quadrant of the dot-plot. E, Dex-treated M0s ingested more aPMNs than control cells
(D). F, Photograph shows a TEP M(j) recovered after a 10 min in vivo phagocytosis assay
and counterstained for F4/80 expression to aid visualisation under fluorescence.
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For the in vivo phagocytosis assay, 200nM Dex treatment was administered by i.p
injection 2d day after the onset of TE peritonitis. Exogenous aPMNs stained with CM-
Green dye were injected i.p into the Dex treated mouse on d3 (refer to in section 2.2-
10.2). Typically, aged PMNs were introduced at a ratio of 3:1 (aged PMNs:M(|)) and
after 10 min cells were harvested. The percentage of TEP M(])s that ingested aPMNs was
approximately 2.5-fold greater in cells recovered from Dex-treated mice than control
mice (Fig.4-IB). Figure 4-2F shows an F4/80 stained, Dex-treated TEP M(|) containing a
number of aPMNs after a 10 min in vivo assay.
A flow cytometry based protocol was also used to quantify phagocytosis of aPMNs
within M(|) populations. BMDM(j)s and aged PMNs separate on a 2-colour plot when
labelled with F4/80 and CM-Green respectively (Fig.4-2C). The comparative shift of a
population of cells into the red/ green quadrant is representative of phagocytosis. 24h
Dex treatment confers a phagocytic effect upon a subpopulation of the M(|)s (33.7%)
gated in the F4/80 population (Fig.4-2E), approximately double that observed in control
cells (Fig.4-2D).
4.2-2 Macrophage 11P-HSD1 activity is inhibited by carbenoxolone
For many of the experiments in this chapter, the effect of 11 P-reductase activity, and the
consequence of its inhibition, on M()) phagocytic function was demonstrated. Derivatives
of liquorice (such as glycyrrhetinic acid) and carbenoxolone (the hemisuccinate of
glycyrrhetinic acid) have previously been shown to inhibit 11P-HSD activity in human
and murine cells (Monder, Stewart et al. 1989; Stewart, Wallace et al. 1990).
Monolayers of d3 TEP M0s were pre-treated with increasing concentrations of
carbenoxolone for lh before commencement of 11 P-reductase assays. No significant
11 P-reductase inhibition was observed at concentrations of carbenoxolone below 10"6M
(Fig.4-3). Approximately 60% inhibition was detected with 10"5M, increasing to almost
complete inhibition with a concentration of 10"4M (Fig.4-3).
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Figure 4-3: Carbenoxolone, inhibits liP-reductase activity in TEP M<J>s. 106 TEP
M())s harvested at d3 were pre-treated for lh with carbenoxolone (Cx) at various
concentrations (as indicated) then 11 (3-reductase activity measured over 24h. 11 (3-HSD1
activity is reported as % conversion of 200nM A to B. At 10"6M or below, Cx did not
significantly inhibit reductase activity, whereas approximately 60% and 100% inhibition
was seen with concentrations of 10~5M and 10"4M, respectively. Values shown are mean
+/- SEM of 3 different mice, measured in duplicate. *P<0.05, **P<0.001 (ANOVA),
compared to control.
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4.2-3 Physiological glucocorticoids augment the phagocytosis of apoptotic
neutrophils by macrophages
Dose response studies performed by Liu showed that phagocytosis was maximally
augmented by Dex over 24h at a concentration of 200nM (Liu, Cousin et al. 1999). 24h
incubation with either B or A at 200nM was as effective in augmenting phagocytosis of
aPMNs by TEP M(j)s as 200nM Dex over the same time period (Fig.4-4). The assays
were repeated using high physiological levels of physiological steroids comparable to
those detected in plasma during stress (Harris, Kotelevtsev et al. 2001). Either 20nM B
or A increased phagocytosis, although the effect of A was suggestive since significance
was not established (Fig.4-4). Lui et al showed that greater augmentation of
phagocytosis was possible with the same concentration of Dex if the duration of
exposure to GC increased (Liu, Cousin et al. 1999). In the case of A, significant
increases were observed at concentrations of 20nM and less in later experiments when
the duration of exposure was increased to 48h (data not shown, refer to 6.2-1).
4.2-4 Carbenoxolone inhibits 11-dehydrocorticosterone, but not corticosterone
augmentation of phagocytosis by macrophages
To investigate the specificity of 11(3-HSD1 action on the effect augmented by A, 11(3-
reductase activity was inhibited with carbenoxolone. Pre-treatment of TEP M())s for lh
with 10"4M carbenoxolone before GC addition, abolished the effect of A upon
phagocytosis of aPMNs, but had no effect on B augmentation of phagocytosis (Fig.4-4).
Inhibition of 11(3-reductase activity by carbenoxolone had no effect on control of
phagocytosis, although a trend towards marginally decreased phagocytosis was
frequently observed with carbenoxolone treatment.
4.2-5 Physiological glucocorticoids augment phagocytosis of apoptotic neutrophils
by mesangial cells
24h treatment of rat MC with either 200nM B or A augmented phagocytosis by
approximately 2-fold. This increase was comparable to that resulting from Dex
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Figure 4-4: Physiological GCs augment phagocytosis. Carbenoxolone inhibits the
capacity of A, but not B, to augment phagocytosis by TEP M0s. TEP M(|)s were
harvested on d3 of peritonitis and cultured 24h in the presence of Dex, A or B. Aged
PMNs were allowed to interact with the M([)s (at a ratio of 4:1) for 30 mins, and % of
M(|)s that ingested 1 or more aPMNs were assessed by microscopy. Pre-treatment for lh
with 10"4M carbenoxolone (Cx) before A addition abolished the effect of A on
phagocytosis, but had no effect on phagocytosis by B-treated or control cells. Values
shown are mean +/- SEM of counts of 600 M(|)s from 6 mice, carried out in duplicate.
*P<0.05 (ANOVA), as indicated
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treatment (Fig.4-5). Note that the low levels of ingestion achieved after 2h interaction
with aged PMNs is consistent with published observations (Savill, Smith et al. 1992).
Inhibition of 11 (3-reductase activity by inclusion of carbenoxolone lh prior to addition
ofA abolished the effect ofA (Fig.4-5).
4.2-6 Human monocytes are responsive to corticosterone, but not 11-
dehydrocorticosterone
So far this chapter has focused on the effect of GC upon mature M(J)s. In the human
system, Dex treatment ofmonocytes has recently been shown to affect monocyte to MD
M(|) differentiation (Giles, Ross et al. 2001). The phagocytic potential of mature MD
M())s can be increased by an initial 24h exposure of the fresh monocytes to Dex at day 0
(dO) (Giles, Ross et al. 2001). This effect was conferred before the induction of 11(3-
HSD1 observed on d2 of differentiation (Chapter 3). In the present study it is predicted
that monocytes will have differing responses to physiological GCs, by virtue of a lack of
11(3-HSD1 expression. Furthermore, it would be of interest to determine whether there
may be a role for 11(3-HSD1 in differentiation.
The phagocytosis of aPMNs by MD M([) was augmented in response to 24h GC
treatment (Fig.4-6). 24h incubation with either, lpM Dex, B or A added at d3 of
differentiation increased phagocytosis by at least 2-fold. Similarly, consistent with
previous studies (Giles, Ross et al. 2001), inclusion of Dex or B at dO with fresh
monocytes conferred an increased capacity for phagocytosis upon MD M())s at d4, even
when the GCs were removed upon the standard d2 replacement of medium (Fig.4-6).
However this was not the case when monocytes were treated with A. MD M(])s were
responsive to the effects of A, but monocytes were not (Fig.4-6). Monocytes do not
express 11(3-HSD1 so therefore do not have the ability to generate B from exogenously
added A, thus phagocytosis levels remain similar to control levels.
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Control 200nM Dex 200nM B 200nM A
Figure 4-5: Physiological GCs augment phagocytosis. Carbenoxolone inhibits the
capacity of A, but not B, to augment phagocytosis by rat MC. Rat MC were cultured
for 24h in the presence of Dex, A or B. Aged PMNs were allowed to interact with the
MC (at a ratio of 4:1) for 2h in the presence of 10% serum, and % of MC that had
ingested 1 or more aPMNs were assessed by microscopy. Pre-treatment of MC for lh
with 10"4M carbenoxolone (Cx) before GC addition abolished the effect of A upon
phagocytosis of aPMNs. Values shown are mean +/- SEM of counts of at least 500 MC
from 3 separate experiments, carried out in duplicate. *P<0.05 (ANOVA), as indicated.
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Figure 4-6: Augmentation of phagocytosis by inert A only occurs once 11P-HSD1
expression has been induced during human monocyte differentiation. GCs were
added to 4X106 human monocytes on either dO or d3 of culture and phagocytosis assays
performed on d4. Control cells remained untreated. Aged PMNs were allowed to interact
with the MD M(])s(at a ratio of 4:1) for 30 mins, and % of M(|)s that had ingested 1 or
more aPMNs were assessed by microscopy. A treatment conferred augmentation on M(|)s
when added at d3 but not dO, whereas B and Dex augmented phagocytosis when added
at either time-point. Values shown are Mean +/- SEM of counts of at least 600 M(|)s of 5
different experiments, carried out in duplicate. *P<0.05 (ANOVA), as indicated.
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4.2-7 Glucocorticoid treatment of monocytes promotes acquisition of phagocytic
competency
It was of interest to determine if the availability of GC early during monocyte
differentiation affected the rate at which MD M(()s become competent to phagocytose
aPMNs. Human MD M([)s did not acquire the ability to phagocytose aPMNs until d3 of
differentiation (Fig.4-7). In contrast, monocytes treated with lpM Dex or B attained this
ability by d2 of differentiation. Interestingly, monocytes treated with A did not differ
from controls in acquisition of phagocytic competency (Fig.4-7).
4.3 DISCUSSION
Previous work has shown that synthetic GCs augment the phagocytic capacity of M(j)s
and MC for aPMNs (Liu, Cousin et al. 1999). In the present study, these findings have
been extended to show that the physiological GC, B can confer a similar effect.
Moreover, this effect can also be conferred by the reactivation of B from inert A by the
action of phagocyte 11 (3-reductase, thus suggesting that, in vitro at least, M(j) and MC
clearance of aPMNs can be facilitated by virtue of 11 (3-HSD1 activity. In vivo, however
such an effect may only be conferred in instances where A is present and free B is low.
Work in this chapter validates Liu's findings (which were in BALB/C mice) in the
C57BL/6 strain ofmouse. Despite apparent differences in abilities to elicit inflammatory
responses (Mills, Kincaid et al. 2000), no differences were observed between M(|)s from
BALB/C or C57BL/6 mice in their pro-phagocytic response to Dex. Furthermore, this
response was validated in vivo, using a model of sterile thioglycollate-induced
peritonitis. 24h i.p Dex treatment led to a 2-fold augmentation of phagocytosis of
aPMNs. Not only did GC treatment increase the number of M(J)s capable of ingestion but
it also augmented the capacity of individual M0S to ingest multiple aPMNs. Indeed, in in
vivo phagocytosis assays, M(()s recovered after only 10 min exposure to aPMNs often
contained multiple phagocytic bodies and, when longer assays were performed, rapid
degradation of the ingested aPMN was observed (data not shown). Therefore it is
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□ assay on d2
■ assay on d3
Control 1pM Dex 1pM B 1 JLIM A
Figure 4-7: GC treatment of human monocytes promotes the attainment of
phagocytic competency for aPMNs. Freshly isolated human monocytes were cultured
in the presence of 1 pM Dex, B or A. Aged PMNs were allowed to interact with the Mc()s
(at a ratio of 4:1) for 30 mins at d2 and d3 ofmonocyte to M(|> differentiation, and % of
M(|)s that had ingested 1 or more aPMNs were assessed by microscopy. Untreated M(|)s
(Control) attained the ability to ingest aPMNs on d3 whereas M(|)s treated with Dex or B
from dO attained this ability by d2. Treatment with A did not advance this rate of
phagocytic competency, and phagocytosis levels did not differ from control. Values are
Mean +/- SEM of counts of at least 600 M([)s of 3 separate experiments carried out in
duplicate. *P<0.05 (ANOVA), compared with control on the same day.
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reasonable to speculate that increasing phagocytic capacity, in vivo, would represent a
possible therapeutic approach towards promoting resolution of inflammation.
Quantifying phagocytosis levels by flow cytometry proved to be an inconsistent method
of analysis. This was largely due to the levels of auto-fluorescence emitted by the M<j)s,
in particular TEP M(|)s. Nevertheless, this method has been validated by others (Brown,
Heinisch et al. 2002) and may be better suited for assay of human MD M(j) phagocytosis
rather than mouse. Unfortunately therefore, this form of phagocytosis analysis had to be
abandoned in favour of the time-consuming but accurate method of counting by eye.
A potentiating effect similar to that of Dex was observed after 24h or 48h treatment of
phagocytes, in vitro with either B or A, respectively. The action of A requires 11(3-
HSD1, as it was abolished by pre-treatment with the 11(3-HSD inhibitor, carbenoxolone.
Importantly, this effect was apparent with 48h exposure to concentrations within the
physiological range such as 20nM. The equipotency of B to Dex was somewhat
surprising given that B is more readily metabolised by cells than Dex. However, it is
possible that Dex is subject to active transport from within M(J)s by drug-transporting
glycoproteins such as MDR3, effectively lowering the intracellular Dex concentration
(Schinkel, Smit et al. 1994). However, despite the potency of physiological GCs in this
culture system, in vivo their effect would be compromised by diffusion, CBG binding
and metabolism by 11(3-HSD2 unless the pro-phagocytic effect was specifically targeted
to M0 populations.
Longer incubations with carbenoxolone (>48h) appeared detrimental to the cells,
particularly when added to differentiating monocytes (unpublished observation). In view
of the fact that 11(3-HSD1 -deficient M(j)s were viable (refer to section 3.2-3) cell loss
during this prolonged treatment is most likely due to other pathways inhibited by
carbenoxolone rather than a consequence of 11(3-HSD inhibition (Stewart, Wallace et al.
1990).
Recently published work from our group suggests that, in addition to augmenting
phagocytosis of differentiated MD M(J)s, Dex can confer an effect on the differentiation
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process itself, even if present during only the first 24h only (Giles, Ross et al. 2001). In
the present study it was shown that MD M(J)s could be programmed to be pro-phagocytic
by exposure to Dex or B whilst still at the monocytic stage (despite medium change and
removal of GCs at d2), whereas exposure to A was without effect. In vitro, A only
conferred enhanced phagocytosis on MD M(J)s when added after appearance of 11(3-
HSD1 induction on d2. Additionally, exposure to GC also promoted the attainment of
phagocytic competency for aPMNs. For example monocytes treated with Dex or B were
able to ingest aPMNs 24h earlier than control or A treated cells. This raises the question
of whether early induction or over-expression ofmonocyte 11(3-HSD1 by differentiation
agents or by transgene is possible? Such a strategy would target the pro-phagocytic
effects of B earlier to differentiating monocytes yet may only necessitate non-toxic
physiological concentrations of A - either by administration of A therapeutically, or by
utilising the endogenous supply.
Liu et al showed that Dex specifically promoted phagocytosis of apoptotic cells
(including PMNs, eosinophils and Jurkat T lymphocytes) by various populations of
phagocytes that usually employ different phagocytic receptors (such as avp3) to engage
apoptotic cells (Liu, Cousin et al. 1999). Despite the "pan-phagocyte" effect of Dex, the
increase in phagocytosis was specific for apoptotic cells since the ingestion of other
classes of 'feed' such as opsonized erythrocytes was unaffected by Dex (Liu, Cousin et
al. 1999). Moreover, as seen with untreated phagocytes, GC-treated phagocytes also
retain the ability to suppress the release of pro-inflammatory mediators after
phagocytosis of apoptotic cells (Meagher, Savill et al. 1992; Liu, Cousin et al. 1999). In
comparison, the ingestion of opsonized zymosan elicits a pro-inflammatory response
from GC-treated phagocytes (Liu, Cousin et al. 1999), and thus the suppression of M(J)
secretion seen after the ingestion of apoptotic cells was not due to a generalised GC-
suppression of phagocyte responses. It is hypothesised that these novel anti¬
inflammatory properties of pharmacological GCs combine to promote the successful
resolution of an inflammatory response (Liu, Cousin et al. 1999). Could endogenous B
play an equivalent role during an acute, self-resolving infection? In this present study,
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data are presented showing that phagocytes possess the machinery to generate
physiological GC from its inert precursor, and that, given sufficient substrate, this
amplification can facilitate an increased clearance of aPMNs in vitro. This action is not
unique to any single class or species of phagocyte and appears to be induced upon
differentiation. It will be of great interest to determine whether this phenomenon takes
place in vivo, and to determine the extent to which 11 (3-HSD1 activity is controlled
locally by the inflammatory environment.
4.4 SUMMARY
• Mcjis from C57BL/6 mice augmented phagocytic capacity for aPMNs in response
to Dex treatment.
• Physiological GCs were effective in augmenting phagocytosis of aPMNs by
murine M([)s, human monocyte-derived M(|)s and rat mesangial cells.
• Carbenoxolone inhibited 1 l(3-reductase activity in M<|)s and abrogated the
increased phagocytic levels seen in response to A treatment.
• Human monocyte capacity and acquisition of capacity to ingest aPMNs was both
accelerated and increased by active GC.
• Augmentation of phagocytosis by inert A only occurred once 11 (3-HSD 1
expression had been induced during human monocyte differentiation.
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5.1 INTRODUCTION
The data presented in Chapter 3 suggested that 11 (3-HSD1 activity in TEP M0s may
have been greater than in RP M(|)s. Since variation in cell number and viability were
unlikely to account for the differences, it appeared possible that 11 (3-HSD 1 expression
was influenced by the inflammatory environment. Reports of 11 (3-HSD 1 modulation in
the literature show that hepatic, brain and adipose 11 (3-HSD 1 mRNA levels can be
influenced by a number of factors including TNFa (refer to section 1.4-3). The aim in
this chapter was to determine whether M(|) 11P-HSD1 expression could be influenced by
inflammatory mediators - in particular cytokines.
During the course of this thesis, a report of cytokine regulation of M(J) 1 lp-HSDl was
published (Thieringer, Le Grand et al. 2001). 11[3-HSD1 expression in MD M())s was
shown to be increased by the Th2 cytokines, IL-4 and IL-13, an effect that was
abrogated in the presence of pro-inflammatory IFN-y (Thieringer, Fe Grand et al. 2001).
In addition it was also reported that EPS up-regulated 11P-HSD1 expression in the M([)-
like cell line, THP-1 (Thieringer, Fe Grand et al. 2001). In contrast, in rat MC 1 lp-
HSDl mRNA was increased by pro-inflammatory cytokines TNF-a and IF-ip (Escher,
Galli et al. 1997).
Thus, both pro- and anti- inflammatory cytokines have been shown to regulate 11P-
HSD1 mRNA, albeit in different phagocyte cell types. Given the suggestion of increased
11P-HSD1 activity in inflammatory M())s compared to resident M(])s it was important to
examine the regulation M()) 11P-HSD expression. 2 systems were investigated: (i) 11P-
HSD1 activity in M(|)s elicited into the peritoneum during the course of peritonitis and,
(ii) function consequences of cytokines on differentiation and phagocytic ability during
differentiation of human monocytes to MD M(|)s.
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5.2 RESULTS
5.2-1 11P-HSD1 is up-regulated in inflammatory peritoneal cells during sterile
peritonitis
To determine whether 11(3-HSD1 expression changed during TE peritonitis, 11(3-
reductase was assayed in cultured peritoneal cells harvested at various times after i.p
thioglycollate injection.
In an initial experiment 11(3-HSD1 activity increased rapidly after thioglycollate
injection, so that at dl, cells fully converted 200nM A to B over a subsequent 24h,
whereas RP M(J)s only converted 30% of the added A (Fig.5-1). Conversion levels
remained close to 100% until d3, after which 11 (3-HSD1 activity decreased to a level
comparable to that of RP Mt)>s (Fig.5-1). 11 (3-HSD1 levels in this assay were clearly
saturated by dl, therefore to further investigate the rapid induction of 11P-HSD1 activity
and determine the magnitude of induction, cells taken 4h after thioglycollate injection
were adhered to plastic, and changes in 11(3-HSD1 activity assayed following 4h, 8h and
24h incubation. Compared to RP Mt|)s, the TE peritoneal cells showed a rapid and
dramatic increase in 11P-HSD1 activity after 4h culture (> 12-fold) (Fig.5-2). With
longer assays, the 200nM A was completely converted to B, in contrast to RP M(])s
which converted just 30% in a 24h assay (Fig.5-2).
5.2-2 Identification of cell type responsible for 11|3-HSD1 induction
The rapid and marked induction of 11 P-reductase activity during d 1 of peritonitis was
surprising. It was therefore of interest to discover whether this increase in activity
occurred in cell populations resident to the peritoneal cavity or whether it was due to
cells recruited during peritonitis. Accordingly, it was investigated whether the RP Mc|)
population or the recruited cell populations (predominantly monocytes and PMNs)
(reviewed Chapter 1, section 1.4) were responsible for the increased 11 P-reductase
activity.
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Figure 5-1: 11 P-reductase activity in murine peritoneal cells during TE
peritonitis. Peritoneal cells were lavaged from mice at dl-5 after 3% thioglycollate
injection. 11P-HSD1 activity is reported as % conversion of 200nM A to B by 106 cells
over a 24h period. Cells harvested at dO converted 30% of available substrate over 24h.
Id after thioglycollate injection conversion levels increased to 100% and remained
maximal until d3. By d5 the conversion level had returned to a level comparable with
that of dO (unstimulated peritoneum). Values are Mean +/- SEM of conversion levels of
cells derived from 4 mice at each time-point. *P<0.05 (ANOVA), compared to d3.
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Figure 5-2: liP-reductase activity is rapidly induced during the early stages of
TE peritonitis. Conversion rates were compared between RP M(])s and peritoneal cells
harvested 4h after i.p injection of thioglycollate. 11(3-HSD1 activity is reported as %
conversion of 200nM A to B by 106 adherent cells at specified times. Values shown are
Mean +/- SEM of cells derived from 4 mice carried out in duplicate. **P<0.001
(ANOVA), as indicated.
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5.2-2.1 Effect of pro-inflammatory supernatant on 11P-HSD1 activity:
It was of interest to see whether the addition of thioglycollate alone, or factors present at
the inflamed site was necessary for the increased 11 P-reductase activity observed during
peritonitis. Both RP M(J)s and murine WBC demonstrate 11 P-reductase activity (refer to
section 3.2-3) and therefore these cells were chosen to represent the resident or recruited
populations (that may contribute to the increased activity), respectively.
Cell-free inflammatory supernatant was generated by the centrifugation of undiluted
peritoneal fluid collected 4h after i.p thioglycollate injection (refer to section 2.2-8.2).
Addition of supernatant to cultures of RP M0s and WBC caused the rapid induction of
11P-HSD activity (Fig.5.3B and C). Furthermore, 11P-HSD activity was unaffected by
preparations of thioglycollate (Fig.5.3 B and C), and therefore 11P-HSD1 induction was
likely to be mediated by an endogenous substance rather than as a direct effect of
inflammatory agent. In summary, both RP M0s and WBC have an inducible 11P-HSD1
that can be up-regulated by pro-inflammatory mediators. Also, this data suggest that
11 P-reductase activity can be re-induced in mature 3d inflammatory TEP M(j)s by
addition of this supernatant (Fig. 5-3A).
Time only allowed an initial experiment to begin to identify the 1 ip-HSDl-inducing
mediator(s) within the peritoneal fluid. By ELISA, it was possible to detect low levels of
TNFa in diluted peritoneal fluid (collected from the peritoneal cell lavages) (Fig.5-4).
TNFa was detected between 4h and Id after the onset of peritonitis, but was
undetectable between d2 and d4 (Fig. 5-3). The significance of this finding has yet to be
explored, as is monocyte/ TEP M(J) 11 P-reductase activity after the direct addition of
recombinant IL-4.
5.2-2.2 Cell sorting of monocytes and PMNs:
Since 11 P-reductase activity was inducible in WBC, the hypothesis that murine
monocytes up-regulate 11P-HSD1 expression in response to differentiation (in an
analogy to human monocytes) was explored. Thus, it was necessary to distinguish the
monocytes from the PMNs and therefore, attempts were made to sort peritoneal cells
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Figure 5-3: Pro-inflammatory supernatant induces 11P-HSD1 activity in M(|)s and
WBC. Supernatant (4h Sup) was generated by the centrifugation of peritoneal exudate
collected 4h after onset of TE peritonitis. 50pl was added to 106 cells and 11P-HSD1
activity measured at 4h, lOh and 24h after addition. Similarly, 50|il 3% thioglycollate
(thio) was added, and activity measured at lOh. 11(3-HSD1 activity is reported as %
conversion of 200nM A (added at t=0) to B. A, B and C, thio had no effect on 11(3-
HSD1 activity at lOh, whereas 4h Sup appeared to induces 1 ip-reductase activity at 4h,
lOh and 24h.
D, no conversion was detected in the absence of cells (control), and the supernatant had
no intrinsic 1 lP-reductase activity. Values shown are Mean +/- range from 2
experiments done in duplicate. Significance not established.
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Figure 5-4: TNFa is detected in peritoneal lavages taken 4h and Id after the onset
of TE peritonitis. 3ml peritoneal supernatant was returned from the 4ml PBS bolus used
to harvest peritoneal cells. Cells and debris were removed by centrifugation, and TNFa
concentrations were measured by ELISA. TNFa was present at detectable levels in
samples taken 4h and Id after i.p thioglycollate injection. The dotted line indicates
detection threshold of the ELISA kit.
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collected 4h after the onset of peritonitis into monocyte/M()) and PMN populations by
FACSVantage.
It is particularly difficult to separate monocytes from PMNs as they share many surface
molecules including GR-1 (Lagasse and Weissman 1996). This experiment attempted to
sort these cells on the basis that by 4h of peritonitis, the infiltrating monocytes and
PMNs would be sufficiently differentiated to be distinguishable by expression of their
mature surface markers, F4/80 and GR-1 respectively. Peritoneal cells harvested 4h after
thioglycollate injection separate into 2 populations of cells (based on forward and side
scatter properties), both of which contain cells positive for anti-F4/80 and anti-GR-1
(Fig.5-5). Interestingly, a clear difference in fluorescence was seen between GR-1
positive cells in R1 and R2, whereas no difference was observed in F4/80 positive cells
between the 2 populations (Fig.5.5B and C).
To determine which, if either of the cell populations contained high levels of 1 lp-HSDl
expression, cells were sorted from R1 or R2 on the basis of F4/80 or GR-1 expression
and were bioassayed for 11(3-HSD1 activity over 24h. No differences in 11 (3-reductase
activity were seen between F4/80 or GR-1 positive cells within or between R1 and R2
(data not shown). Furthermore, microscopic examination clearly showed that the GR-1
positive cells contained significant numbers of M(])s, and therefore could not be
representative of a PMN population.
However, many of the recovered cells were irreparably damaged by the sorting process
and were either apoptotic or had fragmented- despite the use of a medium buffered with
serum to minimise shear forces. After 1 repeat with similar observations, it was decided
that cell sorting of peritoneal cells on the basis of F4/80 and GR-1 was not a viable
method for determining the source of 11(3-HSD1 activity.
5.2-2.3 Monocyte depletion during peritonitis:
Using a different approach, it was decided to establish the 11 (3-reductase contribution of
the infiltrating monocytes indirectly by eliminating them from TE peritonitis. The
diphtheria-toxin receptor (DTR) mouse was generously provided by Dr. Jeremy Hughes
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Figure 5-5: Cell sorting of F4/80 and GR-1 positive cells taken 4h after the onset of
TE peritonitis. Peritoneal cells were harvested after 4h of TE peritonitis and stained for
surface expression of either F4/80 or GR-1. A, 2 populations, R1 and R2 separated on
the basis of size. However both R1 and R2 contained cells that were F4/80 positive (B),
or GR-1 positive (C). The gate Ml represents a shift greater than that of isotype control.
C, the cells in R1 had a greater level of GR-1 staining than those in R2. Data
representative of 50,000 cells collected per gate in 2 separate experiments.
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CIR, in which it is possible to temporarily delete the majority of circulating monocytes
by intra-venous exposure to diphtheria toxin (DT) (refer to section 2.2-4.4).
DT was administered, followed 24h later by i.p thioglycollate injection. Cells collected
4h after onset of peritonitis were assayed for 1 1 (3-reductase activity and viewed by
microscopy. Figure 5-6A shows that DT pre-treatment reduced (but did not completely
eliminate) the proportion of recruited monocytes by -95%. Cells taken at this time-point
were cultured and 11 (3-reductase activity was assayed 4h and 20h after plating. No
significant differences were seen in 11 (3-reductase activity at either time-point (Fig.5-
6B). Even though the monocyte population was not completely eliminated, these data
suggest that the increased 11 (3-reductase activity was present in either the infiltrating
PMNs or the activated RP M0 population.
5.2-3 Phagocytosis of apoptotic neutrophils by macrophages is apparently
augmented by inflammatory supernatant
Data from the present study suggests that 11 (3-reductase activity within inflammatory
TEP M(|)s was re-induced upon exposure to inflammatory supernatant (Fig.5-3A).
Within in a few hours, 106 TEP M0s converted virtually 200nM A into B (100%
conversion, see Fig. 5.3A). It was of interest to discover if this increased rate of
conversion (and thus longer exposure of cells to B) could confer an even greater
phagocytic potential upon TEP M(|)s, and therefore whether induction of 11 (3-HSD1
activity is relevant to phagocytosis.
3d TEP M(J)s were treated with A and/ or inflammatory supernatant for 24h before a
30min phagocytosis assay was carried out. Control cells had no treatment (Fig.5-7A). As
expected, phagocytosis was augmented above control levels by treatment with A (Fig.5-
7C). Interestingly, a similar augmentation was seen after exposure to inflammatory
supernatant alone (Fig.5-7B). However, addition of both together appeared to be
additive, (Fig.5-7D and E). Due to difficulty of maintaining sterility during collection of
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Figure 5-6: Monocyte depletion has no effect on the induction of 11(3-HSD1 activity
in TE peritoneal cells. Diphtheria toxin (DT) was administered to 'DTR' mice 24h
prior to i.p thioglycollate treatment. Control mice were treated with thioglycollate alone.
A, cytospins of peritoneal lavages showing elicited PMNs and monocytes from
thioglycollate treated control mice, and depleted numbers ofmonocytes in washes from
DT-treated mice. B, TE cells harvested at 4h were cultured and 1 l(3-reductase activity
measured in 106 cells measured over 20h. 11 (3-HSD1 activity is reported as %
conversion of 200nM A to B. No significant difference in activity was seen in samples
taken from monocyte depleted cultures compared to control at either 4h or 20h after
plating. Photographs representative of 2 different mice of each group, and values are
Mean +/- range of conversion levels of 2 mice of each group. Significance was not
established.
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Figure 5-7: Phagocytosis of aPMNs by TEP M0S is augmented by inflammatory
supernatant. 106 3d TEP M(J)s were incubated with 200nM A and/ or 50pl
inflammatory supernatant for 24h, and then a 30min phagocytosis assay carried out with
aged PMNs. A, control cells, no addition. B, addition of inflammatory supernatant alone.
C, addition ofA alone. D, addition of inflammatory supernatant and A.
E, addition of supernatant or A alone augmented phagocytosis over control levels. When
combined, phagocytosis was increased approximately 2-fold over control levels.
Photographs are representative of phagocytosis levels, and values are mean +/- range of
counts of at least 600 TEP M(|) from 2 separate expts carried out in duplicate. Due to
difficulty ofmaintaining sterility during collection of supernatant it was only possible to
successfully carry out this experiment twice, so significance was not established.
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supernatant it was only possible to successfully carry out this experiment twice, so
significance was not established.
5.2-4 IL-4 treatment up-regulates macrophage 11|3-HSD1 activity, but does not
itself promote phagocytosis
In the human model, IL-4, an anti-inflammatory cytokine has also been shown to up-
regulate M(J) 11 (3-HSD1 expression (Thieringer, Le Grand et al. 2001). Therapeutically
there is more rationale to modulate 11 (3-reductase activity for the promotion of
phagocytosis with anti-inflammatory rather than pro-inflammatory cytokines. Therefore,
it was of interest to determine if the kinetic observations of Thieringer et al had a
functional consequence for phagocytosis.
Initially, a range of IL-4 concentrations were used to establish effect on MD M(]) 11(3-
reductase activity. The addition of 50ng/ml IL-4 proved detrimental to MD M0S,
particularly when added to monocytes, causing rapid loss of morphology and
detachment of cells (data not shown). Addition of lower concentrations of IL-4, (0.1-
lOng/ml) to monocyte cultures on dl caused induction of 11 (3-HSD 1 activity above
control levels within 24h (Fig.5-8A). At 48h, 200nM was completely converted in MD
M())s treated with 1 and lOng/ml IL-4, and 3-fold greater after O.lng/ml treatment, than
control levels (Fig.5-8A). Similar trends were seen when IL-4 was given on d2 (Fig.5-
8B), but when given on d3 the difference in induction over the next 48h was less
pronounced because un-stimulated MD M(J)s were also strongly expressing 11 (3-HSD 1
(Fig.5-8C).
Therefore these studies suggest that 11 (3-HSD 1 was up-regulated in MD M(|) by IL-4
with maximum effect at lng/ml. Unfortunately from this data it was not possible to
determine whether the time-point at which 11 (3-HSD 1 was first expressed was also
accelerated.
To address the functional significance of this, it was of interest to discover whether the
ability of IL-4 to up-regulate 11 (3-HSD 1 was accompanied by an augmentation of
phagocytosis in the presence of A. MD M0s were treated with lOng/ml IL-4 and/ or
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Figure 5-8: IL-4 treatment up-regulates 11P-HSD1 activity by human MD M(J)s.
4X106 monocytes were differentiated and bioassayed for 11(3-HSD1 activity (%
conversion 200nM A to B). ljaM A and various doses of IL-4 (0-10ng/ml) were added to
monocyte cultures on dl, d2 or d3 of differentiation. 4h, 24h and 48h later 11 ^-reductase
activity was measured. _A, control M0S (A only) treated on dl had levels of 11(3-
reductase activity that were barely detectable at 24h, increasing to 16% conversion by
48h. In contrast, 11 (3-reductase activity at the same time-points was up-regulated by co-
incubation with IL-4. The effect of IL-4 upon 11(3-HSD1 activity in cells which have
been differentiated for 2d or 3d was similar (B and C). Maximal effect was seen with
lng/ml IL-4. Values shown are Means from 1 experiment carried out in duplicate.
Significance was not established.
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lp,M A at either dO or d2 of differentiation, and assayed for phagocytosis ability at d4.
Control groups treated with A alone, at d2 (to coincide with 11 (3-HSD1 induction)
showed increased phagocytosis over that of groups treated with A at dO (Figs.5-9A and
C). However cells treated with both IL-4 and A exhibited distinct morphological
changes characteristic of giant cells, as well as cell loss and reduced levels of
phagocytosis (Figs.5-9B and D). The earlier the exposure to IL-4, the more severe the
morphological change (Fig.5-9B). This was an IL-4 specific effect and not an effect of
GC exposure since cells exposed to IL-4 alone show identical changes (data not shown).
Therefore, IL-4 was shown to induce 11 (3-HSD 1 activity in MD M(J)s. However,
increased rates of A to B conversion did not augment phagocytic capacity, probably
because ofmorphological changes to MD M0s caused by IL-4 treatment. Giant cells are
poorly phagocytic for apoptotic cells (J Savill, personal communication). Time did not
allow it possible to establish if similar changes were caused by lng/ml IL-4.
5.3 DISCUSSION
Following i.p injection of thioglycollate, 11 (3-HSD 1 was dramatically up-regulated in
cells resident to, or recruited to, the peritoneal cavity. This induction was rapid, with
> 12-fold increase in conversion for A to B detected at the first time-point (4h culture of
peritoneal cells harvested 4h after thioglycollate injection), with 100% conversion of
200nM A achieved easily within 24h. This was followed with a decline to normal
(resident) levels between d3 and d5. These data are in marked contrast to the timing of
11 (3-HSD 1 induction during the in vitro differentiation of human monocytes. The rapid
induction of 11 (3-HSD 1 in response to thioglycollate is unlikely to be a consequence of
differentiation and is probably mediated by the pro-inflammatory environment. In
support of this, peritoneal supernatant taken 4h after thioglycollate injection induced
11(3-HSD1 activity in RP M<J)s and WBC. However LPS, thioglycollate or non¬
inflammatory peritoneal supernatant (taken at d4) had no effect when added directly to
the cells, suggesting that 11 (3-HSD 1 activity was increased by an endogenous
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A control B +10ng/mllL-4
Figure 5-9: IL-4 treatment changes MD M<|> morphology and does not augment
phagocytosis of aPMNs. Human monocytes isolated from peripheral blood were
differentiated into MD M<j>s, and lpM A added at either dO or d2. In addition, IL-4
(lOng/ml) was added at either dO or d2 (B and D). Phagocytosis assays were carried out
on d4 and ingested aPMNs stained with MPO. The photographs show that A augmented
phagocytosis approximately 2-fold when added to d2 MD M(j>s (C), but not dO
monocytes (A). IL-4 addition inhibited phagocytosis to below control levels when added
at either dO (B) or d2 (D) and resulted in the formation of giant cell complexes.
Monocytes were more susceptible to this morphological change than MD M<j>s (B and
D). Images representative of 3 different experiments.
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inflammatory mediator rather than directly by the inflammatory stimulus. This mediator
is unknown but by virtue of the rapid up-regulation of 11(3-HSD1 activity early in the
inflammatory response, it is more likely to be a pro-inflammatory factor (or factors)
rather than the Th2 cytokines reported to increase 11(3-HSD1 expression during the
differentiation of human monocytes in vitro (Thieringer, Le Grand et al. 2001).
One obvious candidate for mediating this effect is TNFa, which has been shown to
increase 11(3-HSD1 activity both in MC and adipocytes (Escher, Galli et al. 1997;
Tomlinson, Moore et al. 2001). TNFa was detectable in diluted peritoneal supernatant
4h and Id after induction of peritonitis. Clearly it will be more informative to repeat
these experiments using undiluted supernatants. The other active constituents of this pro¬
inflammatory supernatant are as yet unknown and it will be of interest to identify
potential modulators within this mileu. The ability to generate GC so early during an
immune response suggests that the function of 1 lp-HSDl may not only be to promote
phagocytic function but also to modulate its pro-inflammatory responses. This data
shows that synergy may exist between the pro-inflammatory activation of the HPA axis
leading to increased release of adrenal-GC into the circulation (Mandrup-Poulsen, Nerup
et al. 1995), and the induction of 11(3-HSD1 activity in activated immune cells leading
to increased GC in the tissues.
Data presented in Chapter 3 show that all M<|)s studied exhibit 11(3-HSD1 activity.
During the latter stages of peritonitis TEP M(|)s were the predominant cell type present,
and it is most likely that, at these stages at least, they account for the 11 (3-reductase
activity detected. Elowever, it is not clear whether this reduction in activity following d3
is due to a down-regulation of TEP M(|) 11 (3-HSD1 activity, or to the disappearance of
another population of high 11(3-HSD1 expressing cells. To address this problem, a
number of experiments were carried out to distinguish the contribution of monocytes
and PMNs to this induction, however, the results were somewhat contradictory. Firstly,
when cells, collected 4h after induction of thioglycollate, were plated and subsequently
washed, the majority of the 11 (3-reductase activity was retained in the adherent cultures
(data not shown). This therefore suggests that the adherent monocytes/ M(J)s were
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responsible. However, upon eosin and haematoxylin staining and examination by
microscope it was apparent that the population was heterogenous and that activated
granulocytes had unexpected adherence properties (data not shown).
Secondly, both cells within the WBC population and RP M0 population increased 11(3-
reductase activity in response to the addition of inflammatory supernatant. This data
suggests that 11P-HSD1 was induced by an endogenous agent, since no induction was
observed with thioglycollate treatment alone. Should cells within the WBC population
be contributory to the induction of 11 (3-reductase, this suggests that 11P-HSD1 may be
induced directly and not be dependent on transmigration across activated endothelial or
mesothelial layers. However, the roles of resident M(|)s are somewhat ill-defined and
whilst a primary function is to protect against spontaneous bacterial leakage from the
gut, it remains to be seen whether they might also act as sentinels to co-ordinate the
influx and activation of immune cells. RP M(J) induction of 11P-HSD1 in the peritoneum
may be a means of priming infiltrating monocytes for phagocytosis, regulating PMN
apoptosis or controlling infiltration of leukocytes (Schleimer 1993; Meagher, Cousin et
al. 1996; Giles, Ross et al. 2001). There are however, reports that RP M(() emigrate from
inflamed sites during the initial stage, to return when resolution is complete and
therefore may play a very limited role in the progression of inflammation (Melnicoff,
Horan et al. 1989).
Thirdly, cell sorting on the basis of F4/80 and GR-1 was unsuccessful - ultimately,
because the sorting process irreparably damaged the cells. This was contrary to
expectation based on CIR experience in handling human blood-derived cells; thus the
problem might relate to murine or inflammatory cell origins. However, it is believed that
the monocytes were not sufficiently differentiated at 4h to be distinguishable from
PMNs by GR-1 population, nor did monocyte F4/80 expression appear to be strong.
Therefore, should the protocol be developed such that cells remain viable, other
monocyte markers such as Mac-1 should included so that monocytes can be sorted on
the basis ofMac-1 (high), GR-1 (low) double staining (Lagasse and Weissman 1996).
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Finally, an attempt was made to deplete the circulating monocytes by DT treatment of
DTR mice prior to induction of peritonitis. Although monocytes were not completely
eliminated, no differences in 11(3-reductase were seen between control and depleted
groups, thus suggesting that monocytes do not contribute to the intra-peritoneal 11 (3-
reductase levels, whereas RP M([)s and/ or PMNs might.
Therefore, at this time, this important issue remains unresolved. Whilst murine M<|)s
have both a constitutive and inducible 11(3-HSD1 activity, it is very possible that
activated PMNs exhibit activity as a way of regulating their own inflammatory functions
and apoptosis.
Other approaches, should time have permitted, would have been either (i) to localise
1 1 (3-HSD1 mRNA transcripts in specific peritoneal inflammatory cells by in situ
hybridisation analysis, (ii) isolate mononuclear cells and granulocytes from peritoneal
lavages via an adaptation of the discontinuous Percoll gradient method for isolating
human leukocytes, or (iii) separate the monocytes, RP M([)s and PMNs from a mixed
population by passing the cells through columns of immuno-magnetic beads specific for
each cell type.
In humans it is clear that monocytes, fresh PMNs and aged PMNs do not exhibit 11(3-
HSD1 activity under non-inflammatory conditions. 11 (3-HSD 1 induction can be
promoted in differentiating monocytes by IL-4 treatment, but in the culture system
employed in this study the MD M0 phenotype changed and characteristic morphology
and phagocytic capacity was lost. During the course of this work, Thieringer and
colleagues published a study in which 11 (3-HSD 1 induction in human monocytes was
reported with IL-4 at a concentration of 50ng/ml (Thieringer, Le Grand et al. 2001)- a
concentration, which in this thesis proved toxic to monocytes. No functional responses
ofmonocytes or phagocytes were tested in the Thieringer study (Thieringer, Le Grand et
al. 2001). It is unlikely that such an anti-inflammatory Th2 cytokine would be present in
an inflammatory mileu early in the infection. Unfortunately, it was not possible to source
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a human pro-inflammatory exudate to test the induction potential of monocytes or
activated human PMNs, in the same way that murine cells were tested.
Finally, preliminary experiments suggest that phagocytosis of aPMNs by TEP M(|)s can
be augmented by inflammatory supernatant. When combined with A treatment however,
this supernatant augmented phagocytosis even further. It is to be deduced that the
induction of 11(3-HSD1 in an environment where substrate concentration is not limiting
serves to increase the rate of B amplification and increases phagocytic capacity of M<J)s
through concentration and time-dependent mechanisms.
At this stage, it is worth comparing how data from this thesis supports the two
contrasting phagocyte 11(3-HSD1 regulatory mechanisms recently published by Escher
and Thieringer (Escher, Galli et al. 1997; Thieringer, Le Grand et al. 2001).
The 'Thieringer hypothesis' is that the curbing of an inflammatory response via anti¬
inflammatory cytokines (IL-4 and IL-13) and the generation of active GC (by 11(3-
HSD1 induction) would facilitate both immune suppression and increase M(() clearance
capacity. In support of this is the finding that ingestion of apoptotic cells does not trigger
pro-inflammatory mediator release, even when the M(j) is subsequently challenged with
LPS, but actually promotes the release of anti-inflammatory cytokines associated with
the resolution phase such as TGF-(3 (Meagher, Savill et al. 1992; Fadok, Bratton et al.
1998). Therefore, a shift from Thl towards Th2 cytokines during inflammation would
up-regulate 11(3-HSD1, augment phagocytosis and thus create a positive feedback
mechanism until resolution was complete (Fig.5-10).
From the study by Escher et al, it can be hypothesised that MC were limiting the chance
of inappropriate tissue damage, in an autocrine fashion, by curbing their own pro¬
inflammatory secretion through the production of suppressive GC. Furthermore, as with
M([)s, ingestion of apoptotic cells by MC is not accompanied MC by pro-inflammatory
cytokine release (Hughes, Liu et al. 1997). Therefore, in this system, pro-inflammatory
cytokines would induce 11 (3-HSD1 and the resulting amplification of B would augment
clearance as well as suppress subsequent pro-inflammatory action. This might not be
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counter-intuitive since M(J) phagocytic capacity can be programmed by GC exposure
early in its differentiation pathway (Giles, Ross et al. 2001). The down-regulation of
pro-inflammatory mediators occurring after phagocytosis might act as a safety
mechanism to further curb inappropriate cytokine release during the resolution phase
(Fig.5-10). The data in this thesis supports Escher's work, in that it suggests (albeit
indirectly) that pro-inflammatory mediators are most likely responsible for 11 (3-HSD1
up-regulation, in a fashion that does not appear to lead to M(J) dysfunction or phenotypic
change. It is of note therefore, that preliminary experiments detected TNFa present in
peritoneal fluid 4h and Id after onset or peritonitis. It will be of interest to identify other
possible inducers within the inflammatory mileu.
Next, the consequences of 11 (3-HSD 1-deficiency, in vivo, during TE peritonitis were
examined.
5.4 SUMMARY
• 11 (3-HSD 1 activity was up-regulated by peritoneal cells in vivo within the first
4h of peritonitis.
• 11 (3-HSD 1 activity remained induced until d3 of peritonitis, and returned to
control level once inflammation had resolved.
• Induction of 11 (3-HSD 1 was mediated by endogenous factors rather than as a
direct effect of inflammatory agents.
• It was not been possible to identify the cell types responsible for the dramatic up-
regulation of 11 (3-HSD 1 activity. The most likely candidates were resident
peritoneal M<|)s or infiltrating monocytes - but it cannot be discounted that 11 (3-
reductase induction is an, as yet, unrecognised property of the inflammatory
PMN.
• Addition of inflammatory supernatant induced 11 (3-HSD 1 activity, and when
combined with A treatment further augmented phagocytic potential of the M()).
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• IL-4 was able to up-regulate 11P-HSD1 activity but did not promote a pro-
phagocytic MD M0 phenotype, instead stimulating giant cell formation.
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Figure 5-10: Diagram of proposed mechanisms of regulation of M<j) 110-HSD1
expression.
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6.1 INTRODUCTION
It has been shown in previous chapters that 11 (3-HSDI is expressed in M0s and in vitro,
inert A can augment phagocytosis of aPMNs - but not if the enzymic activity is
inhibited. Furthermore, phagocytic capacity of TEP M<t>s for administered aPMNs can be
increased by Dex treatment in vivo. The rapid induction of 11 (3-HSD1 during sterile
peritonitis suggests that activity may play a physiological role in promoting the safe
resolution of inflammation. To explore the importance of this in vivo, a mouse model
was used in which the 11 (3-HSD1 gene has been disrupted by homologous
recombination (Kotelevtsev, Holmes et al. 1997). The allele was subsequently crossed
from the original 129/Ola strain to C57BL/6 strain by Dr. Janice Paterson, CIR.
It was important to determine whether differentiation of the 11 [3-HSD 1-deficient M(J)
was different to WT, by examining basic M([) functions and competency to phagocytose
aPMNs. Furthermore, it was also necessary to establish if 11 (3-HSD 1-deficient M<))s
were GC-responsive to a similar degree as WT M(|)s. Then, the effects of 11(3-HSD1-
deficiency were examined during an acute inflammatory response, in vivo, by directly
comparing the course of sterile peritonitis when induced in WT and 11 (3-HSD 1-deficient
mice. Using this model, inflammatory M(J) maturation, clearance capacity and cytokine
profile were also examined.
6.2 RESULTS
6.2-1 11P-HSD1 is required for augmentation of phagocytosis of apoptotic
neutrophils by 11-dehydrocorticosterone
To investigate whether phagocytic responses were normal in 11 [3-HSD 1 -deficient M<|)s,
BMD M(|)s were cultured for 7d in a non-inflammatory environment and assessed for
phagocytic competency. Both genotypes of BMD M(|)s ingested saturating numbers of
latex beads, suggesting that no intrinsic defect in phagocytosis was apparent in 11(3-
HSD1-deficient BMD M(|)s, compared to WT M(j)s (Fig.6-1).
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WT M<j> 11P-HSD1 deficient BMD M(>
Figure 6-1: WT and lip-HSDl-deficient BMD M<j>s ingest similar numbers of
latex beads. A saturating number of latex beads (approx 5:1) were added to cultures of
61 WT BMD M<j)S or 1 lp-HSDl-deficient BMD M<j>s for 30 min. Both populations of
M((> ingested high numbers of latex beads, and individual M<j>s were observed to ingest
multiple beads. No differences between the genotypes were detected.
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Next, to establish that M(|) responses to B were normal in 11(3-HSD1-deficient M(J)s, both
WT and 11(3-HSD1-deficient BMD M(])s were incubated with concentrations of B or A
within the physiological range for 48h and the effect upon phagocytosis measured.
As expected, both B and A elicited a concentration dependent increase in phagocytosis
by WT M0s over 48h, with significant effects seen even at low nM concentrations
(Fig.6-2A). Phagocytosis by 11(3-HSD1-deficient Mc()s was identically promoted by
active B. However, A was completely without effect on phagocytosis by M0S from 11 (3-
HSD1-deficient mice (Fig.6-2A). This confirmed that the augmentation of phagocytosis
in response to A is due its re-activation to B by 11 (3-HSD 1.
In addition to increasing phagocytosis, GCs also increased the ability of M(j)s to ingest
multiple cells (the "phagocytic index" being the number of aPMNs ingested by 100 M0S
(Giles, Ross et al. 2001)). B and A were similarly effective upon WT M<])s, increasing
phagocytic index 3-fold over control levels (Fig.6.2B). B was equally effective in
augmenting the phagocytic index of 11 {3-HSD1 -deficient M(|)s. In contrast, A was
completely ineffective upon 11 (3-HSD 1 -deficient M(()s (Fig.6.2B).
6.2-2 Time-course of sterile peritonitis in WT and 11|3-HSD1-deficient mice
To establish the importance of local modulation of GC by 11 (3-HSD 1 during an
inflammatory response, the dynamics of TE peritonitis were compared in WT and 11(3-
HSD-deficient mice. Both genotypes of mice were injected i.p with 1ml 3%
thioglycollate, and peritoneal cells harvested over the course of 4d. F4/80 (M(J>) and GR-
1 (PMN) positive cells in the peritoneal lavages were assessed by flow cytometry using
CellQuest software (refer to section 2.2-10.3). Cytospins of these cells were also stained
with eosin and haematoxylin for microscopic examination.
Appendix 1 shows flow cytometry data and cytospin images for mice of each genotype,
studied over a 4d time-course of peritonitis. Briefly, peritoneal cells from healthy state
animals (which had not been injected with thioglycollate) stained strongly for F4/80 by
flow cytometry, consistent with a cell population predominately consisting of RP M())s
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Figure 6-2: liP-HSDl-deficient M<|>s show normal augmentation of phagocytosis
by B, but not A. BMD M())s were cultured for 7d, with A or B added at d5. On d7, aged
PMNs were allowed to interact with the M(|)s (at a ratio of 4:1) for 30 min, and % of
M(|)s that had ingested 1 or more a PMNs was assessed by microscopy.
A, WT Mc|)s respond in a dose-dependent manner to both B and A. 11P-HSD1 -deficient
M(|)s, however, were similarly responsive to B, but not A. B, phagocytic index of
ingested aPMNs per 100 M(j)s shows that A or B enhance the capacity of individual WT
M())s to ingest multiple aPMNs, thereby further augmenting clearance potential. Only B
was effective in increasing phagocytic index of 11P-HSD1-deficient M([)s. Values shown
are mean +/- SEM of counts of at least 600 M(])s from 4 mice of each genotype, carried
out in duplicate. *P<0.05, **P<0.001 (ANOVA), as indicated.
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(Appendix 1, Figs.7-1 and 7-2). Also the absence of GR-1 positivity is consistent with
negligible numbers of PMNs and monocytes being present. 4h after the onset of
peritonitis, PMNs and monocytes were elicited into the peritoneum and the level of GR-
1 staining increased accordingly. The level of F4/80 staining decreased at 4h. The reason
for this was unclear since RP M())s were still visible on the cytospins (Appendix 1,
Figs.7-3 and 7-4). However, F4/80 staining was increased Id later, consistent with the
maturation of inflammatory TEP M())s (Appendix 1, Figs.7-5 and 7-6). Over the next 2d
(d3 and d4 of peritonitis), the level of GR-1 staining decreased and PMNs were deleted
from the peritoneal cell population. By d4, only F4/80 staining was present, consistent
with a cell population that was predominantly TEP M(|)s (Appendix 1, Figs.7-11 and 7-
12).
By flow cytometry, no differences were seen between WT and 11(3-HSD1-deficient
mice at any time-point studied. However microscopic analysis of the cytospins revealed
subtle differences in the deletion of PMNs and is described below (refer to sections 6.2-4
and 6.2-5).
6.2-3 Ratios of inflammatory cells during peritonitis
The flow cytometry analysis described in section 6.2-2, did not give a quantitative
measure of the cell types present. It was of interest to discover whether 11 (3-HSD1 -
deficiency resulted in differences in the ratios of cell-types during the course of
peritonitis. At least 2000 cells per cytospin were scored for each time-point, and the
percentage ofM(|)s, PMNs, aPMNs and aPMNs within M(()s (ingested aPMNs) within the
total population calculated (Table 6-1). No significant differences were seen in the
proportions (within the total cell population) ofWT Mijis to 11(3-HSD1-deficient M(j)s, or
WT PMNs to 1 lp-HSDl-deficient PMNs at any time-point (Table 6-1). Similarly, there
were no differences between other low number cell types such as eosinophils (data not
shown).
The total numbers of cells harvested from the peritoneum on d2 of peritonitis were
counted by haemocytometer. A significantly greater number of inflammatory cells were
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Table 6-1: Ratios of M(j)s and PMNs during TE peritonitis. M0s and PMNs were
scored as a % of the total cells harvested in peritoneal lavages at specified time-points
after onset of peritonitis. Values represent Mean +/- SEM of counts of at least 2000 cells
from each of 4 mice per time-point. No significant differences between WT and 11(3-
HSD1-deficient mice were found.
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present in the lavages from 11 (3-HSD1 -deficient mice (Fig. 6-3). Interestingly no
differences were seen in the proportions (within the total cell population) ofWT M0s to
11 [3-HSD 1 -deficient M0s, or WT PMNs to 11 (3-HSD 1-deficient PMNs (Table 6-1), and
therefore the observation cannot be attributed to a condition such as neutrophilia.
6.2-4 Free apoptotic neutrophils are observed in 11|3-HSD1-deficient mice at d2
and d3 of peritonitis
The number of free aPMNs present on each cytospin was scored and expressed as a % of
total cells. Id after the onset of peritonitis, significantly greater proportions of free
apoptotic cells (mainly aPMNs) were observed in peritoneal lavages harvested from WT
mice compared to 11 (3-HSD 1-deficient mice (Fig.6-4). By d2 and 3 there was a greater
than 2-fold reduction in the proportion of free aPMNs present in WT lavages, however,
at these times there was approximately a 2-fold increase in free aPMNs present in 11(3-
HSD1-deficient lavages, compared to dl (Fig.6-4).
6.2-5 11 (3-HSD1-deficient mice exhibit evidence of delayed clearance of apoptotic
neutrophils during peritonitis
The number of M(|)s that contained ingested apoptotic cells on each cytospin was
counted and expressed a % of total M(|)s. At d2 and d3 of peritonitis, greater proportions
of M(|)s containing ingested apoptotic bodies were observed in 11 (3-HSD 1 -deficient cell
populations than in WT populations (Fig.6-5). In WT mice, the vast majority of PMNs
had been cleared by d2 (Table 6-1) - suggesting that ongoing clearance in 11(3-HSD1-
deficient mice at this time was abnormal (Fig.6-6).
These data show that 11(3-HSD1 -deficient M<()s were able to ingest aPMNs, but the
increased presence of ingested aPMNs inside the M(|)s at d2 and d3, as well as the higher
level of free aPMNs suggested that the clearance process had been delayed or prolonged,
possibly due to a defect in recognition, engulfment or degradation.
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Figure 6-3: More inflammatory cells are present in lavages from 11P-HSD1-
deficient mice than WT mice on d2 of peritonitis. The total number of cells lavaged
from the peritoneums ofmice on d2 of TE peritonitis were counted by haemocytometer.
A significant increase in cell numbers was seen in lavages from 1 lp-HSDl-deficient
animals. Values are Mean +/- SEM of haemocytometer counts of cells contained in 5ml
of peritoneal lavage from each of 5 mice. *P<0.05 (t-test).





Figure 6-4: More free apoptotic cells are present in lavages from 11P-HSD1-
deficient mice than WT mice on d2 and d3 of peritonitis. The proportion of free
apoptotic cells was scored as a % of the total cells on each cytospin of peritoneal cells.
WT mice had a greater % of free apoptotic cells at dl, whereas 11P-HSD1-deficient
mice had a greater % at d2 and d3. Values represent Mean +/- SEM of counts of at least
2000 cells from each of 4 mice per time point. *P<0.05, **P<0.001 (ANOVA), as
indicated.





Figure 6-5: Greater levels of phagocytosis are observed by ll|3-HSDl-deficient
M<|>s than WT M<t>s on d2 and d3 of peritonitis. Phagocytosis was expressed as % of
the total M([)s in the peritoneal lavage that contained an apoptotic body. Greater
phagocytosis was observed in M(|)s from 1 lp-HSDl -deficient mice compared to WT, at
d2 and d3 of peritonitis. No significant differences were seen between the genotypes at
dl. Values represent Mean +/- SEM of counts of at least 2000 cells from each of 4 mice
per time point. **P<0.001 (ANOVA), as indicated.






Figure 6-6: Free apoptotic cells and ingested apoptotic cells are observed in
lavages from lip-HSDl-deficient mice 2d after onset of peritonitis. Representative
image taken from cytospins of cells from a 1 lp-HSDl-deficient mouse during d2 TE of
peritonitis. Note the free apoptotic cells (| ) and the ingested apoptotic cells within the
M<j)s (^).
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6.2-6 11 P-HSDl-deficient macrophages have a delay in achieving phagocytic
competency in vivo
To investigate whether the delayed clearance of aPMNs in 11P-HSD1-deficient mice
was due to a phagocytosis defect or a delay in achieving phagocytic competency,
exogenous aPMNs were administered by i.p injection to both WT and 11(3-HSD1-
deficient mice at dl and d2 of TE peritonitis (refer to section 2.2-10.2). Figure 6-7
shows that phagocytosis of aPMNs by WT TEP M())s at dl was greater than by 1113-
HSD1 -deficient TEP M(])s. However, at d2, the level of phagocytosis by WT M())s was
reduced, but phagocytosis by 11P-HSD1 -deficient M<J)s was significantly augmented to
levels comparable to the WT M(J) at dl (Fig.6-7).
These data confirm that 11(3-HSD1 -deficient M(|)s had a delayed attainment of
phagocytic capacity for apoptotic cells.
6.2-7 TNFa and nitric oxide levels during peritonitis
GCs modulate the transcription of numerous genes encoding inflammatory mediators
(reviewed in section 1.2-3). It is possible that the local amplification of GC action within
the peritoneum by 11P-HSD1 may also have immunomodulatory consequences.
Expression of TNFa and iNOS (the inducible form of nitric oxide (NO)), both potent
pro-inflammatory regulators, have been shown to be inhibited by GCs (Di Rosa,
Radomski et al. 1990) (reviewed in (Barnes 1998)). Therefore, this part of the study
attempted to address the question of whether a consequence of inability to amplify GC
during peritonitis, would be the dysregulation of i.p levels ofTNFa and NO.
Time only allowed preliminary experiments in which TNFa and nitrite levels in diluted
supernatant (collected by centrifugation of peritoneal lavages) were measured by ELISA
and Griess assay respectively (refer to section 2.11). Whilst TNFa was detected at 4h
and Id after the onset of peritonitis, no clear differences in TNFa levels were observed
between peritoneal fluid from WT and 11P-HSD1-deficient (Fig.6-8). The Griess assay
did not prove sensitive enough to detect nitrite levels at any time-points from either
genotype ofmouse (data not shown).
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time after thioglycollate injection
Figure 6-7: liP-HSDl-deficient M(|)s have a delayed acquisition of phagocytic
competency in vivo. Aged PMNs were administered by i.p injection at dl and d2 after
the onset of TE peritonitis. At dl, a significantly greater number ofWT M(|)s, than 11(3-
HSD1-deficient M())s were able to ingest aPMNs. By d2, 11(3-HSD1 -deficient M(|)s had
acquired the ability to ingest aPMNs. Values shown are Mean +/- SEM at least 500 cells
counted by microscopy for each of 4 mice of each genotype. *P< 0.05, **P< 0.001
(ANOVA), as indicated.







Control 4h 1d 3d 4d
time after onset of peritonitis
Figure 6.8: No differences in the i.p levels of TNFa are detected in peritoneal
lavages from WT and liP-HSDl-deficient mice. 3ml peritoneal supernatant was
returned from the 4ml PBS bolus used to harvest peritoneal cells. Cells and debris were
removed by centrifugation, and TNFa concentration was measured by ELISA. Even in
diluted samples, TNFa was present at detectable levels in samples taken 4h and Id after
i.p thioglycollate injection. The dotted line indicates detection threshold of the ELISA
kit.
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6.3 DISCUSSION
The data presented in previous chapters show that 11 (3-HSD1 expression could
potentially amplify GC action during an inflammatory event such as peritonitis. In order
to address the possible role of 11 (3-HSD 1 and its contribution via conversion of
endogenous A to B during inflammation, peritonitis was induced in 11 (3-HSD 1-deficient
mice and subsequent events and resolution assessed.
The availability of 11 (3-HSD 1-deficient mice allowed both the in vitro, and in vivo,
maturation of M0S in the absence of 11 (3-HSD 1 activity. The data suggest that 11(3-
HSD1 expression is not a pre-requisite for M0 differentiation and maturation to a
phagocytic phenotype. In vitro, BMD M(j)s of both WT and 11 (3-HSD 1-deficient
genotypes ingested saturating numbers of latex beads, and untreated cells displayed a
similar phagocytic index, thus demonstrating that, in vitro at least, non-specific and
specific engulfment mechanism may be independent of 11P-HSD1.
Similarly, in vitro deficiency of 11|3-HSD1 did not alter a M(J)'s responsiveness to active
GC, and in fact, 1 lp-HSDl-deficient M0s were identical to WT in their GC-sensitivity
as shown by similar phagocytic responses to B. However, 11P-HSD1-deficient M())s
were completely unresponsive to A - confirmation again that the action of 11P-HSD1 is
responsible for the re-activation and subsequent effect ofA.
Therefore, in a non-inflammatory in vitro environment at least, Mc|) differentiation and
GC-dependent pathways are not dependent on 11P-HSD1 induction. It is important to
note that the effect ofA on WT M(|)s was apparent with 48h exposure to concentrations
as low as 2nM, which is well within the l-5nM range of A concentration normally
detected in plasma (Kotelevtsev, Holmes et al. 1997; Harris, Kotelevtsev et al. 2001).
Tissue levels ofA in WT mice are not known but they are probably of significance since
recent data suggests that maintenance of B levels within tissues are largely dependent on
the action of 11P-HSD1, in which A is the substrate (Yau, Noble et al. 2001).
GCs are known to inhibit leukocyte influx through suppression of chemo-attractants and
endothelial-activating cytokines (Schleimer 1993). An intriguing observation made on
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d2 of peritonitis was that during the initial stages of inflammation, 11 (3-HSD 1 -deficient
mice recruited greater numbers of inflammatory leukocytes to the peritoneum than WT
mice. This however, was not due to abnormal recruitment of any one cell-type, since the
proportions of recruited leukocytes between the genotypes were very similar. This not
only implies that the inability to regenerate GC in the peritoneum resulted in a prolonged
period of cell infiltration, but also that the hyper-secretion of B seen in 11 (3-HSD1 -
deficient mice had no consequence in the peritoneal cavity. Studies by Yau et al suggest
that WT mice are largely dependent on the action of 11 (3-HSD 1 for intra-brain levels of
B (Yau, Noble et al. 2001). Preliminary attempts were made to determine the i.p
concentration ofB during peritonitis using a B-specific radioimmunoassay (section 2.11-
3). Unfortunately these were unsuccessful and it will be of great interest to measure
levels of both B and A in the peritonea ofWT and 11|3-HSD1 -deficient mice, and thus
determine whether 11 (3-HSD 1 action significantly contributes to B levels during
peritonitis. It is possible to speculate that low i.p B levels might fail to suppress
leukocyte secretion of pro-inflammatory cytokines such as TNFa. Detection of TNFa
levels in peritoneal supernatants was possible, however no differences were seen
between WT and 11P-HSD1 -deficient mice in preliminary experiments.
Analysis of the cell surface expression of F4/80 by flow cytometry found no discernable
difference between WT and 11P-HSD1 M0s at all time-points studied. F4/80 is a
commonly used marker of M(J) differentiation, but its expression may not be an indicator
of function. In fact, it has been reported that M(|) F4/80 surface expression decreases
upon activation (Ezekowitz and Gordon 1982). This perhaps explains the reduction in
F4/80 staining seen by flow cytometry, despite the continued presence of RP M(])s in
peritoneal populations recovered 4h after onset of peritonitis.
Similarly, no differences in the emergence and disappearance of GR-1 positivity,
indicative of infiltration and clearance of PMNs was observed between WT and 11(3-
HSD1-deficient mice. In addition, both genotypes of mouse had fully resolved
peritonitis by d4, such that the granulocyte population had all but disappeared. Therefore
TE peritonitis was self-resolving in 11 (3-HSD 1-deficient mice.
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Phagocytosis and degradation of aPMNs, in vivo, is a rapid process and therefore
evidence of a small number of phagocytic events in a 'snap-shot' of inflammation is
most probably representative of substantial, on-going cell deletion (Savill 1997). In
peritoneal lavages of 11 (3-HSD 1-deficient mice collected on d2 and d3 of peritonitis,
there was clear evidence of not only increased numbers of free apoptotic cells but also of
significant numbers of M(j)s containing ingested apoptotic cells. In contrast, WT mice
showed greater numbers of free apoptotic cells than 11 (3-HSD1 -deficient mice on dl of
peritonitis. This suggested that 11 (3-HSD 1-deficient mice may have delayed or deficient
clearance of apoptotic cells.
Finally, the abnormality in clearance of apoptotic cells in 11 (3-HSD 1-deficient mice
appeared to be due to a delay in M<|)s attaining competency to ingest apoptotic cells (24h
later than WT), rather than a defect in phagocytosis. TEP M<|)s from WT mice were
capable of ingesting exogenously administered aPMNs Id after induction of peritonitis,
whereas TEP M([>s from 11 (3-HSD 1-deficient M(])s attained this capacity by d2. Although
it was not possible to determine whether the rate of degradation of phagocytosed aPMNs
was normal, clearly 11 (3-HSD 1-deficient TEP M(j) are able to phagocytose. In this
experimental model of sterile peritonitis, the delay in phagocytosis did not compromise
the resolution of TE peritonitis, however, it is possible that such a delay may be costly in
conditions of neutrophilia, such as sepsis.
It is unknown whether the rate of constitutive apoptosis of granulocytes, in vivo, is
affected by GCs. It has been shown that pharmacological levels of GCs can increase the
rate of apoptosis of human eosinophils and delay that of human PMNs in vitro
(Meagher, Cousin et al. 1996). However, PMNs have been shown to express
considerably less GR than other leukocytes and are therefore less responsive to
physiological concentrations of GC than other leukocytes (Miller, Spencer et al. 1998).
Also, the rate at which aging PMNs become apoptotic, in vitro, is delayed as the cell
density increases (Hannah, Nadra et al. 1998), and therefore, with regard to the
observations in 11 (3-HSD 1-deficient mice, it cannot be discounted that either increased
plasma B levels, or the increased i.p cellular density have the potential to affect the rate
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of granulocyte apoptosis. Whilst no differences were observed in the proportions of
PMNs present in WT or 11 (3-HSD1 -deficient mice at any time-point during peritonitis, it
is not possible to discount whether subtle differences in the apoptotic programme of
11 (3-HSD 1-deficient PMNs would account for the phenotype observed, and further
investigation is warranted.
6.4 SUMMARY
• In a non-inflammatory in vitro environment, 11(3-HSD1 BMD M(J)s were fully
GC-responsive but, unlike WT M0S, phagocytic mechanisms were unresponsive
to the inert GC, A. Furthermore, no basic M(J) phagocytic defect was observed
between genotypes, judged by the capacity to ingest either apoptotic cells or
latex beads.
• Both genotypes of mice fully resolved TE peritonitis within 4d.
• During peritonitis, greater numbers of inflammatory cells were elicited into the
peritonea of 11 (3-HSD1 -deficient mice, although no differences were apparent in
the ratios of the peritoneal cells types present between WT and 11 (3-HSD 1 -
deficient mice.
• 11 (3-HSD 1 -deficient mice appeared to have delayed clearance of aPMNs and/ or
increased rates of PMN apoptosis. Peritoneal lavages taken at dl from WT mice
contained greater proportions of free aPMNs than lavages taken from 11(3-
HSD1-deficient mice. In contrast, lavages taken at d2 and d3 from 11 (3-HSD 1 -
deficient mice contained greater proportions of free aPMNs than lavages taken
from WT mice, as well as greater proportions of TEP M(J)s that show evidence of
aPMN ingestion.
• No gross differences between WT and 11 (3-HSD 1 TEP M0s were seen using the
maturation marker F4/80, but acquisition of phagocytic competency by
inflammatory TEP M<|)s was delayed by 24h in 11 (3-HSD 1-deficient mice.
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The significance of the apoptotic cell and its swift, non-inflammatory deletion by the
M((), has been defined by others, both in vitro and in vivo (reviewed in Chapter 1).
Furthermore, new benefits of GC treatment have recently been suggested after the
finding that pharmacological doses of GCs have regulatory effects upon M(J) capacity for
apoptotic cells (Liu, Cousin et al. 1999; Giles, Ross et al. 2001). Work contained within
this thesis has, for the first time, demonstrated that local metabolism of physiological
GCs at the inflammatory site may be important in determining the fate of apoptotic cells.
Briefly, it is shown that all phagocytes studied (human and murine) express 11P-HSD1
mRNA and the resulting enzyme activity is exclusively in the GC-reactivating, reductase
direction. Human monocytes acquire this ability during differentiation. In vitro, the
functional consequence of this is that inert A is converted to active B, which augments
the phagocyte's capacity to ingest aPMNs. Upon induction of sterile peritonitis in mice,
there is a dramatic up-regulation of 11P-HSD1 activity within the cells resident to, or
recruited to, the peritoneal cavity. For peritonitis to resolve, apoptotic cells within the
peritoneal cavity must be cleared by M^s. In 11(3-HSD1 -deficient mouse M([)s, A fails to
promote phagocytosis in vitro and, in vivo, phagocytic competency is attained as much
as 24h later than in WT M(|)s. As a result, 11 (3-HSD1 -deficient mice show a clearance
deficiency of apoptotic cells during the resolution of peritonitis, suggesting a
physiological role for 11P-HSD1 in promoting clearance of apoptotic cells.
There are great similarities between different inflammatory conditions and it is likely
that 11P-HSD1 has a role in other classes of phagocyte. Preliminary in vitro data showed
that 11P-HSD1 expression in MC can also increase phagocytosis in response to A,
suggesting that "semi-professional" phagocytes may also have the potential via 11 P~
HSD1 to regulate their phagocytic capacity in pathologies such as glomerulonephritis.
This work raises interesting questions about the importance of local modulation of GCs
and with particular relevance to phagocytes, further investigations are warranted.
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7.2 GENERAL DISCUSSION AND FUTURE STUDIES
7.2-1 What factors regulate macrophage 11P-HSD1 expression?
Evidence from this thesis supports that of Escher et al, and Tomlinson et al, who
reported 11P-HSD1 up-regulation by pro-inflammatory cytokines in MC and adipocytes,
respectively (Escher, Galli et al. 1997; Tomlinson, Moore et al. 2001). Furthermore, not
only did the effects of peritoneal pro-inflammatory supernatant induce 1 lP-reductase
expression in cells resident in, or recruited to, the peritoneum, it also augmented
phagocytic capacity (Ren et al have also reported that pro-inflammatory cytokines
augment the phagocytosis of aPMNs by MD M(|)s (Ren and Savill 1995)). It seems
unlikely that pro-inflammatory cytokine-based treatments hold therapeutic potential, but
it is intriguing that pro-inflammatory stimuli should confer beneficial effects to a process
important in the successful resolution of an inflammatory response. A related concept is
that this may be an example of early events, previously thought to be exclusively
involved in initiation and amplification of an inflammatory response, "programming"
the inflammatory response for successful resolution later on. Thus it is possible that the
early and rapid amplification of GC within inflamed tissue serves to control the extent of
the physiological (and sometimes detrimental) immune response, whilst priming the M(J)
for a timely phagocytic response. It is also conceivable that the local generation of GC
by phagocytes co-ordinates the action and lifespan of their 'prey'.
Evidence is also presented to suggest that an anti-inflammatory cytokine, IL-4, can
regulate 11 (3-HSD1 expression, although an increased phagocytic phenotype was not
conferred. Should 11 [3-HSD1 induction not be merely a consequence of differentiation,
then this raises the possibility that the nature of the 11(3-HSD1 induction may influence
the differentiation and phenotype of the Mc(). Indeed, this idea is consistent with both
11 (3-HSD 1 -deficient M0s, and C/EBP-e-deficient M0S being viable, yet dysfunctional. It
will be of interest to determine which, if any, exogenously added cytokines regulate the
expression of 11 (3-HSD 1 and whether differences in M0 functionality are associated.
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In vitro, human MD M0S express 11(3-HSD1 by d2 of culture. It is unknown whether
induction occurs rapidly during inflammation, as it does in the murine system. Again,
the use of cytokines or indeed human pro-inflammatory supernatant (if available) would
help determine the responsiveness of 11(3-HSD1 in human cells. The work of Giles et al
has obvious parallels to this discussion (Giles, Ross et al. 2001). They showed that early
exposure to GC altered differentiation of human monocytes resulting in a pro-phagocytic
phenotype. Although a comparison across species, if a similarly rapid induction of
monocyte 11P-HSD1 occurs in response to an inflammatory stimulus during human
inflammation (as seen during murine peritonitis), it may deliver an early, pro-phagocytic
phenotype-determining "dose" of physiological GC to the differentiating monocyte -
particularly within tissues where "free" B levels may be substantially less than in
plasma.
During peritonitis, 1 lP-HSDl activity decreased from d3 onwards, to a level comparable
to that prior to inflammation. Whilst it is possible that this is due to the gradual deletion
of a small population of cells strongly expressing 11P-HSD1, it most likely reflects
decreased 11 (3-reductase activity in the TEP M([) population - particularly since TEP M0S
are by far the most predominant cell type by that stage. Two possibilities exist; (i) a
down-regulation of lip-HSDl by TEP M(])s occurs in response to the clearance of
apoptotic cells, or (ii) the emigration of a sub-population of TEP M(j)s that have a
strongly induced 1 lP-HSDl.
Further experiments will include analysis of 11 p-reductase activity in 'fed' and 'non-
fed' cultures of M(j)s. It will also be of interest to determine whether 1 lP-HSDl activity
is down-regulated differently in response to different classes of 'feed', such as aPMNs,
thymocytes, latex beads, opsonized zymosan etc. Also, if a down-regulation of 11P-
HSD1 in TEP M())s is confirmed, it would be informative to discover whether this is
reciprocated in a reduction in GC-sensitivity by determining GR levels.
A more challenging idea to address is that of TEP M(f) emigration. M(j)s emigrate to the
lymphatics after inflammation has resolved (Bellingan, Caldwell et al. 1996). Direct
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comparisons of 11 ^-reductase activity between M(j)s recovered from these structures and
those still in the peritoneum on, for example, d4 of peritonitis should be attempted.
A reduction in GC amplification, or a reduction in GC-sensitivity once the inflammation
has resolved is likely to be beneficial in avoiding inappropriately prolonged exposure to
GCs.
7.2-2 11P-HSD1 and chronic inflammation
Chronic arthritis has been shown to up-regulate hippocampal 1 lp-HSDl activity, but not
heptatic 11 (3-HSD1 activity (Low, Moisan et al. 1994). No data exist as yet on 11(3-
HSD1 activity in Mc()s during chronic inflammation.
The factors controlling the progression from acute infection to chronic inflammation are
not yet elucidated, but there is increasing evidence that the failure to clear apoptotic cells
leads to necrosis and exacerbation of the response (reviewed in Chapter 1). In fact there
is evidence that reduced numbers of phagocytic M(()s that contain ingested apoptotic
cells are recovered from the synovial fluid of rheumatoid arthritic patients, than from
patients with acute reactive arthritis (Jones, Denton et al. 1993). This therefore suggests
that phagocytosis is either down-regulated or inhibited. Furthermore, M())s have been
shown to undergo a phenotypic change after phagocytosis in which they fail to release
pro-inflammatory cytokines upon subsequent inflammatory challenge (Voll, Herrmann
et al. 1997), and have a reduced ability to engulf apoptotic cells during subsequent
phagocytosis assays (Erwig, Gordon et al. 1999).
By failing to respond to an inflammatory stimulus, it is possible that low or down-
regulated M(j) 11(3-HSD1 activity is either a causative factor, or a consequence of
chronic inflammation. It will be of interest to compare 11 (3-HSD1 expression and
phagocytic abilities of M([>s collected from chronically inflamed sites. A candidate model
is that of rat arthritis, in which inflammation in different joints could be manipulated
individually to represent normality, acute inflammation (eg. collagen) and chronic




Finally, the ideal model to assess the role of 11 (3-HSD1 expression during chronic
inflammation is the 11 (3-HSD 1-deficient mouse. Its ability to resolve a number of acute
challenges of varying degrees of severity, from repeated doses of i.p thioglycollate to
resolving nephritis should be assessed.
7.2-3 The consequences of 11P-HSD1 deficiency
The inability to re-amplify B from inert A has identified a phenotype of delayed
clearance of apoptotic cells in 11 (3-HSD 1 -deficient mice compared to WT. Clearly, in
terms of a self-resolving peritonitis this deficiency has had no obvious detrimental
effect. However, it will be interesting to determine whether the 11P-HSD1-deficient
mouse can successfully resolve other types of inflammatory response (refer to section
7.2-2).
Another interesting phenotype that was observed was that of an increased inflammatory
cell peritoneal infiltrate in the 1 lP-HSDl-deficent mice at d2 - the only time I was able
to assess owing to limited animal supply. GCs can inhibit leukocyte influx (reviewed in
(Schleimer 1993)), and whilst the mechanism behind this is not clear, it may be the case
that the local amplification of GC by 11P-HSD1 action in tissues, rather than plasma
GC, plays an important part in modulating the duration of inflammatory cell influx.
Again, resolution of inflammation of a different severity, or within a different tissue or
compartment could be compromised by increased cell load.
With regard to the plasma GC levels, it is unclear what influence circulating B levels
have on intra-tissue B concentrations. Despite raised plasma levels in the 11P-HSD1-
deficient mouse (refer to section 1.3-4), B levels, in the brain at least, are lower than
WT, which suggests that tissues in the periphery may also be substantially dependent on
11P-HSD1 action for B (Yau, Noble et al. 2001). In the present study, it was not
possible to determine peritoneal levels of B during peritonitis for either genotype of
mouse. Therefore, it will be important to establish the concentrations of B and A during
the evolution and resolution stages of peritonitis by radioimmunoassay or alternative
analyses. In particular, if B levels are low in comparison to A during the initial stages of
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peritonitis, this would imply that the generation of B from A by 11 (3-HSD1 is of
physiological importance.
A future experiment that would, in part, address the contribution of the B-levels to the
11 (3-HSD1-deficient phenotype is that of adoptive transfer of 11(3-HSD1 -deficient
monocytes to WT mice at various stages of peritonitis. Such cells would be harvested,
stained with CM-Green and injected back into a WT mouse at an identical stage of
peritonitis. By performing in vivo phagocytosis assays at different stages of peritonitis it
would then be possible to determine if either 11(3-HSD1 expression or B levels were key
to the attainment of phagocytosis competency by comparing phagocytic abilities ofWT
and 11P-HSD1-deficient M<j)s. Preliminary experiments have shown that inflammatory
cells taken from the peritonea ofWT C57 BL/6 mice Id after the onset of TE peritonitis,
can be stained with CM-Green and successfully transferred to the peritonea of donor
mice, within which labelled M(J>s differentiate to a normal phagocytic phenotype
(unpublished observations).
Should the high plasma-B levels not be reflected within the peritoneum, then 11(3-
HSD1-deficient M(|)s might be expected to have a prolonged Thl response in the
absence of a GC-mediated switch to an anti-inflammatory Th2 profile. Analysis of
peritoneal supernatant or culture medium of ex-vivo TEP M(J)s by ELISA may be
sufficient to identify inappropriate cytokine secretion should it exist. Mature 11|3-HSD1-
deficient M(|)s appear to phagocytose normally, yet it will be important to determine
whether they down-regulate pro-inflammatory secretion in response to phagocytosis of
apoptotic cells in the same way as WT cells. Interestingly it was found that mice
deficient for C/EBP-e have a complete absence of IL-10 mRNA and activity (Tavor,
Vuong et al. 2002) (refer to section 1.4-3).
It has been suggested that the deficient clearance of apoptotic cells, in vivo, may lead to
the development of autoimmunity (Taylor, Carugati et al. 2000). It is, therefore, possible
that the levels of auto-antibody present in the serum or kidneys of aged 11(3-HSD1-
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deficient mice may be higher than aged WT mice. Mice currently being aged for
neurological studies will provide tissues for such a study.
Finally, an important, and unresolved issue is that of GR levels in the absence of 11(3-
HSD1. GR is often negatively regulated by GC levels, at least in the short term (Kitraki,
Karandrea et al. 1999) (reviewed in 1.2-5). It is therefore likely that a 11(3-HSD1-
deficient M(|)'s sensitivity to GC will also be determined by an altered GR density.
Analysis of GR mRNA levels in WT and KO TEP M(|)s by competitive RT-PCR are
currently in progress.
7.2-4 Is modulation of 11 (3-HSD 1 action a potential therapeutic target?
The efficacy of high dose, long-term, GC-based therapeutic regimes are compromised
by side effects. It may therefore be desirable to target the beneficial effects of GC to
phagocytes. This thesis has provided a novel therapeutic idea - that phagocyte 11 (3-
HSD1 can be modulated such that the beneficial, phagocytic effects of GCs can be
targeted locally to phagocytes using non-toxic concentrations of inert GC. Liposomes,
injected systemically during arthritis, pass through the 'leaky' vasculature and are
preferentially taken up by inflammatory M(|)s in the inflamed joint (personal
communication from Dr Bart Metselaar, Utrecht). Therefore, it may be possible to target
liposomes packaged with either (i), 11 (3-HSD1 inducers (if 11 (3-HSD 1 expression is
found to be down-regulated in chronic inflammation) or (ii), inert GCs, directly to the
inflammatory foci. Inert GCs are preferable to active GCs because inappropriate leakage
or delivery would only mediate effects on 11 (3-HSD 1 expressing cells.
7.2-5 Would over-expression of 11|3-HSD1 sensitise macrophages to the effects of
A?
Murine TEP M<))s are able to convert 200nM A to B over 24h, typically conferring a 2-
fold augmentation of phagocytosis. 200nM was determined to be the most effective
concentration for both A and B, implying that 11 (3-HSD 1 is not the rate-limiting factor
in mediating the effect ofA. However, A was only equipotent to B over a treatment time
of 48h. Therefore, to ask the question ofwhether an increased rate of conversion ofA to
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B is required to accelerate the availability of B (thereby enhancing the effect of B over a
shorter period), defined numbers of 11 (3-HSD1 transgenes could be introduced to the
M(])s using Bacterial Artificial Chromosomes.
The murine data suggested that 11 (3-HSD 1 expression was induced rapidly upon the
induction of peritonitis. In contrast, 11 (3-HSD 1 expression in human monocytes was
constitutively induced during d2 of culture. Whether this is the case in vivo, or is an in
vitro artefact in the absence of appropriate inflammatory signals remains to be
determined. Nevertheless, it may still be of benefit to drive the expression of 11 (3-HSD 1
in differentiating monocytes to promote the earlier acquisition, and greater capacity for
phagocytosis. It may therefore be possible to use transgene technology to construct a
monocyte-specific 11 (3-HSD 1 transgene under the control of either the macrophage
metalloelastase (MME) or the CD68 promoters. The MME promoter would induce 11 (3-
HSD1 expression as the monocyte entered the inflamed tissue (Shapiro, Griffin et al.
1992), and the CD68 promoter would induce 11(3-HSD1 expression in circulating
monocytes (Li, Guidez et al. 1998). However, should it be confirmed that murine blood-
borne monocytes already express 11 (3-HSD 1, then this transgenic approach would serve
to increase expression.
7.2-6 How do GCs potentiate phagocytosis?
It is of great interest to determine the down-stream mechanism by which 11 (3-HSD 1
action may be augmenting phagocytosis. In the study by Liu et al, it was found that
synthetic GC had no effect on the surface expression of components of the av(33
vitronectin receptor/thrombospondin/CD36 recognition mechanism, and had little effect
on CD-14 (Liu, Cousin et al. 1999). Thus, GC action appeared to exert a 'pan-
phagocyte' action in which different classes and lineages of phagocytes from different
species were affected - some of which use distinct apoptotic cell receptor mechanisms.
Recent work has established that members of the scavenger receptor family (putative
apoptotic cell clearance receptors on human and murine M(|)s) are up-regulated on
human monocytes during Dex treatment (Galon, Franchimont et al. 2002). It is therefore
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possible that the earlier clearance of aPMNs achieved by WT M(|)s in comparison to
11P-HSD1-deficient M0s, is through a GC-inducible scavenger receptor expressed on
the M(j) surface as a consequence of the rapid induction of 1 lp-HSDl. Future work will
determine the levels of scavenger receptor expression on WT and 11P-HSD1-deficient
M())s in response to GC by Ab staining (eg. anti-2F8 for scavenger receptor A). Overall
densities of surface expression could be assessed by flow cytometry, whereas receptor
clustering could be assessed by fluorescence microscopy.
Evidence from human monocyte studies suggests re-organisation of cytoskeletal
elements is necessary for GC-augmented phagocytosis (Giles, Ross et al. 2001).
However, this was accomplished with pharmacological doses of Dex, in which Dex-
treated monocytes adopted a distinct rounded morphology and were less adherent to
plastic (Giles, Ross et al. 2001). This therefore may not be applicable to the present
physiological murine system since WT M(|)s did not appear to differ in morphology to
11P-HSD1-deficient M(|)s. However Dex may be acting through 2 different mechanisms.
In the in vitro culture of human MD M(|)s, Dex treatment for only 24h to monocytes was
sufficient to effect the human monocyte to macrophage differentiation programme
(Giles, Ross et al. 2001), whereas Dex addition for 24h to fully differentiated MD M(f>s
did not change morphology, but increased phagocytic potential, possibly through the
induction of a phagocytic receptor (Liu, Cousin et al. 1999).
7.2-7 Does 11P-HSD1 action affect other functions of macrophage biology?
11 p-HSD-1-deficient mice have recently been reported to have altered lipoproteins,
insulin sensitivity and triglycerides, and may therefore be less susceptible to
atherosclerosis (Morton, Holmes et al. 2001). It is therefore very likely that M(J) 11P-
HSD1 biology will extend to new studies in which may for example, determine a link




The work in this thesis has contributed to the fields of endocrinology and M<() biology.
Most notably, it has identified a physiological role for 11P-HSD1 in promoting
clearance of apoptotic cells.
Understanding the M(|)-specific biology of 11(3-HSD1 will increase our understanding of
its role in the pathophysiology of inflammatory diseases. This may lead to novel
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Time-course of sterile peritonitis
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Appendix 1
Both WT and 11P-HSD1 -deficient mice were injected i.p with 1ml 3% thioglycollate,
and peritoneal cells were harvested over the course of 4d. F4/80 and GR-1 positive cells
of the peritoneal lavages were assessed by flow cytometry. Cytospins of these cells were
also prepared for morphological examination.
Control mice:
Figure 7-1A shows that, in a non-inflammatory state the resident peritoneal cells
separate into 3 distinct populations based on forward and side scatter properties. There is
no difference in the F4/80 properties of the RP M(|)s in either the WT or 11 (3-HSD1 -
deficient mice, with the majority of the F4/80 positive cells lying in gate R7 (Fig.7-IB).
There are minimal numbers of PMNs present in the peritoneum of these control mice
and any GR-1 positivity detected in lavages of both genotypes is representative of
contamination by peripheral blood during surgery (Fig.7-IB). These observations are
consistent with analysis of the eosin and haematoxylin stained cytospins shown in
Figure 7-2.
4h after onset of TE peritonitis:
Cells harvested at 4h do not retain the strong F4/80 positivity seen before peritonitis is
induced. Staining in the R7 population is weak and detectable in the 2nd log order in both
R8 and R9 populations (Fig.7-3B). There is a significant increase in the number of cells
in the R9 population (Fig.7-3A). Figure 7-3B shows that these cells are positive for GR-
1 and are confirmed as infiltrating PMNs by morphological analysis (Fig.7-4). There is
debate as to whether RP M<|)s lose surface F4/80 expression, emigrate or adhere to the
peritoneal wall. However, cytospins indicate that they are still present in the peritoneum
in significant numbers so it is difficult to explain their weak staining (Fig.7-4). No
differences were detected between WT and 11(3-HSD1-deficient cell populations.
Id after onset of TE peritonitis:
There is strong F4/80 staining in all 3 populations of cells harvested Id after the onset of
peritonitis (Fig.7-5A). In contrast, low staining for GR-1 is observed in R7 and R8, but
staining is strong in R9 (Fig.7-5B). However, GR-1 staining is lower than seen at 4h,
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and this is representative of fewer PMNs present in the lavages at this later time-point
(Fig.7-6). It is of interest that low numbers of free aPMNs and evidence of ingestion
within M())s are detectable in the WT cells (Fig.7-6A). Such occurance was not apparent
in the 11(3-HSD1 -deficient cells. However no gross differences in F4/80 and GR-1
staining between the genotypes were observed.
2d after onset of TE peritonitis:
At d2, there is strong F4/80 staining in all 3 populations, whereas GR-1 staining is lower
than dl (Fig.7-7). Again no differences are visible between the 2 genotypes by flow
cytometry, however there are clearly greater numbers of free aPMNs and TEP M(j)s
containing recently ingested aPMNs in the lavages from 11(3-HSD1 -deficient mice
(Fig.7-8B).
3d after onset of peritonitis:
There is still a strong F4/80 staining in both WT and 11(3-HSD1 cells, however GR-1
staining is minimal (Fig.7-9). This is consistent with the cytospins, which show
predominantly TEP M(|)s and very few PMNs (Fig.7-10). A greater number of
phagocytic 'events' are observed in 11P-HSD1-deficient cells than WT, although very
few free aPMNs are now observed (Fig. 7-1 OB).
4d after onset of peritonitis:
The peritonitis has fully resolved, flow cytometry detects no GR-1 positivity and no
PMNs are apparent in the cytospins (Figs. 7-1 IB and 7-12B). All 3 populations stain
strongly for F4/80 and R8 now shows a bi-modal distribution (Fig.7-11A). No
differences are observed between the genotypes.
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Figure 7-1: FACS analysis of Control lavages. Peritoneal cells were lavaged from
control WT and 1 lp-HSDl-deficient mice. 0.5X106 cells were labelled with F4/80 Ab,
GR-1 Ab or IgG2b PE isotype control Ab as described in methods, and 10,000 events
were collected for each of 4 mice of each genotype. A; unstained cells separate- on the
basis of size- into 3 distinct populations, R7, R8 and R9. The ungated population is
debris. B; histogram showing 4 isotype controls (black) overlayed on 4 F4/80 Ab stained
samples (multicoloured) of each genotype for each gated population. C; histogram
showing 4 isotype controls (black) overlayed on 4 GR-1 Ab stained samples
(multicoloured) of each genotype for each gated population. GR-1 positivity is due to
blood contamination of a single lavage during surgery.
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Figure 7-2: Images of WT and 11(5-HSD1 -deficient mice. Control. Cytospins
showing cell types present in the peritoneums of A, healthy WT and B, lip-HSDl-
deficient C57 BL/6. Each panel is a representative photograph of each of 4 mice. Note
that the low numbers of red blood cells present are from the result of surgery and not
normally present in the peritoneum.
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Figure 7-3: FACS analysis of lavages 4h after onset of peritonitis. Peritoneal cells
were lavaged from WT and 1 lp-HSDl-deficient mice. 0.5X106 cells were labelled with
F4/80 Ab, GR-1 Ab or IgG2b PE isotype control Ab as described in methods, and
10,000 events were collected for each of 4 mice of each genotype. A; unstained cells
separate- on the basis of size- into 3 distinct populations, R7, R8 and R9. The ungated
population is debris. B; histogram showing 4 isotype controls (black) overlayed on 4
F4/80 Ab stained samples (multicoloured) of each genotype for each gated population.
Note that the F4/80 positivity is between the 2nd and 3rd log order. C; histogram showing
4 isotype controls (black) overlayed on 4 F4/80 Ab stained samples (multicoloured) of
each genotype for each gated population.
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Figure 7-4: Images of lavage cytospins 4h after onset of peritonitis. Cytospins
showing cell types present in A, WT and B, 1 lfi-HSDl -deficient peritoneums 4h after
i.p injection of 3% thioglycollate. Each panel is a representative photograph of each of 4
mice.
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Figure 7-5: FACS analysis of lavages Id after onset of peritonitis. Peritoneal cells
were lavaged from WT and 1 lp-HSDl-deficient mice. 0.5X106 cells were labelled with
F4/80 Ab, GR-1 Ab or IgG2b PE isotype control Ab as described in methods, and
10,000 events were collected for each of 4 mice of each genotype. A; unstained cells
separate- on the basis of size- into 3 distinct populations, R7, R8 and R9. The ungated
population is debris. B; histogram showing 4 isotype controls (black) overlayed on 4
F4/80 Ab stained samples (multicoloured) of each genotype for each gated population.
C; histogram showing 4 isotype controls (black) overlayed on 4 GR-1 Ab stained
samples (multicoloured) of each genotype for each gated population.
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Figure 7-6: Images of lavage cytospins Id after onset of peritonitis. Cytospins
showing cell types present in A, WT and B, 1 ip-HSDl-deficient peritoneums Id after
i.p injection of 3% thioglycollate. Each panel is a representative photograph of each of 4
mice. Note the increased numbers of free apoptotic cells (I) and M<J>s that contain
apoptotic bodies (-+•) in the WT populations.
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Figure 7-7: FACS analysis of lavages 2d after onset of peritonitis. Peritoneal cells
were lavaged from WT and 1 lp-HSDl-deficient mice. 0.5X106 cells were labelled with
F4/80 Ab, GR-1 Ab or IgG2b PE isotype control Ab as described in methods, and
10,000 events were collected for each of 4 mice of each genotype. A; unstained cells
separate- on the basis of size- into 3 distinct populations, R7, R8 and R9. The ungated
population is debris. B; histogram showing 4 isotype controls (black) overlayed on 4
F4/80 Ab stained samples (multicoloured) of each genotype for each gated population.
C; histogram showing 4 isotype controls (black) overlayed on 4 GR-1 Ab stained
samples (multicoloured) of each genotype for each gated population.
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Figure 7-8: Images of lavage cytospins 2d after onset of peritonitis. Cytospins
showing cell types present in A, WT and B, 11P-HSD1-deficient peritoneums 2d after
i.p injection of 3% thioglycollate. Each panel is a representative photograph of each of 4
mice. Note the increased numbers of free apoptotic cells (I) and M<f>s that contain
apoptotic bodies (-+•) in the 1 lp-HSDl-deficient populations.
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Figure 7-9: FACS analysis of lavages 3d after onset of peritonitis. Peritoneal cells
were lavaged from WT and lip-HSDl-deficient mice. 0.5X106 cells were labelled with
F4/80 Ab, GR-1 Ab or IgG2b PE isotype control Ab as described in methods, and
10,000 events were collected for each of 4 mice of each genotype. A; unstained cells
separate- on the basis of size- into 3 distinct populations, R7, R8 and R9. The ungated
population is debris. B; histogram showing 4 isotype controls (black) overlayed on 4
F4/80 Ab stained samples (multicoloured) of each genotype for each gated population.
C; histogram showing 4 isotype controls (black) overlayed on 4 GR-1 Ab stained
samples (multicoloured) of each genotype for each gated population.
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Figure 7-10: Images of lavage cytospins 3d after onset of peritonitis. Cytospins
showing cell types present in A, WT and B, 1 lf?-HSDl-deficient peritoneums d3 after
i.p injection of 3% thioglycollate. Each panel is a representative photograph of each of 4
mice. Note the increased numbers of M<j>s that contain apoptotic bodies (-►) in the llp-
HSD1-deficient populations.
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Figure 7-11: FACS analysis of lavages 4d after onset of peritonitis. Peritoneal cells
were lavaged from WT and lip-HSDl-deficient mice. 0.5X106 cells were labelled with
F4/80 Ab, GR-1 Ab or IgG2b PE isotype control Ab as described in methods, and
10,000 events were collected for each of 4 mice of each genotype. A; unstained cells
separate- on the basis of size- into 3 distinct populations, R7, R8 and R9. The ungated
population is debris. B; histogram showing 4 isotype controls (black) overlayed on 4
F4/80 Ab stained samples (multicoloured) of each genotype for each gated population.
C; histogram showing 4 isotype controls (black) overlayed on 4 GR-1 Ab stained
samples (multicoloured) of each genotype for each gated population.
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Figure 7-12: Images of lavage cytospins 4d after onset of peritonitis. Cytospins
showing cell types present in A, WT and B, 1 lp-HSDl-deficient peritoneums 4d after
i.p injection of 3% thioglycollate. Each panel is a representative photograph of each of 4
mice.
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